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ADP adenosine diphosphate 
AIBN azoisobutyronitrile 
AMP adenosine monophosphate 
APCI atmospheric pressure chemical ionisation 
ATP adenosine triphosphate 
Bn benzyl 
Boc tert-butoxycarbonyl 




CAL-B Candida antarctica lipase B 
d doublet 
dba dibenzylideneacetone 
DBU 1 ,8-diazabicyclo[5 .4.O]undec-7-ene 
DDQ 2,3-dichloro-5 ,6-dicyano- 1 ,4-benzoquinone 
DEAD diethyl azodicarboxylate 
DHP 3 ,4-dihydro-2H-pyran 




DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DPPA diphenylphosphoryl azide 
EE ethoxyethyl 
e.e. enantiomeric excess 
El electron impact 
ES electrospray 
Et ethyl 
FAB fast atom bombardment 
HMDS hexamethyldisilazane 
HPLC high performance liquid chromatography 
IBX o-iodoxybenzoic acid 
LDA lithium diisopropylamide 
m multiplet 
MCPBA m-chloroperbenzoic acid 
Me methyl 
MOM methoxymethyl 
mp melting point 
Ms methylsulfonyl (mesyl) 
NBS N-bromosuccinimide 
NMO 4-methylmorpholine N-oxide 
NMR nuclear magnetic resonance 
VII 
nOe nuclear Overhauser enhancement 
PCC pyridinium chlorochromate 
PDC pyridinium dichromate 
PG protecting group 
Ph phenyl 
PMB p-methoxybenzyl 
PPTS pyridinium p-to luenesulfonate 
Pr propyl 
PRPP 5-phosphoribosyl-a- 1 -pyrophosphate 
PTSA p-toluenesulfonic acid 
Red-Al sodium bis(2-methoxyethoxy)aluminium hydride 
s singlet 
t triplet 
TBAF tetrabutylammonium fluoride 
TBDMS tert-butyldimethylsilyl 
TBDPS tert-butyldiphenylsilyl 
Tf trifluoromethylsulfonyl (triflyl) 




TPAP tetrapropylammonium perruthenate 




The numbering system of the carbocyclic nucleoside analogues and their 
precursors agrees with the numbering employed for nucleosides with the carbon 
replacing the oxygen of the furanose ring being designated as C-6'. 
Base 	 Base 




adenine 	X = NH2, Y = H 
</ 7 	IN  guanine X = OH, Y = NH2 




N< 	cytosine X=NH2,Y=H 
kf1-J6 	
thymine X= OH, Y=CH3  





Aristeromycin 4 and neplanocin A 5 are biologically active carbocyclic 
nucleosides produced by the organism Streptomyces citricolor. Previous studies 
towards elucidating their biosynthesis have led to a proposed biosynthetic pathway in 
which D-glucose is converted via a number of carbocyclic intermediates to 
neplanocin A and aristeromycin (Figure 1.2). 
This thesis describes the studies that have been carried out in order to: 
identify the first formed carbocyclic intermediate on the biosynthetic pathway 
(Chapter 2). 
determine the identity of the phosphorylated intermediates prior to neplanocin A 
(Chapter 3). 
The novel (2R,3S,4R), (2S,3R,45) and (2R,3S,45) keto-tetrols 95, ent-95 and 116 
have been prepared and their syntheses are described. To determine whether these 
intermediates lie on the biosynthetic pathway, feeding studies have been carried out 
using a mutant of Streptomyces citricolor. The results of these studies, described 
within, suggest that both the (2R,3S,4R) keto-tetrol 95 and its diastereomer 
(2R,3S,45) keto-tetrol 116 lie on the biosynthetic pathway. 
The syntheses of the known intermediate tetrol 83a, the proposed phosphorylated 
intermediate 5-phosphate 83b and the corresponding 1-phosphate 152, via multi-step 
syntheses from the cyclopentenone 61, prepared from either D-ribose 126 or 




1.1 	Nucleoside Analogues as Therapeutic Agents 
Nucleosides and their analogues display a wide range of biological activities and 
have attracted particular attention as anti-tumour and anti-viral agents. For example, 
5-fluoro-2 '-deoxyuridine 1 shows anti-cancer activity; 2 '-fluoro-5-iodo- 1 --D-
arabinothranosylcytosine (FIAC) 2 displays anti-herpes simplex virus properties; and 
3'-azido-3'-deoxythymidine (AZT) 3 has been used for the treatment of the human 
immunodeficiency virus (HIV) infection.' 
HO 	0 
N— 
As a result of their properties many modifications have been made to both the 
heterocyclic base and the sugar moiety. One such modification is the replacement 
of the oxygen atom of the furanose ring by a methylene group as shown in Figure 
1.1. This change is of particular interest since the resulting carbocyclic nucleosides 
exhibit biological activity as well as possessing greater metabolic stability to the 
phosphorylase enzymes, which cleave the N-glycosidic linkage between the 
heterocyclic base and the sugar of normal nucleosides. 
HO ^,~Base 
HO\ç7 y Base 
Hd OH 
nucleoside 	carbocyclic nucleoside 
Figure 1.1 	Comparison of a nucleoside and a carbocyclic nucleoside 
Introduction 
Interest in the synthesis and biological activities of carbocyclic nucleoside 
analogues was stimulated by the discovery that the naturally occurring carbocyclic 
nucleosides aristeromycin 4 and neplanocin A 5 displayed potent biological 
activity.',' Aristeromycin and neplanocin A will be discussed in more detail in 
Section 1.3. 
NH2 






For the past fifteen years much of the research on the chemistry of nucleoside 
analogues has been directed towards the development of agents showing activity 
against HIV. 	More effective treatment has also been sought for other viral 
infections, in particular herpes simplex virus (HSV types 1 and 2), varicella zoster 
virus (VZV), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and hepatitis B 
virus (HBV), since infections of these types can be potentially lethal to AIDS 
patients and other immunocompromised individuals. 	The search for clinically 
useful nucleoside analogues has resulted in an explosion of synthetic activity in the 
field of carbocyclic nucleosides which has led to the discovery of several derivatives 
with potent anti-viral activity. 	For example, carbocyclic 5-bromovinyl- 
deoxyuridine (BVDU) 6 which has activity against HSV and VZV infections and 
carbocyclic 2'-ara-fluoroguanosine 7 which is more active against HSV-1 and HSV-









Presently, another important area in which carbocyclic nucleosides are receiving 
attention is as building blocks for antisense oligonucleotides.8 
Of particular interest amongst the carbocyclic nucleosides are carbovir 8 and its 6-
cyclopropylaminopurine analogue 1592U89 (abacavir) 9, as both compounds possess 
potent anti-HIV activity.9"° Carbovir 8 is in clinical use for the treatment of the 
acquired immunodeficiency syndrome (AIDS) but its long-term usefulness is limited 
because of its toxicity. However, abacavir 9 operates by a unique pathway which 
enables it to overcome the toxicological deficiencies of carbovir 8 whilst maintaining 
potent and selective anti-HIV activity." Abacavir 9 has completed all clinical trials 
and is being marketed by GlaxoWellcome under the name of Ziagen®. 
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The exact mechanism of action of these compounds is not completely known, 
however it is clear that they are pro-drugs and are sequentially phosphorylated by 
cellular kinases to the corresponding triphosphates. 	The triphosphate is then 
incorporated into the replicating viral DNA chain by HIV reverse transcriptase, and 
chain termination results as there is no 3'-hydroxyl group for further elongation of 
the chain. In addition, the 5 '-triphosphate of the oligonucleotide may act as a 
competitive inhibitor of the reverse transcriptase.6 
A further carbocyclic nucleoside of interest is BMS-200475 10, which contains an 
exo-cyclic double bond. This compound displays potent anti-hepatitis B virus 
activity and is currently in phase II clinical trials at Bristol-Myers-Squibb." 
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1.2 	The Synthesis of Chiral Carbocyclic Nucleosides 
The pharmaceutical importance of carbocyclic nucleoside analogues has focused 
attention on new syntheses of these compounds. Furthermore, since the biological 
activity of a nucleoside analogue normally resides in one enantiomer, and with the 
increasing demand for new drug substances to be enantiomerically pure, the 
development of enantioselective routes to carbocyclic nucleosides is of paramount 
importance. In this thesis the literature from the beginning of 1997 to the end of 
1999 is discussed. The reader is referred to earlier reviews for coverage of the 
literature prior to 1997. 1,4-1 
1.2.1 Methods for coupling the heterocyclic base with the carbocyclic ring 
Carbocyclic nucleosides are generally prepared by initial formation of a 
functionalised cyclopentane or cyclopentene ring followed by coupling of a purine or 
pyrimidine base. The heterocyclic base can either be incorporated intact onto the 
carbocycle in a convergent approach, or constructed around an amino function on the 
carbocycle in a linear synthesis. 
(a) 	Convergent approaches 
Direct coupling of the heterocyclic base to a functionalised carbocyclic ring is the 
most common approach for the synthesis of carbocyclic nucleosides. This route 
does however introduce the problem of regioselectivity with respect to attack by the 
heterocyclic base. In the case of purines, attachment at the N9, N7 and N3 nitrogen 
atoms is possible and all three regioisomers are often observed. 
Five main ways in which the base can be directly coupled to the carbocyclic ring 
have been described: 
4 
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Nucleophilic substitution of an activated hydroxyl group 
The displacement of a mesylate, tosylate, triflate or halide can be used for the 
direct coupling as illustrated in the preparation of MDL 201449A 11 (Scheme 1.1).' 
This reaction takes place with a net inversion of the hydroxyl stereochemistry. 
NH2 	 NH2 





N b 	 N 
AcO 	 HO 
11 
Scheme 1.1 Reagents and conditions: a. adenine, NaH, DMF, 55-60°C, 53%; b. 6 M 
HC1, EtOH, reflux, 87%. 
Mitsunobu reaction 
One of the most common methods used is the Mitsunobu reaction (Scheme 1.2).' 
Cl 
TBDPSO\ç




Scheme 1.2 Reagents and conditions: a. 2-amino-6-chloropurine, Et02CNNCO2Et, 
PPh3; b. TBAF, 36%. 
Activation of the secondary alcohol by a complex formed from an 
azodicarboxylate and triphenyiphosphine allows direct substitution with net 
inversion of stereochemistry. 
A disadvantage of this approach is the laborious purification procedures which are 
often associated with Mitsunobu reactions for the removal of triphenyiphosphine 
oxide from the final product.'5 
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(iii) Palladium catalysed displacement of an allylic ester or carbonate 
The most recently described and extremely useful strategy for the coupling is the 
palladium(0) catalysed substitution of allylic esters, carbonates or epoxides (Scheme 
1.3).16 A variety of Pd(0) catalysts have been employed. 
C' 
N 	/ 





Scheme 1.3 Reagents and conditions: a. 2-amino-6-chloropurine, Pd(PPh3)4, NaH, THF, 
DMSO, 65%. 
This reaction which was initially described by Trost" proceeds with retention of 
configuration, although allylic rearrangement can occur. 
—(Lv) _Jig opening of an epoxide 
Epoxk, cyclic sulfates and sulfites can be used for the coupling of the base to 
the carbocyclic ring (Scheme 1.4).18 
NH2 
BnO 	 a BnO N 
BnO— OS:..0 BnO— 
Scheme 1.4 Reagents and conditions: a. adenine, NaH, DMF, 18-crown-6, 50%. 
A limit of this method is the lack of regioselectivity in the opening of the epoxide, 
cyclic sulfate and sulfite. Nucleophilic attack can occur at two sites which leads to a 
mixture of isomers being formed. 
(v) 	Michael 1,2 addition 
A small number of examples which involve the Michael addition of a heterocyclic 
base to a nitrocyclopentene derivative have been described (Scheme 1.5)." 
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a 	 \rNH b 	 \rNH 
BnO OBn 	 HO OH 	 HO OH 
Scheme 1.5 Reagents and conditions: a. CsF, silylated uracil, DMF, 50%; b. Bu3SnH, 
AIBN, 21%. 
(b) 	Linear approaches 
In a linear approach carbocyclic nucleosides are prepared by construction of the 
purine or pyrimidine base from the appropriate precursor onto a cyclopentylamine. 
The use of a linear synthesis is less common due to the increased number of steps 
which results in low overall yields, however it does have the advantage that a large 
number of carbocyclic nucleoside analogues with modified bases can be easily 
prepared and then screened for biological activity. 
(i) 	Synthesis ofpurines 
The synthesis of adenine derivatives is carried out as shown in Scheme 1.6.20 
Cl 
H2N 
HO 	 HO 	 N 
a 
H(5 OH 	 HO OH 
 
Cl 	 NH2 
N 	I N 
HO HO\\/,P N 	 N 
HO OH 	 HO OH 
Scheme 1.6 Reagents and conditions: a. 5-amino-4,6-dichloropyrimidine, Et3N, t-BuOH, 
reflux, 78%; b. CH(OE03, 12 M HCL, 70%; c. NH3, dioxane, 80°C, 100%. 
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Guanosine derivatives can be synthesised by a similar procedure which is outlined 










Cl 	 Cl 
C1 	 NN 	 H2N 
H / N 
HO 	 N / HO 	 N 
N\ 
N NH2 	 H2 
_____C d __ 
C1 	 0 





Scheme 1.7 Reagents and conditions: a. 2-amino-4,6-dichloropyrimidine, i-Pr2NEt, 
BuOH, reflux, 80%; b. 4-ClC6H4N2 CI, AcOH, NaOAc, H20, 69%; c. Zn, AcOH, EtOH, 
H20, 50%; d. CH(OE03, HCL, H20; e. NaOH, H20,74%. 
Other nucleophiles such as amines and alkoxides can be used to incorporate a 
variety of substituents at the 6-position of guanine or adenine. 
(ii) Synthesis ofpyrimidines 
Uridine and thymidine derivatives can be synthesised by a procedure originally 
developed by Shaw and Warrener22'23 which is shown in Scheme 1.8.24 
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NHZ H 	 H 
M42 	NHZ 
0 N 0 	NHZ 0 N 0 
BnO2C 	
NH 	 N 
BnO2C 'H BnO2C 
+ 	a 	FI\=I'H OEt 	
b 	
' \=I 'H 
_>-< *:::::: C=O EtO 
X = H, Me 
Scheme 1.8 Reagents and conditions: a. benzene-DMF, 85%; b. I M H2SO4,  dioxane, 
reflux, 88%. 
These pyrimidine derivatives can also be prepared by the reaction of the 
carbocyclic amine with 3-ethoxy-N-carboethoxy-2-ethylacrylamide 12 as described 
in Scheme 1.9.6 
	
RNH2 	 H 	 H 
0 N 0 0 N 0 
+ a  10. 	 b  Y 
H NH 









Scheme 1.9 Reagents and conditions: a. Et3N, dioxane; b. 2 M HC1, dioxane, 80% 2 
steps. 
Various substituents can be incorporated at the 5-position of the pyrimidine by 
this approach. 
Cytidine derivatives can be prepared from the uridine analogue 13 by 
ammonolysis of either the 4-chloro 14, 4-methylthio 15 or 4-(1,2,4-triazol-1-yI) 16 
derivatives (Scheme 1.10).' 




0 N Y 0 N NH2 
NJ 	 NJ 
R 	 R 
14 Y= Cl 
15Y=MeS 
16 Y = 1,2,4-triazol-1-yl 
Scheme 1.10 
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1.2.2 Syntheses of chiral carbocyclic rings 
Substantial efforts have been made towards the enantioselective synthesis of the 
carbocyclic ring moiety of carbocyclic nucleosides. Two main approaches have 
been described: 
Synthesis from racemic/achiral compounds such as norbornene and 
cyclopentadiene, which require enzymatic or chemical resolution at some point in 
the synthesis in order to obtain chiral compounds. 
Synthesis using a starting material from the chiral pool e.g. a carbohydrate. 
More recently, the use of asymmetric synthetic methods for the enantioselective 
synthesis of carbocyclic nucleosides have been described.2532 Methods such as 
asymmetric cycloadditions, catalytic asymmetric desymmetrisations and chiral 
auxiliary-based asymmetric reactions have been employed. 
In this thesis, only the approaches that exploit synthesis by enzymatic resolution 
or from the chiral pool will be discussed. 
(a) 	Enantioselective synthesis by enzymatic resolution 
The application of enzymes to organic synthesis is one of the most useful and 
practical methods for the preparation of chiral compounds in high optical purity. 
The enzymatic desymmetrisation of meso intermediates and enzymatic resolution of 
chiral, racemic mixtures have commonly been used for the enantioselective synthesis 
of carbocyclic nucleosides. Desymmetrisation of meso intermediates offers the 
advantage that all the material can be utilised. 
(i) 	Synthesis from bicyclic lactams 
The bicyclic lactam, 2-azabicyclo[2.2. l]hept-5-en-3-one 17, which is derived 
from the cycloaddition product of cyclopentadiene and tosyl cyanide by aqueous 
hydrolysis,"," is a versatile building block in the synthesis of many carbocyclic 
nucleosides. 	Both optically pure forms of the lactam (+)- and (-)-17 are 
10 
HO2C Hjf' .+ 4 NH2 





commercially available and are obtained via enzymatic resolution of the racemic 
azanorbornenone (±)-17 using Pseudomonas fluorescens (ENZA22) or 
Aureobacterium (ENZA25) (Scheme 1.11). The amino acids (+)- and (-)-18 which 
are produced from this enzymatic hydrolysis with high optical purity are also useful 




Scheme 1.11 Reagents and conditions: a. Aureobacterium (ENZA25); b. Pseudomonas 
fluorescens (ENZA22). 
Katagiri et al.2° have developed an efficient synthesis of carbocyclic cyclaridine 
(+)-19, an adenosine deaminase-resistant ara-A derivative, from the laevorotatory 
lactam (-)-17 as shown in Scheme 1.12. 
NE 	 AcO\7'N. 
NHAc 
a, b 	OjAc C, d  
0 	 AcO OAc 
(-)-17 
	
Cl 	 NH2 
J N 





HO OH 	HO OH 	 HO OH 
(+)-19 
Scheme 1.12 Reagents and conditions: a. Ac20, Et3N, DMAP, CHC13, 78%; b. MCPBA, 
CHC13, 68%; c. NaBH4, MeOH; d. Ac20, pyridine, 63% 2 steps; e. 2 M HC1, 70°C; f. 5-
amino-4,6-dichloropyrimidine, Et3N, t-BuOH, reflux, 78% 2 steps; g. CH(OE03, 12 M HC1, 
70%; h. NH3, dioxane, 80°C, 100%. 
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This procedure involves the regioselective cleavage of an epoxide ring by 
neighbouring participation of an N-acyl amino group. 
Elaboration of the bicyclic lactam epoxide into intermediates suitable for the 
synthesis of 2'-deoxy- and 3'-deoxy-cyclopentyl carbocyclic nucleosides has 
recently been reported by Cullis (Scheme 1.13).36 
NHBoc 
a 
N 	 N 
 , b 0- 















HBoc oc N  
TBDMSO '\ cç7fr g H 	 NHB HO'\,Z7.fr 
e 2'-deoxy 
- 	 analogues 
O HO 	 HO 
(+)-24 
Scheme 1.13 Reagents and conditions: a. MCPBA, CH2C12, 71%; b. NaBH4, MeOH, 89%; 
c. Red-Al, toluene, 71%; d. H20, reflux, 100%; e. standard base synthesis; f. TBDMSOTf, 
2,6-lutidine, CH2C12, 97%; g. Red-Al, toluene, 85%. 
The N-Boc bicyclic lactam 20, prepared by treatment of bicyclic lactam (-)-17 
with Boc anhydride, was reacted with MCPBA to give the exo epoxide 21. 
Reduction of 21 with sodium borohydride afforded the cyclopentyl epoxide 22, 
which was converted to cyclopentylamines 23 and 24. These intermediates provide 
a convenient route to 2'-deoxy- and 3'-deoxy- carbocyclic nucleoside analogues.36 
Carbocyclic 2'-deoxy-nucleosides have also been prepared from the 5-exo 
hydroxy lactam 	Compound 26 has been synthesised by Palmer et al.37' 38 using 
either a microbial biohydroxylation of the saturated lactam 27, prepared by 
12 
Introduction 
hydrogenation of the bicyclic lactam (-)-17; or an oxymercuration reaction of the 
unsaturated N-benzyl lactam 25 (Scheme 1.14). 
a, b, c 	 d, e 
TBDMSO 
(-)-25 	 (-)-26 	 (-)-27 
Scheme 1.14 Reagents and conditions: a. Hg(OAc)2, aq. THF; b. NaBH4; c. TBDMSC1, 
imidazole; d. Beauveria bassiana; e. TBDMSOTf, 2,6-lutidine. 
This biohydroxylation has the potential to be developed into a synthetically useful 
procedure for the preparation of multigram quantities of the useful protected alcohol 
2  37 6. 
All previous syntheses of carbocyclic nucleosides from the bicyclic lactam 17 
involve cyclopentylamines as intermediates, which are formed by 2,3-bond fission of 
the lactam 17. These methods have the disadvantage that the time-consuming 
reaction steps associated with purine ring construction result in low overall yields. 
Katagiri and co-workers39 were the first to report the efficient synthesis of carbovir 8 
and abacavir 9 from lactam 17 via ir-allylpalladium complex formation by ring 











5 4 3\\ 	
/ 
Lj2a b NH SO2 




Cl 	 Cl 




HO 	 9 
C) 	 NCHO 
2 	 I 
C6H4(o-NO2) 	 Boc 
Scheme 1.15 Reagents and conditions: a. i. n-BuLi, THF, -78°C; ii. (o-NO2)C6H4SO2C1, 
83%; b. i. Pd[P(Oi-Pr)3]4, THF; ii. 2-(formylamino)-6-chloropurine (Bu4N salt), 55%; c. i. 
NaH, THF, 0°C; ii. Boc20; iii. Mel; d. NaBH4, MeOH; e. AcOH, 72% 5 steps. 
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Activation of the nitrogen of lactam 17 with the electron-withdrawing o-
nitrobenzenesulfonyl group facilitated the palladium catalysed coupling of 2-
(formylamino)-6-chloropurine to give sulfonamide 28. 
The enantiomerically pure bicyclic lactam (+)-17 has also been prepared by 
asymmetric Diels-Alder cycloaddition using a chiral auxiliary.40 
(ii) Synthesis from norbornane-type compounds 
Several approaches for the synthesis of carbocyclic rings from compounds 
possessing the norbornane-type framework have been reported.4143 	The easy 
availability of these types of compounds in large quantities makes them attractive 
starting materials. 
The meso-diacetate 31 has been prepared in five steps from norbornadiene 29 as 
shown in Scheme 
	43 
ba,bIbHO 
	 OH AcO 
	
OAc 
29 	 30 	 31 
AcO\7/OAc 	HO 	 OAc 
OX0 
31 	 (-)-32 
>99% e.e. 
HO 	 OH 
g
AcO 	 OH 
O,X0 	7K0 
30 	 (+)-32 
>99% e.e. 
Scheme 1.16 Reagents and conditions: a. 0s04, NMO; b. acetone-W, 46% 2 steps; C.  03; 
d. NaBH4, 93% 2 steps; e. Ac20, pyridine, 73%; f. Pseudomonas fluorescens lipase, 
phosphate buffer (pH 7.0), 71%; g. Pseudomonasfluorescens lipase, vinyl acetate, 81%. 
14 
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Enzyme-catalysed hydrolysis of the meso-diacetate 31 using Pseudomonas 
fluorescens lipase" afforded the monoacetate (-)-32. The opposite enantiomer (+)-
32 was also prepared by transesterification of the meso-diol 30 using Pseudomonas 
fluorescens lipase.43 This procedure provides a practical route for the synthesis of 
both enantiomers of carbocyclic nucleosides (Scheme 1.16). 
Recently, Suemune et al.45 have used the monoacetate (-)-32 to synthesise the 
intermediate (+)-35 as outlined in Scheme 1.17. 
/0%Y7 y'oH /0 	 OAc 
si a, b, C, 	
Ms Si—(5OH 











Scheme 1.17 Reagents and conditions: a. HC1, THF, 90%; b. TIPDSC12, pyridine, 96%; c. 
MsC1, Et3N, 98%; d. K2CO3, MeOH, 72%; e. CsOAc, DMF, 65%; f. CH2CHOEt, PPTS, 
96%; g. K2CO3, MeOH, 81%; h. Ru02, Na104, 73%; i. DPPA, Et3N, MeOH, 40%; j. i. KOH, 
MeOH; ii. HC1; iii. Ac20, pyridine, 20%. 
In this synthetic route inversion of the stereochemistry at the C-2 position was 
achieved by treatment of the mesylate derivative (+)-33 with cesium acetate with 
subsequent migration of the acetyl group to the primary alcohol to give compound 
(+)-34. 
The cyclopentylamine (+).35 was then used to prepare the anti-HSV active 
carbocyclic analogue of ara-A, (+)-cyclaridine 19, by the stepwise construction of 










(iii) Synthesis from bicyclic lactones 
The hydroxylactone, 4-endo-hydroxy-2-oxabicyclo[3 .3 .O]oct-7-en-3 -one, 39 is a 
common starting material for the synthesis of carbocyclic nucleosides as both 
enantiomers are available in optically pure form by enzymatic resolution. The 
racemic endo-hydroxylactone (±)-39 is prepared by the water-promoted reaction of 
glyoxylic acid 37 with cyclopentadiene 36 to give a 1:4 mixture of lactones 38 and 
39, which can be separated by chromatography.46 The major isomer, (±)-39 is 
resolved by enzymatic esterification to yield the optically pure (-)-acetyl ester (-)-40 
and the (+)-hydroxylactone (+)-39 (Scheme 1.18). Using the same enzyme, the 
acetyl ester (±)-40 can be resolved by hydrolysis in phosphate buffer solution to 
yield the (-)-hydroxylactone (-)-39 and the (+)-acetyl ester (+)-40.' 1,41 
Scheme 1.18 Reagents and conditions: a. H20, 65%; b. Pseudomonasfluorescens lipase, 
vinyl acetate. 
Olivo et al." have reported the synthesis of the bicyclic carbonate 42 from the 
optically pure endo-hydroxylactones 39 to provide a new route to both enantiomers 
of carbovir 8 and 1592U89 9 (Scheme 1.19). This route avoids the protection-
deprotection steps which have been utilised in previous syntheses.48  
The diol (-)-41 has also been synthesised asymmetrically by Crimmins, using a 
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Scheme 1.19 Reagents and conditions: a. LiA1H4, THF, reflux; b. Na104, Et20-H20; c. 
NaBH4, EtOH, 75% 3 steps; d. triphosgene, Et3N, CH2C12, 76%; e. 2-amino-6-chloropurine, 
Pd(PPh3)4, DMSO-THF, 53%. 
Olivo49 have also used the enzymatically resolved hydroxylactone (-)-39 as the 
starting material in a short, enantioselective synthesis of 5' -homo-carbovir 43 and 5'-
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43 R= OH 
44 R = NHCH(CH2)2 
Scheme 1.20 Reagents and conditions: a. PPh3, ZnBr2, DEAD; b. LiA1H4, THF, 90% 2 




This practical methodology can also provide the opposite enantiomer 5'-homo-
carbocyclic nucleosides.49 
The synthesis of carbocyclic uracil polyoxin C 45, in which the 5'-position is 
substituted by an amino acid, from the hydroxylactone (-)-39 has been accomplished 
by Aggarwal et al.24 as outlined in Scheme 1.21. 
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Scheme 1.21 Reagents and conditions: a. ZnBr2, PPh3, DEAD, THF, 60%; b. NaN3, 
DMSO, 87%; c. PPh3, THF-H20, 92%; d. ZC1, NaHCO3, THF-1120, 0°C, 94%; e. uracil, 
HMDS, TMSC1, Pd(PPh3)4, MeCN; f. BnBr, NaHCO3, DMF, 50% 2 steps; g. 0s04, NMO, 
THF, 44%; h. H2, Pd/C, EtOH-H20, 100%. 
This synthesis involves the regio- and stereoselective palladium-mediated 
substitution reaction of an a-amino substituted unsaturated lactone with bis-silylated 
uracil. 
The hydroxylactone (±)-39 has also been resolved chemically by conversion to 
the 2-acetoxypropionate derivative 46 followed by separation of the diastereomers 
by chromatography as shown in Scheme 1.22.6,50 
The enantiomerically pure lactone derivative (-)-46 can then be converted to the 
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Scheme 1.22 Reagents and conditions: a. (S)-O-acetyllactyl chloride, pyridine, 0°C, 91%; 
b. LiA1H4, THF; c. NaT04, Et20-H20; d. NaBH4, MeOH; e. Ac20, DMAP, pyridine, 30% 4 
steps; f. N6-benzoyladenine (Cs salt), Pd(PPh3)4, DMF, 55°C, 43%; g. N6-benzoylcytosine 
(Cs salt), Pd(PPh3)4, DMF, 55°C, 85%. 
(iv) Synthesis via the monoacetate of cyclopent-2-ene-1, 4-diol 
The monoacetate of cis-cyclopent-2-ene- 1,4-diol 49 has commonly been utilised 
for the enantioselective synthesis of carbocyclic nucleosides. Enzymatic hydrolysis 
of the meso-diacetate 48, prepared in two steps from cyclopentadiene 36, using 
Candida antarctica lipase B (Novo SP-435) gave the (1S,4R)-monoacetate (+)-49 in 
high yield and optical purity (Scheme 1.23).' 1,52 
a 	a b ACc%c::yfrOACc HO\yOAc 





50 	 (-)-49 
>99% e.e. 
Scheme 1.23 Reagents and conditions: a. CH3CO3H; b. Pd(PPh3)4; c. Candida antarctica 











Enzyme catalysed transesterification of the meso-diol 50, which was prepared by 
deacetylation of diacetate 48, afforded the (1R,45)-monoacetate (-)-49 in poor yield 
but high optical purity (Scheme 1.23)." 
Recently, Kobayashi et al.53 have described a novel approach to (-)-aristeromycin 
4, which involves the nickel-catalysed coupling reaction of monoacetate (+)-49 and 
lithium borates where the furyl group on the borate is transferred onto the 
monoacetate 49 to produce the trans-1,4-product 51 as illustrated in Scheme 1.24. 
The incorporation of the furyl group results in high stereoselectivity being obtained 
in the subsequent dihydroxylation step. 
Scheme 1.24 Reagents and conditions: a. lithium 2-furylborate, NiC12(PPh3)2, 63%; b. 
(PhO)2P(0)N3, 75%; c. 0s04, NMO, 72%; d. PPTS, Me2C(OMe)2, 92%; e. i. RuC13, Na104; 
ii. CH2N, 80%; f. LiA1H4; g. standard adenine synthesis, 22% 2 steps; h. deprotection. 
Matsuda and co-workers" have used the optically pure monoacetate (+)-49 to 
synthesise carbocyclic nucleoside analogues 52 that have an hydroxyamino group at 




Z H HOHN N 0 
















Scheme 1.25 Reagents and conditions: a. i. TBDPSC1, imidazole, DMF, 0°C; ii. NaOMe, 
MeOH; iii. C1CO2Et, pyridine, 97%; b. N3-benzoylthymine, Pd2(dba)3.CHC13, PPh3, THF, 
94%; c. TBAF, THF, quant.; d. C1CO2Et, pyridine, quant.; e. NH20Bn, HC1, 
Pd2(dba)3.CHCL3, PPh3, NaOH, THF, 94%; f. NaOMe, MeOH, 97%; g. BC13, CH2C12, 91%. 
Compound 52 is a 4'-hydroxyaminated-carbocyclic equivalent of the anti-HIV 
agent 2' ,3 '-didehydro-2' ,3 '-dideoxythymidine (D4T). 	The synthesis of various 
uracil and cytidine derivatives of compound 52 was also achieved. 14 
The opposite enantiomer of the monoacetate (-)-49 has been used to prepare (+) 
5'-noraristeromycin 53, which has been shown to possess anti-viral and anti- 
55 trypanosomal activity with no undesirable toxic side effects (Scheme 1 
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Scheme 1.26 Reagents and conditions: a. i. N6-benzoyladenine, NaH, DMSO; ii. 
Pd(PPh3)4, PPh3, THF, 59%; b. NH3, MeOH, 120°C, 80%; c. 0s04, NMO, THF, H20, 55%. 




(v) 	Synthesis from substituted cyclopentane systems 
The silyloxy alcohol 54, prepared from ethyl-2-oxocyclopentanecarboxylate by 
reduction followed by monosilylation, can be resolved by enzyme-catalysed 
transesterification with vinyl acetate in the presence of Pseudomonas fluorescens 
	
lipase to give both enantiomers in high optical purity.57 	These optically pure 
compounds have been used by Theil et al.58 to prepare both enantiomers of the novel 
carbocyclic nucleoside 55 (Scheme 1.27). 
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Scheme 1.27 Reagents and conditions: a. 6-chloropurine, DEAD, PPh3, THF, 69%; b. 
AcOH, H20, THF, 95%; c. NH3, MeOH, 86%. 
Kato and co-workers" have recently reported the chemoenzymatic synthesis of 
optically active intermediates for the preparation of 4'-alkylcarbovir derivatives. 
The starting material for the synthesis was the cyclopentanone 56 which upon 
conversion to the racemic secondary alcohol (±)-57 was subjected to enzymatic 
esterification to give both enantiomers of the key intermediate 57 as shown in 
Scheme 1.28. 
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Scheme 1.28 Reagents and conditions: a. TMSOTf, Et3N; b. Pd(OAc)2, 02, 91% 2 steps; 
c. NaBH4, CeC6 91%; d. Ac20, pyridine, 100%; e. PdC12(MeCN)2, benzoquinone; f. K2CO3, 
MeOH, 100%; g. lipase "Amano" P, vinyl acetate; h. K2CO3, MeOH, 95%. 
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Either enantiomer of compound 57 can then be converted to the 4'-alkylcarbovir 
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Scheme 1.29 Reagents and conditions: a. i. DHP; ii. LiA1I-14; iii. TBDPSC1; iv. PPTS, 
72%; b. i. 2-amino-6-chloropurine, PPh3, Et02CN=NCO2Et; ii. TBAF, 36%; c. 1 M NaOH, 
95%. 
Intermediate (-)-57 was also prepared by asymmetric synthesis, in which the key 
step was an asymmetric alkylation of a -keto-ester.59 
(vi) Synthesis from cyclic compounds derived from cyclopentadiene 
Ogasawara and co-workers6° have reported the concise synthesis of (-)-neplanocin 
A 5 from the tricyclic ester (±)-59, which is obtained from the Diets-Alder adduct of 
cyclopentadiene and benzoquinone.6' 	The use of a lipase mediated kinetic 
resolution as shown in Scheme 1.30 gave both enantiomers of the diol (-)- and (+)-60 
in 41% yield, 92% e.e. and 46% yield, >99% e.e., respectively.60 
O CO2Et 	 H 	 OR 
OR \OR 
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Scheme 1.30 Reagents and conditions: a. DIBAL-H, toluene, -78°C, 65%; b. Lipase LIP, 
vinyl acetate, t-BuOMe; c. K2CO3, MeOH, 100%. 
The optically pure diol (+)-60 was then converted to (-)-neplanocin A 5 as 
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Scheme 1.31 Reagents and conditions: a. NBS, CH2CL2, 100%; b. TBDMSC1, imidazole, 
DMF, 97%; c. 0s04, NMO, aq. THF, 80%; d. DMP, PPTS, acetone, 100%; e. Zn, AcOH, 
MeOH, 95%; f. Ph20, reflux, 97%; g. i. PDC, CH2C12, 83%; ii. DIBAL-H, toluene, -78°C, 
100%; h. i. adenine, PPh3, THF, diisopropyl azodicarboxylate, 84%; ii. HCl, MeOH, 90%. 
(b) 	Synthesis from the chiral pool 
Many recent syntheses of carbocyclic nucleosides have been accomplished by 
using starting materials from the chiral pool. 
(i) 	Synthesis from carbohydrates 
The use of carbohydrates and their derivatives as chiral building blocks for the 
synthesis of enantiomerically pure non-carbohydrate compounds continues to be an 
area of active investigation, particularly for preparing carbocyclic nucleosides. 
The first asymmetric synthesis of L-cyclopentyl carbocyclic nucleosides was 
reported by Chu et al.,62 who reported the synthesis of (+)--L-aristeromycin 4 and 
its thymine analogue 62 from the (+)-cyclopentenone 61 which can be prepared from 
D-ribose (Scheme 1.32).63  
24 
Introduction 

























Scheme 1.32 Reagents and conditions: a. (t-BuOCH2)2CuLi, t-BuOMe, THF, -30°C, 87%; 
b. DIBAL-H, CH2C12, -78°C, 82%; c. (CF3SO2)20, pyridine, 0°C, 97%; d. adenine, NaH, 18-
crown-6, DMF, 0-20°C, 32%; e. CF3CO2H:H20 (2:1), 50°C, 80%; f. CH3SO2C1, Et3N, 
CH2C12, 0°C, quant.; g. LiN3, DMF, 140°C, 89%; h. 5% Pd/C, EtOH; i. -methoxy-a-
methacryloyl isocyanate, DMF, -20°C to 20°C, 88% 2 steps; j. 30% NH40H, EtOH, 80-
100°C, 85%; k. CF3CO2H:H20 (2:1), 50°C, 79%. 
Chu and co-workers64 have also described the synthesis of carbocyclic 13-L-2',3'- 
didehydro-2',3'-dideoxyadenosine (134A) 63 and its analogues, again starting from 
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Scheme 1.33 Reagents and conditions: a. BzC1, pyridine, 93%; b. conc. HC1, MeOH, 
93%; c. CH(OMe)3, PPTS; d. Ac20, 120-130°C, 68% 2 steps; e. 2 M NaOH, MeOH, 93%; f. 
6-chioropurine, PPh3, DEAD, dioxane, 35%; g. NH3, MeOH, 80-90°C, 83%; h. 
CF3CO2H:H20 (2:1), 50'C, 93%. 
L-Carbocyclic nucleosides are of particular interest as a number of L-nucleosides 
have proven to be of great importance as anti-viral and anti-tumour agents. Some of 
these L-nucleosides are more potent and less toxic than their D-counterparts.62'64 
The commercially available D-ribonolactone is also a useful starting material for 
the synthesis of optically pure carbocyclic nucleosides. Jeong et al. ' 8 have used this 
compound for the preparation of the novel cyclopropyl-fused carbocyclic nucleoside 
65, in which the bicyclic system was introduced by Simmons-Smith 
cyclopropanation as shown in Scheme 1.34. 
Bicyclic carbocyclic nucleosides are of interest because if the orientation of the 
fused ring is correct, its effect is to freeze the conformation of the 5-membered ring 
into that required for optimum binding to enzyme substrates and therefore improve 
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Scheme 1.34 Reagents and conditions: a. LiCH2P(0)(OCH3)2; b. NaOCH3; c. Cr03-
pyridine; d. K2CO3, 18-crown-6; e. NaBH4, CeC13; f. ZnICu, CH212, 73%; g. PTSA, acetone, 
56°C, 57%; h. TPAP, NMO, CH2C12, 100%; i. CH3P(C6H5)3Br, n-BuLi, THF, 0°C, 90%; j. 
BH3-THF, NaB03-H20, 99%; k. i. BnBr, NaH; ii. 1 M HC1, MeOH-THF, 88%; 1. Et3N, 
SOC12, 0°C, 80%; m. adenine, NaH, DMF, 18-crown-6, 50%; n. i. CS2, CH3I, NaH; ii. EtB, 
n-Bu3SnH; iii. Pd black, HCO2H, 61%. 
The syntheses of the uracil, cytosine and guanosine derivatives of compound 65 
via the cyclic sulfite 64 are also described." 
A novel method for the preparation of aminocyclopentanetriol 66 from D-
ribonolactone, in which the key step is a tributyltin hydride mediated free radical 
cyclisation, has been reported by Marco-Contelles et al. (Scheme 1.35).66 
The purine or pyrimidine base can then be constructed onto intermediate 66 by 





HO 0 O 	HO,,,) 
D-ribonolactone 	a 	\/ 	b, c, d 	\,/ 	e 
° X 0X0 







Scheme 1.35 Reagents and conditions: a. acetone, PTSA, quant.; b. 12, PPh3, imidazole, 
50%; c. DIBAL-H, toluene, -78°C, 77%; d. BnONH3C1, pyridine, 76%; e. n-Bu3SnH, AIBN, 
toluene, 75%; f. PPh3, DEAD, p-nitrobenzoic acid, 78%; g. NaOCH3, MeOH, 90%; h. 
LiA1H, THF, 58%. 
As a carbohydrate precursor D-glucose is very useful due to its ready availability. 
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Scheme 1.36 Reagents and conditions: a. AcOH, 55°C; b. Na104, EtOH; c. Ph3PCH3I, n-
BuLi, -60°C, 66%; d. H2SO4  in CH3CN-H20, 60-65°C; e. PhCH2NHOH, EtOH, 74%; f. 
LiA1H4, THF, reflux; g. Pd/C, cyclohexene, EtOH, 91%; h. 5-amino-4,6-dichloropyrimidine, 
Et3N, n-BuOH, reflux, 43%; i. HC(OE03, PTSA, DMF, 44%;j. NH3, MeOH, 100°C, 80%. 
Mandal and co-workers67 have recently reported the use of an intramolecular 
nitrone cycloaddition (INC) for converting D-glucose into enantiomerically pure 
	
functionalised five-, six-, and seven- membered carbocycles. 	Using this 
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methodology the five-membered chiral trihydroxy-aminocyclopentane 67 has been 
efficiently synthesised and converted to the aristeromycin analogue 68 as described 
in Scheme 1.36.68 
Mandal69 has also described a simple method for the preparation of the pair of 
enantiomers of the carbocylic nucleoside 69 starting with enose-nitrones derived 
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Scheme 1.37 Reagents and conditions: a. 10% Pd/C, EtOH, reflux, 88%; b. 5-amino-4,6-
dichioropyrimidine, Et3N, n-BuOH, reflux, 80%; c. HC(OEt)3, PTSA, DMF, 20°C, 53%. 
Lundt et al.71 have reported the synthesis of the polyhydroxylated 
aminocyclopentane 72 from the bicyclic lactone 70 as shown in Scheme 1.38. The 
bicyclic lactone 70 was prepared by stereoselective radical induced carbocyclisation 
of o-bromo-a-,13-unsaturated heptonolactones.72 
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Scheme 1.38 Reagents and conditions: a. i. HBr, AcOH; ii. AcO, 85%; b. HC1, MeOH, 
quant.; c. K2CO3, acetone, 97%; d. NaN3, NH4C1, DMF, 90°C, 73%; e. H2, Pd/C, HC1, EtOH, 
67%; f. Ca(BH4)2, EtOH, 57%. 
Lundt7' also described the synthesis of a stereoisomer 73 of aminocyclopentane 
72 from bromohydrin 71 as shown in Scheme 1.39. 
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Scheme 1.39 Reagents and conditions: a. NaN3, DMF, 80°C, 35%; b. H2, Pd/C, HC1, 
EtOH, quant.; c. i. HMDS, TMSC1, CH3CN, reflux; ii. BH3.SMe2, dioxane, 76%. 
The aminocyclopentanes 72 and 73 can be converted into carbocyclic nucleosides 
by standard procedures. 
(ii) Synthesis from iridoids 
Franzyk et al.' 5 have used chiral building blocks derived from the iridoid 
glucosides, antirrhinoside 74 and catalpol 77 to prepare optically pure carbocyclic 
nucleosides via polysubstituted cyclopentylmethanols. The interconvertible cyclo- 
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pentylmethanols 75a and b were synthesised in 5 steps from antirrhinoside 74 before 
being converted via a Mitsunobu reaction to the carbocyclic nucleoside 76 as 
outlined in Scheme 1.40.' 
NH2 
HO 	 RO OH 	 N 
Ref. 73 0IIID.,,OH  
b 	
N' 
OG1c 	 - 	 HO OH 
75a R = Bz, R' = H 
74 	 + 	 76 
75b R = H, R' = Bz 
Scheme 1.40 Reagents and conditions: a. 6-chioropurine, PPh3, DEAD, THF; b. NH3, 
45°C, 41% 2 steps. 
Franzyk'5 also reported the synthesis of the functionalised cyclopentane 78 from 
	
the iridoid glucoside, catalpol 77. 	In this case the heterocyclic base was 
incorporated directly via displacement of a triflate as shown in Scheme 1.41. 
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Scheme 1.41 Reagents and conditions: a. -g1ucosidase, H20; b. NaBH4, 82% 2 steps; c. 
BzC1, pyridine, CH2C12, -78°C, 60%; d. (CF3SO2)20, pyridine, CH2C12; e. 6-iodopunne 
(Bu4N salt), CH2C12, -10°C, 73%; f. NH3,  45'C, 86%. 
(iii) Synthesis from monoterpenoids 
Bianco and co-workers74 have rejorted the synthesis of a novel carbovir analogue 
80 from the monoterpenoid aucubin 79, a methyl-cyclopentanoid glucoside present 
in large quantities in plants of Aucuba genus (Scheme 1.42). 
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Scheme 1.42 Reagents and conditions: a. i. Hg(OAc)2, NaBH4 or ii. 3-g1ucosidase, 
NaBH4, 90%; b. Isobutyric anhydride, pyridine, 90%; c. Ac20, pyridine, 99%; d. i. uracil, 
CH3CN, TMSC1, HMDS; ii. SnC1, 56%; e. DIBAL-H, CH2C12, -78°C, 95%. 
1.2.3 Summary 
The synthesis of enantiomerically pure carbocyclic nucleosides has advanced in 
recent years with a variety of new, efficient approaches being developed. The use of 
syntheses which rely on enzymatic resolution have been particularly useful 
especially with the recent low cost, commercial availability of the key chiral 
intermediates. However, new, more efficient syntheses are still required because of 
the great demand for anti-viral and anti-tumour agents. 
A further area of interest is the biosynthesis of the naturally occurring carbocyclic 
nucleosides aristeromycin 4 and neplanocin A 5 by the organism Streptomyces 
citricolor. Elucidation of the biosynthetic pathway would allow for the preparation 
of novel analogues of carbocyclic nucleosides, whilst selective blocking of the 
pathway could provide useful chiral intermediates that would be difficult to prepare 
by alternative chemical procedures. The studies which have been carried out 
towards the elucidation of this pathway will be discussed in Section 1.3. 
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1.3 The Naturally Occurring Carbocyclic Nucleosides Aristeromycin and 
Neplanocin A 
Aristeromycin 4, which is the carbocyclic analogue of adenosine, was first 
isolated in 1967 from the fermentation broth of Streptomyces citricolor having been 
previously synthesised in racemic form.2'75 Subsequently in 1981 neplanocin A 5 
and some closely related compounds were isolated from cultures of Ampullariella 
regularis and more recently neplanocin A has been shown to be co-produced 
alongside aristeromycin by Streptomyces citricolor. 1,71 
As a result of their close structural relationship to natural nucleosides, 
aristeromycin and neplanocin A have been shown to possess potent biological 
activity.',' For example, neplanocin A displays anti-viral and anti-tumour activity 
and both aristeromycin and neplanocin A have been shown to inhibit the enzyme S-
adenosyl-L-homocysteine hydrolase, which plays an important role in regulating 
biological methylation reactions.77 
Due to their potential as therapeutic agents, aristeromycin and neplanocin A have 
attracted considerable synthetic interest which includes several reports of their total 
syntheses, the most recent of which have been described in Section 1.2. 
1.3.1 The biosynthesis of aristeromycin and neplanocin A by Streptomyces 
citricolor 
The biosynthesis of aristeromycin and neplanocin A first received attention in the 
mid 1980's by R. J. Parry et al. and through a combination of their work and from 
more recent studies carried out by N. J. Turner et al. the pathway shown in Figure 
1.2, for the biosynthesis of aristeromycin 4 and neplanocin A 5 from D-glucose 81 by 
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Figure 1.2 	Proposed pathway for the biosynthesis of aristeromycin and 
neplanocin A by Streptomyces citricolor 
The studies that have led to this proposed biosynthetic pathway are outlined 
below. 
(a) 	Origin of the cyclopentane ring 
Early biosynthetic studies carried out by Parry et al. established that the 
carbocyclic skeleton of 4 and 5 was derived from D-glucose 81.76,79  Through a series 
of feeding experiments using isotopically labelled precursors, it was established that 
formation of the carbocyclic ring in aristeromycin results from C-C bond formation 
between the C-2 and C-6 carbon atoms of D-glucose 81. Additionally, Parry 
deduced that the cyclisation proceeded with loss of the 6-pro-S hydrogen atom.76 
In addition to these initial feeding experiments, Parry and Johnson reported the 
preparation of the putative intermediates 85 and 86, and by isotope dilution studies, 
concluded that the saturated tetrol 85 and the aminotriol 86 might be intermediates 






Work within the Turner group involved the use of a series of mutants of 
Streptomyces citricolor developed by GlaxoWeilcome, that were blocked in their 
ability to synthesise either neplanocin A or aristeromycin. However, the production 
of aristeromycin and neplanocin A could be rescued by combinations of certain 
mutants in which the supernatant from cultures of one mutant (secretor) were added 
to a culture of a second mutant (converter). Such cosynthesis experiments identified 
a secretor/converter pairing in which mutant CC914 secreted a compound that 
supported the production of neplanocin A and aristeromycin in a second mutant 
CC940. The structure of this compound was determined to be the unsaturated tetrol 
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Figure 1.3 	Cosynthesis experiments using mutants of Streptomyces citricolor 
Further evidence for the participation of tetrol 83a in the biosynthesis was 
obtained by '3C-isotopic labelling experiments.83 
Further putative intermediates were synthesised and fed to the converter mutant 
CC940. Those compounds that supported aristeromycin production were deemed to 
lie on the biosynthetic pathway. Through these studies it was established that the 
cyclopentenone 82a was an intermediate on the biosynthetic pathway. However, 
when the C-1-epi-tetrol 87, aminotriol 88, saturated tetrol 85 and aminotriol 86 were 
prepared and fed to converter mutant CC940, there was no production of 
aristeromycin or neplanocin A.83 These observations suggest that contrary to the 
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previous proposal by Parry and Johnson, the saturated tetrol 85 and aminotriol 86 do 






(b) 	Mechanism of conversion of D-glucose to the cyclopentane ring 
The processes by which nature is able to convert carbohydrates to 6-membered 
carbocyclic rings is now well understood owing to the detailed studies that have been 
carried out on the biosynthesis of inositols and shikimic acid.78 By comparison, 
very little is known about the way in which carbohydrates are enzymatically 
converted to 5-membered carbocyclic rings. There are only four examples in the 
literature, including aristeromycin and neplanocin A, for which any biosynthetic 
studies have been reported. 	Pactamycin 89 which has been isolated from 
Streptomyces pactam var. pactam; bacteriohopanetetrol 90 which was isolated from 
Methylobacterium organophilum, Rhodopseudomonas acidophilia, and Zymomonas 
mobilis; and allosamidin 91 isolated from a Streptomyces sp. However, in contrast 
to the biosynthesis of neplanocin A and aristeromycin where the carbocyclic ring is 
formed between C-2 and C-6 of D-glucose; in the case of pactamycin 89, 
bacteriohopanetetrol 90 and allosamidin 91, the carbocyclic ring is formed between 
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By analogy with the shikimate biosynthetic pathway,78 it is possible to suggest the 
route from D-glucose 81 to the cyclopentenone 82a shown in Figure 1.4. 
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Figure 1.4 	Proposed route for the conversion of D-glucose to the carbocyclic ring 
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In this route D-glucose 81 is converted to fructose-6-phosphate 92 which 
undergoes oxidation at C-4 to give 93. Elimination of phosphate from 93 followed 
by reduction at C-4 yields the enol 94 which would undergo an intramolecular aldol 
cyclisation to give the keto-tetrol 95 which would then undergo elimination to 
cyclopentenoñe 82a, which is a known intermediate on the biosynthetic pathway. 
Indirect evidence has been obtained for the possible participation of some of the 
intermediates between 81 and 82a.84 Direct evidence could be obtained by the 
synthesis of keto-tetrol 95, phosphates 92 and 93, and diketone 94 and feeding to 
converter mutants of Streptomyces citricolor. 
(c) 	Origin of the adenine base 
By comparison to previously published work on purine biosynthesis," isotopic 
labelling studies carried out by Parry's group" suggested that the adenine ring is 
derived from de novo purine biosynthesis i.e. the adenine ring is biosynthesised by 
stepwise construction of the adenine ring on a carbocyclic analogue of 5-
phosphoribosyl pyrophosphate containing a pre-existing amino group at C-i (96). 
However, some evidence was obtained for the operation of a salvage pathway in 
which the adenine ring is incorporated intact i.e. the adenine ring is incorporated 









In order to probe further the origin of the adenine ring, studies carried out by 
Turner et al.83 centred on the isolation of mutants of Streptomyces citricolor that 
were defective in purine biosynthesis and required exogenous addition of adenine in 
order for normal growth to occur. One such mutant, cc268, was grown on a 
defined medium containing 8-13C-adenine as the only source of purines. The 
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labelled aristeromycin that was produced contained the '3C label only at C-8 in the 
adenine ring (approx. 75% incorporation) as shown in Figure 1.5, therefore 
establishing the existence of a pathway in which adenine can be incorporated intact 
into aristeromycin. However, it was also shown that 1-"C glycine could function as 
a precursor leading to the production of 4-13C aristeromycin (approx. 20% 
incorporation) as shown in Figure 1.5. This observation may be due to some 
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Figure 1.5 	Origin of the adenine base in aristeromycin 
Further evidence for the operation of a salvage-type pathway has been obtained 
by recent studies carried out within the Turner group.86 	'4C-labelled adenine 
together with tetrol 83a were fed to the converter mutant CC940. After incubation 
at 30°C for 24 hours, the incorporation of labelled adenine into neplanocin A (3.6% 
based on radioactive yield) was suprisingly high given the level of incorporation 
previously reported by Parry. 76 
These results strongly support the direct incorporation of adenine as the major 
route to aristeromycin, whilst the involvement of a de novo pathway cannot be 
completely eliminated. In addition, direct incorporation of the adenine base via the 




(d) 	Conversion of neplanocin A to aristeromycin 
The co-production of neplanocin A and aristeromycin in cultures of the wild-type 
Streptomyces citricolor suggested that these two metabolites, differing only in the 
presence of a double bond between C-4' and C-6', might be closely related on the 
biosynthetic pathway. Furthermore, mutant strains were isolated which produce 
increased levels of neplanocin A relative to aristeromycin. Preliminary experiments 
had also shown that a number of mutants which were unable to produce either 
aristeromycin or neplanocin A, were able to convert added neplanocin A into 
aristeromycin." However, the observations of Parry, in which evidence for the 
participation of the saturated intermediates 85 and 86 was obtained, suggested that 
neplanocin and aristeromycin might be biosynthesised along independent parallel 
biosynthetic routes.80'8' 
In order to establish whether or not the normal biosynthetic route to aristeromycin 
by Streptomyces citricolor proceeded via neplanocin A by saturation of the double 
bond, studies within the Turner group were stimulated by an earlier experiment 
reported by Parry.79 Using wild-type Streptomyces citricolor, Parry showed that 6-
2H2-D-glucose was converted to 6'-2H-aristeromycin in which the deuterium atom 
was located only in the 6'-pro-S site as shown in Figure 1.6. 
Furthermore, by feeding tritium labelled forms of D-glucose Parry concluded that 
the cyclisation reaction proceeded with loss of the 6-pro-S hydrogen atom of D-
glucose and that the 6-pro-R atom of D-glucose became the 6'-pro-S hydrogen atom 
in aristeromycin. 
An analogous experiment was carried out by Turner et al.83 using a mutant of 
Streptomyces citricolor (CC 1026) which produced neplanocin A but no 
aristeromycin. Administration of 6-2H2-D-glucose to the CC 1026 mutant gave 6'-
2H-neplanocin A. This material was then fed to a second mutant (CC826) which 
was blocked in the production of both aristeromycin and neplanocin A and was also 
able to act as an efficient converter of neplanocin A to aristeromycin. The 6'-2H-
aristeromycin isolated from this experiment was stereochemically identical to that 
derived from the 6-2H2-D-glucose experiment as shown in Figure 1.6, which 
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Figure 1.6 	Stereochemistry of deuterium incorporation into aristeromycin 
Further evidence for the direct conversion of neplanocin A to aristeromycin was 
obtained by Parry using cell-free extracts of wild-type Streptomyces citricolor.87 
Parry demonstrated that a partially purified cell-free extract was able to catalyse the 
NADPH-dependent reduction of neplanocin A to aristeromycin. Furthermore, it 
was shown that the reaction proceeded with anti-geometry and involved the transfer 
of the 4-pro-R hydrogen atom of NADPH to the 6'13  position of aristeromycin as 



















Figure 1.7 	Conversion of neplanocin A to aristeromycin using a cell-free extract 
of Streptomyces citricolor 
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This result, which is consistent with those described above, suggested that the 
mechanism of conversion of neplanocin A 5 to aristeromycin 4 may involve initial 
oxidation of the C-5 hydroxymethyl group of neplanocin A 5 to the corresponding 
unsaturated aldehyde 97, followed by conjugate reduction to the aldehyde 98, and 
then reduction of the aldehyde 98 back to the alcohol to yield aristeromycin 4 as 
outlined in Figure 1.8. 
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Figure 1.8 Proposed mechanism for the reduction of neplanocin A to 
aristeromycin 
Supporting evidence for the operation of the mechanism shown in Figure 1.8 was 
obtained by Turner et al.84 By feeding deuterium labelled U-2H7-D-glucose Turner 
et al. have been able to map out the fate of all the C-H bonds of D-glucose during 
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Figure 1.9 Summary of source of all C-H bonds in aristeromycin 
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In this experiment, the level of deuteration at C-6'S and C-3' showed that no loss 
of the deuterium label had occurred which indicated that these C-H bonds were 
retained intact from D-glucose. At C- I', C-2', C-5' and C-6'R, however, the level 
of deuterium incorporation was much lower which suggested that carbon-deuterium 
bond cleavage occurred somewhere along the pathway, followed by partial 
reintroduction of deuterium via NAD2H. The observed partial deuterium 
incorporation at C-6'R and complete wash-out at C-5' agreed with previous 
experiments reported by Parry" and supported the proposed mechanism for the 
reduction of neplanocin A to aristeromycin shown in Figure 1.8. Furthermore, at C-
1' and C-2' the observed low level of deuterium incorporation was consistent with 
the participation of the biosynthetic intermediates 82a and 93, respectively. No 
incorporation of deuterium was observed at the C-4' position which suggested that 
this hydrogen was derived from water. 
(e) 	Conclusions and future experiments 
Consideration of the results outlined above has led to the proposed pathway 
shown in Figure 1.2 for the biosynthesis of aristeromycin and neplanocin A by 
Streptomyces citricolor. 
Although the core of the biosynthetic pathway is known, many issues remain to 
be resolved concerning the exact detail of the biosynthesis, in particular: 
the identity of the intermediates between D-glucose 81 and the cyclopentenone 
82a. 
the exact nature of the intermediates 83b, 84a and 84b, and in particular the exact 
identity of the precursor that undergoes the addition of the adenine base. 
the mechanism of reduction of neplanocin A to aristeromycin. 
1.4 Aims 
The aim of this project was to investigate two aspects of the biosynthesis, namely: 
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the mechanism of conversion of D-glucose 81 to the cyclopentenone 82a, by 
identification of the first formed carbocyclic intermediate on the biosynthetic 
pathway. 
the transformation of tetrol 83a to neplanocin A 5 i.e. the incorporation of the 
purine base, by identification of the phosphorylated intermediates prior to 
neplanocin A. 
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2 Investigations into the Conversion of D-Glucose to the 
Carbocyclic Ring - Identification of the First Formed 
Carbocyclic Intermediate 
Of considerable interest in the biosynthetic pathway is the nature of the 
intermediates between D-glucose 81 and the cyclopentenone 82a. By analogy with 
the biosynthesis of shikimic acid it is possible to suggest the route from D-glucose 81 
to the cyclopentenone 82a shown in Figure 1.4, in which the key step is the 
intramolecular aldol cyclisation of enol 94 to keto-tetrol 95. From this pathway it 
can be speculated that the keto-tetrol 95 provides the crossover point from acyclic to 
cyclic intermediates and therefore the synthesis of this novel compound became the 
initial goal of the project. 
2.1 	Synthesis of the Proposed First Carbocyclic Intermediate Using a Starting 
Material from the Chiral Pool 
2.1.1 Retrosynthetic analysis 
(a) 	The Fujimoto-Belleau reaction 
The Fujimoto-Belleau reaction, first described in 1951, involves the reaction of a 
nucleophile e.g. a Grignard reagent with an exocyclic y-enol-lactone to give a 
hydroxycyclohexanone derivative." The reaction proceeds by initial attack of the 
nucleophile at the carbonyl centre followed by ring opening to give an enolate at one 
terminus and a carbonyl at the other. Intramolecular aldol cyclisation then affords 
the 3-hydroxycyclohexanone as shown in Figure 2.1. 
Nuc 	 Nuc 	T Nuc 
Figure 2.1 	Mechanism of the Fujimoto-Belleau reaction 
45 
Results and Discussion 
The Fujimoto-Belleau reaction to produce cyclohexanone derivatives has been 
well documented due to its common use in the total synthesis of steroids." By 
comparison, the corresponding reaction to produce five-membered rings is relatively 
rare. However, Manger and Prasit89 have reported the use of this methodology to 
prepare enantiomerically pure cyclopentanones. The Fujimoto-Belleau reaction on 
the enol-lactone ent-99, derived from D-ribonolactone, gave the 3-hydroxy-
cyclopentanone 100 which upon dehydration afforded the synthetically useful 
cyclopentenone 61 as outlined in Scheme 2.1. 
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Scheme 2.1 Reagents and conditions: a. 4 steps, 67%; b. i. LiA1H(t-BuO)3, THF, 0°C; ii. 
aq. NH4C1; c. MsC1, pyridine, CH2C12. 
This transformation provides a useful synthetic route to a carbocyclic nucleus 
from a carbohydrate precursor. 
(b) 	Retrosynthetic plan 
The desired keto-tetrol 95 is structurally related to the 3-hydroxycyclopentanone 
100. By analogy to the synthesis of compound 100, it was envisioned that the keto-
tetrol 95 could be prepared according to the retrosynthetic plan shown in Scheme 
2.2, in which the key step is the Fujimoto-Belleau reaction on the enol-lactone 99 to 
yield the protected derivative 101. 
A potential problem in the synthesis of the keto-tetrol 95 was the expected 
tendency for the product to undergo 13-elimination of water to give the enone 82a. 
The initial work in this area was carried out by I. V. J. Archer, a post-doctoral 
research assistant within the group. 	Archer successfully developed routes to 
intermediates for the preparation of the keto-tetrol 95 and its enantiomer ent-95 
using L-ribose and D-ribonolactone respectively as starting materials. Therefore, the 
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initial aim was to repeat this chemistry and scale-up the steps already developed to 
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Scheme 2.2 
2.1.2 Synthesis of ent-keto-tetrol ent-95 
In order to establish the viability of the proposed synthetic route, the synthesis of 
the ent-keto-tetrol ent-95 was attempted first using the readily available D-
ribonolactone ent-102 as the starting material, rather than the expensive L- 
ribonolactone 102. 	The ent-keto-tetrol ent-95 has the incorrect absolute 
stereochemistry for incorporation into neplanocin A and aristeromycin. However, it 
was felt that it would be a useful substrate for comparative feeding studies alongside 
keto-tetrol 95. These feeding studies are discussed in Section 2.4. 
The ent-keto-tetrol, (2S,3R,45)-4-hydroxymethyl-2,3 ,4-trihydroxy-cyclopentan- 1-
one ent-95 was prepared from D-ribonolactone ent-102 as shown in Scheme 2.3. 
D-ribonolactone ent-102 was firstly protected as its 2,3-acetonide derivative ent-
103. The iodide ent-105 was then formed in 70% overall yield by tosylation of the 
alcohol and then displacement of the tosylate group of ent-104 using sodium iodide 
in refluxing acetone. These reactions were performed successfully on a large scale 
starting from 10 g of D-ribonolactone ent-102 to give 13 g of the iodide ent-105. 
Using methodology based loosely on that of Manger and Prasit,89 elimination of 
HI from iodide ent-105 with DBU followed by filtration by canular gave a solution 
of the enol-lactone ent-99 in anhydrous THF, which was used in the next step 
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Scheme 2.3 Reagents and conditions: a. acetone, PTSA, 99%; b. TsCI, pyridine, CHC13, 
80%; c. NaT, acetone, reflux, 85%; d. DBU, THF; e. i. n-BuLi, Bu3SnCH20PMB 108, THF, - 
78°C; ii. aq. NH4C1, 35%; f. H2, Pd/C (10%), THF, 68%; g. TFA:CH2C12 (1:4),26%. 
[(p-Methoxybenzyloxy)methyl]tri-n-butylstannane 108, the synthesis of which is 
described in Section 3.2.2, was transmetallated with n-BuLi at low temperature to 
afford the alkyl lithium species to which the enol-lactone ent-99 solution was added 
via canular. Work up by quenching at -78°C with saturated aqueous ammonium 
chloride solution gave the desired J3-hydroxycyclopentanone ent-106 as a single 
diastereomer in 35% yield as illustrated in Scheme 2.4. 
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Scheme 2.4 
Confirmation of the stereochemistry of the diastereomer ent-106 was obtained 
from preliminary studies carried out by Archer. When developing the synthetic 
route to the keto-tetrol, initially [(methoxymethoxy)methyl]tri-n-butylstannane 110 
was used in the Fujimoto-Belleau reaction to give the MOM-protected 13-











Scheme 2.5 Reagents and conditions: a. i. Bu3SnCH20CH20CH3 110, n-BuLi, THF, - 
78°C; ii. aq. NH4C1, 52%. 
Purification of compound ent-109 by column chromatography gave a crystalline 
solid whose relative stereochemistry was determined by X-ray crystallography. By 
analogy with this result the absolute stereochemistry of the PMB-protected 
compound ent-106 was assigned. 
The reason for the formation of the 4S diastereomer ent-109 in preference to the 
4R diastereomer was unclear. However a possible explanation for this observation 
is illustrated in Figure 2.2. 
Chelation of the metal cation occurs between the electron rich oxygen atom of the 
MOM ether and the oxygen atom of the acetonide group. Therefore the CH20MOM 
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and the acetonide group end up on the same, more hindered face which results in 







Figure 2.2 Proposed mechanism for the preferential formation of the 4S 
diastereomer of the -hydroxycycIopentanone 
The cyclopentanone ent-106 was typically isolated in yields in the range of 25% 
from iodide ent-105. One reason for this low yield is possibly due to the fact that 
the stannane 108, when lithiated, can undergo an intramolecular Wittig 
rearrangement as shown in Scheme 2.6, to give compound 111 which was isolated 












It was thought that the formation of this by-product could be reduced in a number 
of ways. Firstly, by keeping the temperature of all solutions at -78°C. Secondly, 
by stirring the lithiated stannane solution for no more than five minutes and finally, 
by the very quick addition of the cooled enol-lactone solution to the lithiated 
stannane solution. 	By taking these factors into account the yield of 3- 
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hydroxycyclopentanone ent-106 was increased to 35%, which although not a vast 
increase did make a significant difference to the amount of product obtained. 
Archer investigated a number of different methods for the deprotection of the p-
methoxybenzyl group from the -hydroxycyclopentanone ent-106, including the use 
of DDQ and cerium(IV) ammonium nitrate. However, application of these methods 
resulted in the elimination of water from compound ent-106 to give the conjugated 
a,-unsaturated ketone. Removal of the p-methoxybenzyl group was ultimately 
achieved under mild conditions by catalytic hydrogenation to give the acetonide-
protected diol ent-107 in 68% yield. Treatment of the protected diol ent-107 with 
trifluoroacetic acid in dichioromethane gave the desired keto-tetrol ent-95 in 26% 
yield. However, due to the tendency of this compound to undergo p3-elimination of 
water the keto-tetrol ent-95 was contaminated with minor traces of the eliminated 
compound enone ent-82a (approximately 47:1 mixture of ent-95:ent-82a, 
determined by 250 MHz 'H NMR analysis) as shown in Scheme 2.3. The optimum 
conditions for the TFA deprotection reaction were stirring the protected diol ent-107 
in a 1:4 mixture of trifluoroacetic acid:dichloromethane for three minutes before 
quickly concentrating the solution and then purification by column chromatography. 
In this case although the yield of desired product obtained was poor the product was 
contaminated with only a trace of the eliminated compound. 
It also appeared that elimination of the -hydroxycycIopentanone type 
compounds occurred during their purification due to the acidity of the silica used in 
column chromatography. In order to reduce the acidity of the silica, the column was 
washed before use with the desired eluent containing a small amount of 
triethylamine (2 ml in 500 ml of eluent). However, this appeared to have a 
detrimental effect and resulted in further elimination taking place. 
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2.1.3 Synthesis of keto-tetrol 95 
(a) 	Attempted synthesis from D-lyxose 
Having established a viable synthetic route to the enantiomer of the keto-tetrol 
ent-95, Archer attempted to prepare the desired keto-tetrol 95 from D-lyxonolactone, 
for which syntheses have been reported in the literature.90'9' However, the synthesis 
of D-lyxonolactone proved problematic and even with D-lyxonolactone in hand it 
was not possible to selectively protect the 2,3 positions by acetonide formation due 
to the preferential formation of the 3,5-acetonide - despite literature reports to the 
contrary.92 Archer did however achieve the synthesis of 2,3-0-isopropylidene-D-
lyxonolactone 113 from D-lyxose 112, and using the same conditions as previously 

















Scheme 2.7 Reagents and conditions: a. acetone, H2SO4,  quant.; b. TBDMSC1, 
imidazole, 80%; c. KMn04, 79%; d. HF, 73%; e. i. TsC1, pyridine; ii. Nal, acetone, 70%. 
Unfortunately, elimination of HI from the iodide 114 was not possible, probably 
due to its inability to adopt a conformation in which the iodine and hydrogen atoms 
to be removed are anti-periplanar to each other as shown in Figure 2.3. 
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Figure 2.3 Mechanism of HI elimination 
(b) 	Synthesis from L-ribose 
In view of the successful synthesis of ent-95 using D-ribonolactone as the starting 
material it was concluded that the preparation of the desired keto-tetrol 95 could only 
be achieved by the use of L-ribose as the starting material. L-ribose, although very 
expensive, is commercially available. Using the synthetic route shown in Scheme 
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Scheme 2.8 Reagents and conditions: a. acetone, H2SO4, quant.; b. TBDMSC1, 
imidazole, 80%; c. KMn04, acetone, 78%; d. 48-51% HF, MeCN, THF, 78%; e. i. TsC1, 
pyridine; ii. Nal, acetone, 70%. 
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The iodide 105 prepared by Archer was then used to prepare the desired keto-
tetrol 95 using the previously developed methodology as illustrated in Scheme 2.9. 
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Scheme 2.9 Reagents and conditions: a. DBU, THF; b. i. n-BuLi, Bu3SnCH20PMB 108, 
THF, -78°C; ii. aq. NH4C1, 55%; c. H2, Pd/C (10%), THF, 57%; d. TFA:C112C12 (1:4),40%. 
Elimination of HI from iodide 105 was achieved by treatment with DBU followed 
by filtration via canular to give a solution of the enol-lactone 99 in THF. [(p-
Methoxybenzyloxy)methyl]tri-n-butylstannane 108 was treated with n-BuLi and the 
enol-lactone 99 solution was added quickly to this via canular to give after work up 
the protected 3-hydroxycyclopentanone 106 in 55% yield. The yield obtained 
(55%) was significantly better than for the enantiomeric D-series, which was thought 
to be due to the very rapid addition of the enol-lactone solution to the lithiated 
stannane solution. 	Verification of the stereochemistry of the newly formed 
stereocentre in -hydroxycyclopentanone 106 was obtained by 'H NMR nOe 
experiments, the results of which are discussed in Section 2.2.2 and illustrated in 
Figure 2.4. 
The PMB-protecting group was removed from compound 106 by catalytic 
hydrogenation to give the protected diol 107 in 57% yield. 
Treatment of the diol 107 with trifluoroacetic acid gave the desired keto-tetrol 95 
in 40% yield. As before the keto-tetrol 95 was contaminated with minor traces of 
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the enone 82a (approximately 10:1 mixture of 95:82a, determined by 600 MHz 1H 
NMR analysis). 
2.2 Synthesis of the Proposed First Carbocyclic Intermediate by Enzymatic 
Desymmetrisation 
At this point synthetic routes had been established for the preparation of the keto-
tetrol 95 and its enantiomer ent-95 from L-ribose and D-ribonolactone, respectively. 
The availability of ent-95 was important for comparative feeding studies alongside 
keto-tetrol 95, as discussed in Section 2.4. 	It also became clear that the C-4 
diastereomer of the keto-tetrol 95, namely (2R,3S,45)-4-hydroxymethyl-2,3,4-
trihydroxy-cyclopentan-1-one 116 may be an intermediate on the biosynthetic 
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2.2.1 Retrosynthetic analysis 
In the previous syntheses of the keto-tetrol 95, and its enantiomer ent-95, the 
stereochemistry at the 4-position was established by the Fujimoto-Belleau reaction. 
It had been hoped that the Fujimoto-Belleau reaction would give a mixture of 
separable diastereomers to provide a convenient route to both diastereomers of the 
keto-tetrol. However, the reaction produced a single diastereomer and therefore it 
was not possible to prepare the keto-tetrol 116 from a carbohydrate by this 
procedure. 
Studies by Archer towards the synthesis of the synthetically useful 
cyclopentenone 61 resulted in preparation of the novel 0-acetoxycyclopentanone 
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118. Using a revised procedure to that described by Johnson and Penning," Archer 
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Scheme 2.10 
By conversion of the monoacetate 117 to the cyclopentenone 61 following the 
procedure reported by Johnson and Penning," Archer isolated the novel 3- 
acetoxycyclopentanone 118 in 85% yield. 	It was thought that this 3-acetoxy- 
cyclopentanone 118 could be used to prepare the desired diastereomer of the keto-
tetrol 116 according to the retro synthetic plan shown in Scheme 2.11, in which the 
key step to introduce the stereochemistry at the 4-position is the addition of the 
lithiated stannane 108 to the carbonyl group of the 3-acetoxycyclopentanone 118. 
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I. Jackson, a project student within the group investigated the synthesis of the 
keto-tetrol 116 using this methodology. However due to time constraints he was 
unable to complete the synthesis of the desired keto-tetrol 116. Therefore the initial 
task was to repeat and scale-up the previously developed steps and then to complete 
the synthesis of the keto-tetrol 116. 
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2.2.2 Synthesis of keto-tetrol 116 
The -acetoxycyclopentanone 118 was prepared from cyclopentadiene 36 as 
shown in Scheme 2.12. 
a 0 - 
b AcOs,OAc HO 	Ac 
36 121 48 (+)-49 
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Scheme 2.12 Reagents and conditions: a. CH3CO3H, NaOAc, Na2CO3, CH2C12, 24%; b. 
Pd(PPh3)4, Ac20, THF, 59%; c. CAL-B (Novo SP-435), phosphate buffer (pH 8.0), 85%; d. 
0s04, NMO, THF, acetone, 1120, 88%; e. acetone, PTSA, 93%; f. Jones reagent, acetone, 
60%; g. DBU, THF, 91%. 
Monoepoxidation of cyclopentadiene 36 was performed by treatment of freshly 
distilled cyclopentadiene 36 with buffered peracetic acid solution following the 
procedure described by Knapp '94  to give the racemic cyclopentadiene monoepoxide 
121 in 24% yield based on cyclopentadiene. Although the yield obtained was poor, 
the starting materials were very cheap and the reaction was relatively easy to 
perform on a large scale starting from 96 g of cyclopentadiene. 
Following the literature procedure,5' treatment of cyclopentadiene monoepoxide 
121 with acetic anhydride in the presence of a catalytic amount of 
tetrakis(triphenylphosphine)palladium(0) gave the cis-diacetate 48 in 59% yield. 
Desymmetrisation of the meso-diacetate 48 was achieved by enzymatic hydrolysis 
using Candida antarctica lipase B in phosphate buffer to afford the monoacetate (+)-
49 in 85% yield and >99% e.e. determined by chiral gas chromatography. Candida 
antarctica lipase B (CAL-B) is supplied immobilised as an acrylic supported 
biocatalyst (Novo SP-435). The use of this immobilised enzyme is particularly 
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advantageous as the enzyme can be recovered from the reaction and reused. The 
hydrolysis of diacetate 48 to provide monoacetate 49 in high enantiomeric purity has 
also been carried out by the use of porcine pancreatic lipase (PPL),95 Pseudomonas 
fluorescens lipase (PCL)52 and electric eel acetyicholinesterase (EEACE).96 Archer 
initially investigated the use of EEACE for the desymmetrisation reaction. However 
due to inhibition of this enzyme by AcOH production, which prevented the reaction 
from going to completion, a poorer yield and e.e. were obtained. EEACE is also 
expensive (130/20000 units required for one 10 g reaction). 
cis-Dihydroxylation of the monoacetate (+)-49 from the less hindered face, using 
a catalytic amount of osmium tetroxide in the presence of the oxidant 4-methyl-
morpholine N-oxide afforded the diol 122 in 88% yield. Some problems were 
encountered with the aqueous work-up of this reaction. Extraction of the desired 
diol 122 from the aqueous portion was very difficult and resulted in low overall 
yields. To overcome this problem the crude reaction mixture was concentrated and 
then directly purified by column chromatography without prior work-up. This 
resulted in a high yield of the diol 122 being obtained as an oily white solid. The 
diol 122 was then protected as its 2,3-acetonide derivative 117 by treatment with 
acetone and p-toluenesulfonic acid. 
The final oxidation step for the synthesis followed the same procedure as that 
carried out by Johnson' but did not yield the same product. In our hands, treatment 
of the acetonide protected diol 117 with Jones reagent gave the -acetoxy-
cyclopentanone 118 in 60% yield as a white solid after purification by 
recrystallisation using diethyl ether. In Johnson's work oxidation of the acetonide 
protected diol 117 with Jones reagent afforded the a,f3-unsaturated ketone 61. It 
was thought that the 3-acetoxycyclopentanone 118 was not isolated in Johnson's 
case as the product of the oxidation was purified by column chromatography, which 
due to the acidity of the silica causes elimination of the -acetoxycyc1opentanone 
118 to form the cyclopentenone 61. In our work, purification of the P -acetoxy-
cyclopentanone 118 by column chromatography did indeed result in elimination 
taking place to give a mixture of the -acetoxycyclopentanone 118 and the 
cyclopentenone 61, therefore purification of the f3-acetoxycyclopentanone 118 by 









PMBO '(N0 HO\ç"Np0 
c 	 d DO 	 e 
XOX0 	
OO 










Results and Discussion 
crystalline solid the X-ray crystal structure was obtained, which confirmed the 
absolute stereochemistry of the compound. 	The crystal structure of 3- 
acetoxycyclopentanone 118 is given in Appendix 1. 
The cyclopentenone 61, if required, can easily be obtained by elimination of 
AcOH from the 3-acetoxycyclopentanone 118 using DBU giving the desired enone 
61 in 91% yield. 
The 3-acetoxycyc1opentanone 118 was then converted to the desired keto-tetrol 






Scheme 2.13 Reagents and conditions: a. Bu3SnCH20PMB 108, n-BuLi, THF, 19%; b. 
NH3 sat. MeOH, 92%; c. IBX, DMSO, 88%; d. H2, Pd(C), THF, 36%; e. TFA:CH2C12 (1:4), 
21%. 
Treatment of [(p-methoxybenzyloxy)methyl]tri-n-butylstannane 108 with n-BuLi 
generated the corresponding alkyl lithium species which underwent addition to the 
carbonyl group of the f-acetoxycyclopentanone 118 to afford the PMB-protected 
acetate 120 in poor yield ranging from 7% to 19%. The cyclopentenone 61 (50%) 
and the PMB-protected alcohol 125 (7%) were also isolated from the reaction. The 
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latter was presumably obtained by the addition of the hydroxymethyl anion 
equivalent to the cyclopentenone 61. 
PMBO 4\ç /  
OX 
125 
This result suggests that the majority of the starting 3-acetoxycyclopentanone 118 
is eliminating under the reaction conditions to give the cyclopentenone 61. 
Attempts to reduce the amount of enone 61 and increase the amount of acetate 120 
formed by the use of different temperatures and modes of addition were 
unsuccessful. Replacement of the acetate group of the 3-acetoxycyclopentanone 
118 with a more robust protecting group may reduce the amount of elimination to the 
cyclopentenone 61. However, due to time constraints, investigation of this idea was 
not attempted. 
The cyclopentenone 61 and PMB-protected alcohol 125 produced as by-products 
can however be used to prepare the tetrol 83a which is required as a control in the 
feeding experiments. The synthesis of the tetrol 83a from these compounds is 
described in Section 3.2.2. 
The acetate group was removed from the PMB-protected acetate 120 by the 
addition of ammonia saturated methanol to give the PMB-protected alcohol 123 in 
92% yield, which was then oxidised using IBX in DMSO to the protected 3-
hydroxycyclopentanone 124 in 88% yield. The preparation of IBX is discussed in 
Section 3.2.1. 
'H NMR nOe experiments were performed on both diastereomers of the protected 
3-hydroxycyclopentanone 106 and 124 to verify the stereochemistry at the 4-
position. The results are illustrated in Figure 2.4. 
The nOe enhancements, which result from through space interactions, suggest that 
the p-methoxybenzyloxymethyl group in diastereomer 124 is cis to the CH-3 proton 
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due to the large percentage enhancement (7%) observed compared to that in 
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Figure 2.4 Results of nOe experiments 
The 3-hydroxycyc1opentanone 124 was then converted to the keto-tetrol 116 via 
the same route as used for the previous syntheses. Removal of the PMB group was 
achieved by catalytic hydrogenation in only 36% yield, which is very poor compared 
to that for the previous hydrogenations. The reason for this is not known, however 
it may be due to the inaccessibility of the palladium catalyst to the reaction site in 
this diastereomer. The X-ray crystal structure of the f3-hydroxycyclopentanone 119 
was obtained and confirmed that this diastereomer did indeed have the S-
configuration at the 4-position, which is in agreement with the nOe data presented in 
Figure 2.4. The crystal structure of 3-hydroxycyc1opentanone 119 is shown in 
Appendix 2. 
Finally the acetonide group was removed by exposure of the - 
hydroxycyclopentanone 119 to trifluoroacetic acid in dichioromethane to give the 
desired keto-tetrol 116 in 21% yield. As in the previous syntheses the keto-tetrol 
116 was contaminated with traces of the enone 82a (approximately 8.6:1 mixture of 
116:82a, determined by 600 MHz 'H NMR analysis). 
Having achieved the synthesis of the keto-tetrol 95 and its diastereomer 116 it 
was then necessary to establish whether these compounds lie on the biosynthetic 
pathway. This was done by carrying out feeding experiments using a mutant of 
Streptomyces citricolor. These feeding studies are discussed in detail in Section 2.4. 
Due to the instability of the keto-tetrols, these compounds were synthesised in 
parallel and used immediately in the feeding studies. 
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2.3 	Synthesis of Known Intermediates on the Biosynthetic Pathway for Use in 
Feeding Studies 
In order to carry out the feeding experiments it was necessary to use a control 
compound which is known to be converted by Streptomyces citricolor to neplanocin 
A 5 and aristeromycin 4. The use of a control compound ensures that the organism 
is functioning efficiently and capable of converting the substrates to neplanocin A 
and aristeromycin. The compound which has most commonly been used in this way 
is the tetrol 83a, however the enone 82a has also been used. 
2.3.1 Synthesis of tetrol 83a 
The synthesis of the tetrol 83a has been achieved from D-ribose and is described 
in detail in Section 3.2. 
2.3.2 Synthesis of enone 82a 
The enone 82a, which is a known intermediate on the biosynthetic pathway, was 
prepared from the keto-tetrol 95 as shown in Scheme 2.14. 
HO 




95 	 82a 	 82a 
Scheme 2.14 Reagents and conditions: a. TFA:CH2C12:CH30H (6:4:1), -45%. 
A mixture of the keto-tetrol 95 and enone 82a, obtained from the trifluoroacetic 
acid deprotection reaction of the acetonide protected diol 107, was stirred overnight 
in a solution of trifluoroacetic acid in dichloromethane and methanol (6:4:1). 
Concentration of the solution followed by purification by column chromatography 
gave the enone 82a in approximately 45% yield. 
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2.4 Feeding Studies 
As described in Section 1.3.1(a), previous studies within the Turner group led to 
the isolation of mutant strains of Streptomyces citricolor that were blocked in their 
ability to synthesise neplanocin A 5 and aristeromycin 4. However the production 
of aristeromycin could be rescued by certain combinations of mutants in which the 
supernatant from cultures of one mutant (secretor) were added to a culture of a 
second mutant (converter). 	Such cosynthesis experiments identified a 
secretor/converter pairing in which the sterile aqueous concentrate prepared from a 
freeze-dried culture broth of one mutant (CC914) was able to support production of 
neplanocin A and aristeromycin when fed to a second mutant (CC940) as illustrated 
in Figure 1.3. It was subsequently shown that the aristeromycin precursor from the 
freeze-dried supernatant was the tetrol 83a.82 
The identification of the converter mutant (CC940), which appeared to be blocked 
in the early steps of aristeromycin biosynthesis, allowed putative intermediates to be 
synthesised and fed to the mutant - the production of neplanocin A and 
aristeromycin suggested that the compound lies on the biosynthetic pathway. 
Through these studies it was established that the enone 82a was an intermediate on 
the biosynthetic pathway.83 
The aim of this work was to feed the synthesised keto-tetrol compounds to the 
Streptomyces citricolor converter mutant CC940 and if production of aristeromycin 
and neplanocin A was observed these compounds were deemed to lie on the 
biosynthetic pathway. 
In this study all feeding experiments were performed using the Streptomyces 
citricolor mutant strain CC940 grown on GAM 6:6 medium supplemented with 
uracil. Vegetative mycelium was used to inoculate a conical flask containing the 
medium and after three days of growth at 30°C, 270 rpm, aliquots of the culture were 
transferred to several sterile conical flasks. Following addition of the substrates (to 
give a final concentration of 1 mg/ml) the incubation was continued at 30°C, 270 
rpm for up to 7 days and the transformation was monitored by the production of 
neplanocin A and aristeromycin by HPLC analysis of the fermentation broth at 
regular intervals. 
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2.4.1 Tetrol feeding experiment 
The CC940 mutant strain of Streptomyces citricolor had been stored as a 
lyophilised sample for a number of years. In order to establish that the mutant had 
been successfully revived and would efficiently convert the substrates to neplanocin 
A and aristeromycin, the first feeding experiment carried out used the known 
intermediate on the biosynthetic pathway, the tetrol 83a. 	The results of this 
experiment are shown in Graph 2.1. A control flask is used in each feeding 
experiment which contains no added substrate and therefore shows no conversion to 
neplanocin A and aristeromycin. The plot for this control experiment is not shown 
on any of the graphs for the feeding experiments. 
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Graph 2.1 	Conversion of tetrol to neplanocin A and aristeromycin 
From Graph 2.1 it can be seen that contrary to previous studies within the group 
in which aristeromycin 4 was the major bioconversion product, the mutant CC940 
bioconverts the tetrol 83a to neplanocin A 5 as the major product. However upon 
prolonged incubation the amount of aristeromycin produced gradually increases. In 
order to be certain that neplanocin A and aristeromycin were indeed being produced, 
the fractions corresponding to these compounds were collected from the HPLC and 
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observed at m/z (ES+) 263.8 (MH, 30%) and 285.9 (M + Na, 50%). Unfortunately 
a mass spectrum of the aristeromycin fraction could not be obtained due to the small 
amount of product recovered. 
2.4.2 Keto-tetrol (both enantiomers) feeding experiment 
Having established that the CC940 mutant had been successfully revived and was 
capable of converting substrates to neplanocin A and aristeromycin, the feeding 
experiments using the synthesised keto-tetrol compounds were then carried out. The 
freshly prepared keto-tetrol 95 and its enantiomer ent-95 were fed to the 
Streptomyces citricolor mutant CC940 as well as the tetrol 83a, to ensure that the 
mutant was converting to neplanocin A and aristeromycin. The results of this 
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Graph 2.2a Conversion to neplanocin A 
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Graph 2.2b Conversion to aristeromycin 
The results show that the keto-tetrol 95 is converted by Streptomyces citricolor to 
neplanocin A and aristeromycin. As expected the enantiomer ent-95, which has the 
incorrect absolute stereochemistry for incorporation into neplanocin A and 
aristeromycin, shows no conversion to neplanocin A or aristeromycin as illustrated 
in Scheme 2.15. As in the previous feeding experiment the major product produced 
is neplanocin A. As before the fractions corresponding to neplanocin A and 
aristeromycin were collected from the HPLC and subjected to mass spectrometry. 
Mass peaks corresponding to neplanocin A were observed at m/z (ES+) 263.6 (MH, 
60%) and 285.9 (M+Na, 10%). Mass peaks corresponding to aristeromycin were 
observed at m/z (ES+) 265.8 (MW, 50%) and 287.8 (M+Na, 20%). 
From the result of this experiment it was not known if the keto-tetrol 95 was 
converted to the enone 82a enzymatically by Streptomyces citricolor or if it was 
simply undergoing spontaneous chemical elimination in the fermentation broth to the 
enone 82a and it was subsequently this compound, which is a known intermediate on 
the biosynthetic pathway, that was being converted to neplanocin A and 
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As the keto-tetrol 95 and its diastereomer 116 are both converted to the same 
enone 82a (Scheme 2.15), the next experiment involved feeding both of these 
compounds to the Streptomyces citricolor mutant. If the diastereomer 116 showed 
no conversion to neplanocin A and aristeromycin then it could be deduced that the 
keto-tetrol 95 is enzymatically converted to the enone 82a and that the keto-tetrol 95 
lies on the biosynthetic pathway. 
2.4.3 Keto-tetrol (both diastereomers) feeding experiment 
The keto-tetrol 95 and its diastereomer 116 were fed to the mutant CC940, as well 
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Graph 2.3c 	Conversion to neplanocin A + aristeromycin 
From Graphs 2.3a and b, it can be seen that both the 4R keto-tetrol 95 and 4S 
keto-tetrol 116 are converted by Streptomyces citricolor to neplanocin A and 
aristeromycin. As the diastereomer 116 is also converted it is not possible to be sure 
whether the keto-tetrol compounds are enzymatically converted by Streptomyces 
citricolor or if they undergo spontaneous chemical elimination to the enone 82a. To 
investigate the likelihood of the keto-tetrol compounds eliminating chemically to the 
enone 82a under the conditions of the feeding study, an NMR experiment was 
carried out. The pH of the fermentation broth throughout the duration of the feeding 
experiment was approximately 5, therefore an NMR sample of the keto-tetrol 95 was 
made up in deuterium oxide and the pH was carefully adjusted to 5 using deuterated 
trifluoroacetic acid. The 200 MHz 'H N1'vIR spectrum of the sample was then 
obtained at regular intervals and the ratio of keto-tetrol 95: enone 82a was determined 
by comparison of the integrals. The results of these experiments are shown in Table 
2.1. 
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Keto-tetrol 95 	: 	Enone 82a 
1 day 20.0 	 1 
4days 17.5 1 
9days 10.4 	 1 
13 days 6.1 1 
17 days 5.0 	 1 
24 days 2.8 1 
36 days 2.0 	 1 
then pH of sample adjusted to 4 using deuterated trifluoroacetic acid 
4 min 1.9 1 
4h 1.9 1 
iday 1.8 1 
5 days 1.5 1 
then pH of sample adjusted to 3 using deuterated trifluoroacetic acid 
15 min 1.5 1 
iday 1.5 1 
7days 1.3 1 
15 days 1.1 1 
Table 2.1 	Rate of elimination of keto-tetrol 95 to enone 82a 
These results suggest that the rate of chemical elimination of the keto-tetrol 95 to 
the enone 82a would not be fast enough to have an effect on the feeding 
experiments, the longest of which was run for six days. 
The stability of the keto-tetrol compounds was also established during the 
synthesis of the enone 82a from the keto-tetrol 95 as described in Section 2.3.2. The 
keto-tetrol 95 was treated with an excess of trifluoroacetic acid (pH<< 1) and even 
after stirring at room temperature overnight a small amount of the keto-tetrol 95 still 
remained. This result suggests that at pH 5 the chemical elimination would be very 
slow indeed. 	From these investigations it was concluded that the keto-tetrol 
compounds were undergoing enzymatic conversion by Streptomyces citricolor to the 
enone 82a. 
From Graph 2.3a it can be seen that conversion of the 4S keto-tetrol 116 to 
neplanocin A appears to stop after approximately forty hours whilst the conversion 
of the 4R keto-tetrol 95 and tetrol 83a to neplanocin A continues. It was suggested 
that this conversion observed for the 4S keto-tetrol 116 may not in fact be due to 
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bioconversion of the keto-tetrol but instead it is the conversion of the trace amount of 
enone 82a which is present as an impurity in the starting keto-tetrols. However, the 
total conversion (neplanocin A + aristeromycin) observed is high (approximately 
21%) and the 4S keto-tetrol 116 is contaminated with only a small amount of the 
enone 82a (10.4%). Therefore this amount of enone 82a in the starting sample 
could not account for such a high percentage conversion. This is shown by the 
dotted line on Graph 2.3c. This line represents 100% conversion of the enone 82a, 
which contaminates the 4S keto-tetrol 116, to neplanocin A and aristeromycin. 
The more likely explanation for this halt in conversion is due to the small volume 
of fermentation broth that remains at this point in the experiment. The small volume 
means that the broth cannot be efficiently aerated and therefore the conversion may 
cease. 
The feeding experiment using both diastereomers of the keto-tetrol was therefore 
repeated using a larger amount of substrate and hence a greater volume of medium. 
This allowed the feeding study to be monitored for a longer period of time. 
2.4.4 Keto-tetrol (both diastereomers) feeding experiment 
The freshly prepared 4R keto-tetrol 95 and its diastereomer 4S keto-tetrol 116 
were fed to the Streptomyces citricolor mutant CC940. As in the previous feeding 
experiments the tetrol 83a was also fed to the mutant to ensure that it was converting 
the substrates to neplanocin A and aristeromycin. The results of this study are given 
in Graphs 2.4a, b and c. 
Graphs 2.4a, b and c show that both the 4R keto-tetrol 95 and the 4S keto-tetrol 
116 are converted by Streptomyces citricolor to neplanocin A and aristeromycin. 
Contrary to the previous experiment, the conversion of the 4S keto-tetrol 116 to 
neplanocin A and aristeromycin follows almost exactly the same pattern as for the 
conversion of the 4R keto-tetrol 95. This result suggests that the halt in conversion, 
which was observed in the previous feeding experiment, was a result of the small 
volume of fermentation broth remaining towards the end of the experiment. 
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Graph 2.4b Conversion to aristeromycin 
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Graph 2.4c Conversion to neplanocin A + aristeromycin 
From Graph 2.4a it can be seen that the conversion of the 4R and 4S keto-tetrol to 
neplanocin A reaches its maximum (approximately 15%) after incubation for 
approximately 35 hours. After this time conversion of the keto-tetrol to neplanocin 
A stops and the amount of neplanocin A decreases as the produced neplanocin A is 
converted to aristeromycin. Initially the ratio of neplanocin A:aristeromycin is 
approximately 5:1, however upon prolonged incubation the amount of neplanocin A 
gradually falls with a concomitant increase in the level of aristeromycin to give a 
final ratio of approximately 1:1 after incubation for 142 hours. 
Graph 2.4a shows that the conversion of the tetrol 83a to neplanocin A reaches its 
maximum (approximately 30%) after incubation for approximately 53 hours. This 
level of conversion is much greater that that observed for the keto-tetrol compounds. 
It was thought that the maximum conversion of the keto-tetrols was less than that for 
the tetrol 83a as the keto-tetrols lie further back on the biosynthetic pathway and 
when they undergo conversion more side reactions occur which results in a lower 
amount of conversion to neplanocin A and aristeromycin. To test this hypothesis 
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2.4.5 Keto-tetrol and enone feeding experiment 
The freshly prepared 4R keto-tetrol 95 and enone 82a were fed to the 
Streptomyces citricolor mutant as well as the tetrol 83a. The results of these 
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Graph 2.5b Conversion to aristeromycin 
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- 	Graph 2.5c Conversion to neplanocin A + aristeromycin 
In this experiment the 4R keto-tetrol 95 was incubated for 96 hours after which 
time conversion of the keto-tetrol to neplanocin A has ceased. At this point in order 
to establish whether the organism was still capable of converting the substrate to 
neplanocin A, a further portion of 4R keto-tetrol 95 was added to the fermentation 
broth. From Graph 2.5a further conversion to neplanocin A was seen after addition 
of the substrate, which confirms that the organism was still able to convert the 
substrate to neplanocin A and had simply used up all the initial substrate added and 
required more to continue conversion to neplanocin A and aristeromycin. 
Graph 2.5a shows that conversion of the 4R keto-tetrol 95 to neplanocin A 
reaches its maximum (approximately 17%) after incubation for 65 hours. For the 
enone 82a the conversion to neplanocin A reaches its peak (approximately 23%) 
after incubation for 88 hours. For the tetrol 83a after incubation for 140 hours the 
maximum conversion has not yet been obtained. This result confirms the previous 
hypothesis that since the keto-tetrol is situated further back in the biosynthetic 
pathway than the enone 82a and the tetrol 83a then its maximum conversion is less 
than for the enone 82a. Similarly, the maximum conversion of the enone 82a is less 
than that observed for the tetrol 83a. 
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2.4.6 Conclusion 
The results of these feeding studies show that the 4R keto-tetrol 95 and its 
diastereomer 4S keto-tetrol 116 are converted by the organism Streptomyces 
citricolor to neplanocin A 5 and aristeromycin 4. This strongly suggests that both 
compounds are intermediates on the biosynthetic pathway. However, further studies 
are required to determine conclusively that these compounds do indeed lie on the 
biosynthetic pathway. 
2.5 	Summary of Chapter 2 
The syntheses of the keto-tetrol 95, its enantiomer keto-tetrol ent-95 and its 
diastereomer keto-tetrol 116 have been achieved via multi-step syntheses from L- 
ribose, D-ribonolactone and cyclopentadiene, respectively. 	Good yields were 
obtained throughout the synthetic routes except for the reactions that involved the 
addition of the lithiated [(pmethoxybenzyloxy)methyltri-n-butylstannane 108, 
which resulted in a low overall yield of the desired keto-tetrol being obtained. 
However, synthesis on a large scale allowed sufficient material to be prepared for 
use in feeding studies. 
The synthesised keto-tetrol compounds were then fed to the Streptomyces 
citricolor mutant CC940. From these studies it was established that the 4R keto-
tetrol 95 and the 4S keto-tetrol 116 were converted by Streptomyces citricolor to 
neplanocin A 5 and aristeromycin 4. However in order to establish conclusively that 
these compounds lie on the biosynthetic pathway further studies will have to be 
performed. 
2.6 	Future Work 
In order to determine whether the 4R keto-tetrol 95 and its diastereomer 4S keto-
tetrol 116 lie on the biosynthetic pathway it will be necessary to prepare the 5-' 3C 
labelled keto-tetrols 95 and 116. These compounds could be prepared from the 13C 
labelled [(p-methoxybenzyloxy)methyl]tri-n-butylstannane in which the 13C label 
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would be introduced using 13C labelled paraformaldehyde. These compounds would 
then be fed to the Streptomyces citricolor CC940 mutant and if the neplanocin A and 
aristeromycin produced contains the '3C label at the 5' position then the keto-tetrol 










The experiment outlined in Scheme 2.16 would not rule out the possibility of 
chemical elimination (of the keto-tetrols 95 and 116 to the enone 82a) taking place. 
Therefore it would be important to develop an assay in which the keto-tetrol, enone 
and tetrol could be detected as well as neplanocin A and aristeromycin. This assay 
would provide more information as to what is happening during the feeding 
experiments when the keto-tetrol is converted to neplanocin A and aristeromycin. 
Development of an HPLC assay to do this was investigated however due to time 
constraints no suitable assay was found. 
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3 Investigations into the Incorporation of Adenine into 
Neplanocin A - Identification of Phosphorylated Intermediates 
Two possible methods for the introduction of the adenine base into neplanocin A 
were considered: 
de novo purine biosynthesis: in which the adenine ring is biosynthesised by 
stepwise construction of the appropriate precursors onto a carbocyclic analogue of 
5-phosphoribosyl pyrophosphate containing a pre-existing amino group 96 as 
shown in Scheme 3.1. 
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Scheme 3.1 
purine salvage pathway: in which the adenine ring is incorporated intact onto a 
carbocyclic analogue of 5-phosphoribosyl pyrophosphate 84b as outlined in 
Scheme 3.2. 
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Scheme 3.2 
Previous studies which are discussed in Section 1.3.1(c) strongly suggest that the 
operation of a de novo biosynthesis is unlikely and that direct incorporation of 
adenine is the major route to aristeromycin 4 and neplanocin A 5. 
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By analogy with the salvage pathway for the biosynthesis of natural purine 
nucleosides in which D-ribose 126 is converted to D-ribose-5-phosphate 127 and then 
to 5-phosphoribosyl pyrophosphate 128 in which adenine is incorporated intact, this 
leads to the proposal that adenine is incorporated into neplanocin A via the pathway 
shown in Figure 3. 1, in which the pyrophosphate 84b is proposed to be the 
immediate precursor of neplanocin A. The tetrol 83a is a known intermediate on the 
biosynthetic pathway. 
Salvage biosynthesis of purine nucleosides 
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Figure 3.1 
The aim of this work was therefore to prepare the proposed phosphorylated 
intermediates, the 5-phosphate 83b and the pyrophosphate 84b, and establish 
whether they lie on the biosynthetic pathway. 	These compounds would be 
challenging synthetic targets due to the known instability of allylic phosphates and 
pyrophosphates. 
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3.1 	Retrosynthetic Analysis 
It was envisioned that the proposed phosphorylated and pyrophosphorylated 
intermediates could be prepared according to the retrosynthetic plan shown in 
Scheme 3.3, in which the key intermediate is the methoxymethyl-protected alcohol 




















The initial goal was to repeat the synthesis of the methoxymethyl-protected 
alcohol 130 from D-ribose 126 and to use this compound to prepare the tetrol 83a, 
which is a known intermediate on the biosynthetic pathway and is required as a 
control compound for use in feeding studies. 
3.2 	Synthesis of Tetrol 83a 
3.2.1 Synthesis via methoxymethyl-protected compounds 
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Results and Discussion 
The methoxymethyl-protected alcohol (1 S,2S,3R)-2,3 -(Isopropylidenedioxy)-4-
[(methoxymethoxy)methyl]-cyclopent-4-en- 1-01 130, was prepared from D-ribose 
126 as shown in Scheme 3.4. 
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Scheme 3.4 Reagents and conditions: a. DMP, acetone, HC104, methanol, 81%; b. 12, 
imidazole, PPh3; c. DBU, THF, reflux, 64% 2 steps; d. 0s04, Na104, aq. THF, 67%; e. 
(MeO)2P(0)Me, n-BuLi, THF, -78°C, 49%; f. Bu3SnCH20MOM 110, n-BuLi, THF, -78°C, 
72%; g. Ac20, pyridine, DMAP, CH2C12, 89%; h. PdC12(MeCN)2, benzoquinone, THF, 
reflux, 66%; i. K2CO3, MeOH, 87%; j. TBX, DMSO, 87%; k. NaBH4, CeC13.7 H20, MeOH, 
86%. 
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D-Ribose 126 was protected as its methyl glycoside and 2,3-acetonide derivative 
131 in 81% yield, using DMP, perchioric acid and methanol in acetone.63 
The protected ribose 131 was then converted to the iodide 132 using iodine, 
imidazole and triphenyiphosphine. The iodide 132 obtained was thought to be 
unstable therefore the crude iodide was immediately eliminated to the enol ether 133 
in 64% yield by refluxing in DBU. Problems were encountered in the work-up of 
this "one-pot" reaction due to the presence of the triphenyiphosphine oxide by-
product, which made the residue from which the iodide was to be extracted very 
thick. This resulted in the yield of enol ether 133 being less than expected. 
The preparation of the iodide 132 via the tosylate 139 as shown in Scheme 3.5 
was investigated. However the overall yield of enol ether 133 obtained was only 
45% and due to the large amount of sodium iodide required the reaction was not 
applicable to a large scale. 
O CH3 Tos 	
OCH3 	 ,OCH3  V\ç O y 	 I 
a  _ b 
7K° 7<0 (7<0 
131 139 132 
Scheme 3.5 	Reagents and conditions: a. TsC1, pyridine, DMAP, CH2Cl2; b. NaT, acetone, 
reflux. 
Sodium periodate-osmium tetroxide oxidation of the enol ether 133 gave the 
lactone 134 in 67% yield. 
The subsequent cyclisation of the lactone 134 to the enantiomerically pure 
cyclopentenone 61 caused problems in this synthetic pathway. The reaction was 
extremely unreliable and gave low and variable yields of 0-35%. When this reaction 
was carried out following the procedure described by Borchardt et al.98 the yields of 
cyclopentenone 61 obtained were 8% and 13%. It was found however, that 
quenching the reaction at low temperature increased the yield to 49%. Moreover, 
the reaction was less capricious and more reliable. 
The proposed mechanism for this cyclisation reaction via a Wadsworth-Emmons 
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Figure 3.2 Proposed mechanism for the cyclisation reaction 
Deprotonation of dimethyl methyiphosphonate using one equivalent of n-
butyllithium yields the corresponding anion, which adds to the carbonyl group of the 
lactone 134 resulting in the opening of the lactone ring and elimination of methoxide 
to give an acyclic intermediate. This intermediate then undergoes base-promoted 
cyclisation to the cyclopentenone 61 by the methoxide generated in situ. 
In an attempt to improve the yield and reliability of this procedure, the reaction 
mixture was quenched at -78°C by the addition of saturated aqueous ammonium 
chloride solution. This resulted in no desired product being formed; instead a 61% 
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yield of the novel phosphonate 140, which is proposed to be the first formed 
intermediate in the reaction, was obtained. The structure and stereochemistry of the 







It was hoped that treatment of the phosphonate 140 with base would result in 
formation of the desired cyclopentenone 61. 	However, treatment of the 
phosphonate 140 with sodium methoxide, sodium hydride, n-butyllithium and 
sodium bis(trimethylsilyl)amide under a variety of conditions resulted in 
decomposition of the starting phosphonate 140 and no desired cyclopentenone 61 
being obtained. 
Enantiomerically pure cyclopentenones of this type are important synthetic 
intermediates. For example, they have been used in prostaglandin synthesis and in 
the preparation of carbocyclic nucleosides, the most recent examples of which are 
discussed in Section 1.2.2 (b) (i). This has resulted in many attempts to synthesise 
these compounds, which have included their preparation from cyclopentadiene,93 D-
ribonolactone,89'98 D-ribose and D-lyxose,63 D-mannose,98 fulvene,99 toluene and 
chloro- and bromo-benzene.10° 	However all these syntheses have their 
disadvantages. 
Recently, a reliable and efficient synthetic route to the cyclopentenone 61 from 
cyclopentadiene 36 has been developed within the Turner group, using a revised 
procedure to that described by Johnson and Penning.93 This pathway which is 
described in detail in Section 2.2.2 provides a convenient, alternative route to the 
enantiomerically pure cyclopentenone 61. 
This crystal structure was determined by an Honours project student working under the supervision 
of Dr Lindsay Sawyer in the Institute of Cell and Molecular Biology, the University of Edinburgh. 
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Following work described by Johnson and Medich,'°' the enone 61 was converted 
to the protected diol 135 using [(methoxymethoxy)methyl]tri-n-butylstannane 110. 
The stannane 110 was prepared using a procedure reported by McGarvey et al. 102 in 
which (tri-n-butylstannyl)methanol was alkylated with chloromethyl methyl ether as 
shown in Scheme 3.6. 
Bu3SnH a  Bu3SnLi_b  Bu3SnCH2OH_C  Bu3SnCH20CH20CH3  
110 
Scheme 3.6 Reagents and conditions: a. diisopropylamine, n-BuLi, THF, 0°C; b. para- 
formaldehyde; c. dimethylaniline, CH2C12, chioromethyl methyl ether, 0°C, 85% 3 steps. 
Treatment of Bu3SnCH20MOM 110 with n-butyllithium gave the hydroxymethyl 
anion equivalent which adds to the carbonyl group of the cyclopentenone 61 to give 
the protected diol 135 in 72% yield. 
Acetylation of the allylic hydroxyl group of the protected diol 135 using acetic 
anhydride, pyridine and a catalytic amount of DMAP gave the ester 136 in 89% 
yield. 
Allylic acetates such as ester 136 are known to rearrange upon treatment with 
catalytic PdC12(CH3CN)2 in THF to give the corresponding acetates with complete 
retention of stereochemistry.'°3 	The palladium catalysed [3 ,3]-sigmatropic 
rearrangement of ester 136 to acetate 137 caused problems in this synthetic 
sequence. Examination of both the 1H and 13C NMR spectra of the acetate 137 
showed the presence of a minor contaminant which could not be removed by silica 
column chromatography. Various catalysts and conditions were used in the reaction 
with a view to eliminating the impurity and optimising the reaction, including the use 
of Pd(II) acetate and tris(dibenzylideneacetone)dipalladium(0)-chloroform adduct. 
From the results of these investigations it was observed that the only catalyst which 
gave the desired product was the bis(acetonitrile)dichloropalladium(II) catalyst and 
that the greatest yield for the reaction was obtained when refluxing in THF for 6 
hours. Examination of the 1H and '3C NMR spectra of the acetate 137 product 
obtained in this case showed significantly less impurity than when the reaction 
mixture was refluxed for 8 hours or more. It was not possible to identify the 
impurity that was present, however one possibility is a chlorinated adduct derived 
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from incorporation of chlorine into the compound from the bis(acetonitrile)dichloro-
palladium(II) catalyst used. 
The impure acetate 137 was deacetylated using anhydrous potassium carbonate in 
methanol to give the alcohol 130, which by examination of the 1H NMR spectrum 
showed the presence of the same impurity that was present in the acetate starting 
material 137. 
In order to eliminate the impurity and obtain the alcohol 130 in a pure form it was 
necessary to introduce the oxidation-reduction sequence shown in Scheme 3497 
In this sequence, as an alternative to the reported PCC oxidation," the impure 
alcohol 130 was oxidised using IBX 141 in DMSO to give the enone 138 in 87% 
yield. The enone 138 from this reaction could be obtained in pure form after 
purification by column chromatography. 
IBX 141 was prepared from the inexpensive, commercially available reagents as 
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Scheme 3.7 Reagents and conditions: a. KBr03, H2SO4, 55'C to 84°C, 51%. 
Following the procedure reported by Bestmann and Roth,"' the carbonyl group of 
the enone 138 was selectively reduced using sodium borohydride and cerium(III) 
chloride heptahydrate to give the desired MOM-protected alcohol 130 in 86% yield. 
In order to prepare the proposed phosphorylated intermediates it was necessary to 
selectively deprotect the MOM group in the presence of the acetonide group. 
However, treatment of the MOM-protected alcohol 130 with Amberlite IR 120 (H) 
in methanol and water showed that the acetonide-protecting group was preferentially 
cleaved to give the MOM-protected triol 142 as shown in Scheme 3.8. 
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Scheme 3.8 Reagents and conditions: a. Amberlite JR 120 (H), Me011, H20, 57%. 
Attempts to selectively deprotect the MOM group of the MOM-protected alcohol 
130 were carried out using the following conditions: 
Trifluoroacetic acid:dichloromethane (1:1), room temperature.'°6 
Deprotection of both the acetonide group and the MOM group, the acetonide 
group being cleaved first. 
p-Toluenesulfonic acid, methanol, room temperature. 
The acetonide group was deprotected first followed by cleavage of the MOM 
group. However, deprotection was much slower than observed for the TFA 
deprotection. After stirring at room temperature for two days starting material 
still remained. 
Pyridinium p-toluenesulfonate, propan-2-ol, room temperature. 
Stirring at room temperature for fourteen days resulted in no reaction taking 
place. 
From these results, and the lack of precedence in the literature, it appeared that the 
selective deprotection of the MOM group in the presence of the acetonide moiety 
would not be possible. Therefore the preparation of the desired phosphorylated 
intermediates via this synthetic pathway was therefore abandoned. 
The MOM-protected alcohol 130 could however be used to prepare the tetrol 83a 
in 52% yield by stirring in Amberlite JR 120 (H) for 4 days. 
87 
Results and Discussion 
3.2.2 Synthesis via para-methoxybenzyl-protected compounds 
As the MOM protecting group could not be selectively deprotected it had to be 
replaced with a more suitable protecting group. When replacing the MOM group it 
was necessary to consider that not only did the new protecting group need to be 
orthogonal to the acetonide group but it must also be able to be introduced via the 
corresponding tri-n-butylstannane. 
At this time Parry et al.107  published a paper that described their investigations 
into the conversion of carbocyclic analogues of D-ribose-5-phoSphate to the 
corresponding carbocyclic PRPP analogues using 5-phosphoribosyl a-i-
pyrophosphate synthetases. In this paper the synthesis of the 5-phosphate 83b from 
the cyclopentenone 61 was described using a procedure similar to that proposed by 
us but with the replacement of the methoxymethyl group with the para-
methoxybenzyl group. It was therefore decided to replace the MOM group with the 
PMB group and the synthesis was carried out as shown in Scheme 3.9. 
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Scheme 3.9 Reagents and conditions: a. Bu3SnCH20PMB 108, n-BuLi, THF, -78°C, 
73%; b. Ac20, pyridine, DMAP, CH2C12, 96%; c. PdC12(MeCN)2, benzoquinone, THF, 63%; 
d. K2CO3, MeOH, 61%; e. DDQ, CH2CL2:H20 (20:1),38%. 
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[(p-Methoxybenzyloxy)methyl]tri-n-butylstannane 108 was prepared as shown in 
Scheme 3.10. 





Scheme 3.10 Reagents and conditions: a. i. LDA, ii. (CH20); b. i. NaH, ii. C13CCN; c. 
CF3SO3H, 42% overall. 
(Tri-n-butylstannyl)methanol 146 was prepared according to the procedure 
reported by Still'" in which tri-n-butyltin hydride is deprotonated with LDA and 
then alkylated by the addition of paraformaldehyde. Meanwhile the commercially 
available p-methoxybenzyl alcohol was converted to the (p-
methoxybenzyl)trichloroacetimidate 147 by treatment with sodium hydride and 
trichloroacetonitrile. 	These two fragments were then coupled together in the 
presence of triflic acid to give the desired [(p-methoxybenzyloxy)methyl]tri-n-
butylstannane 108 after purification by column chromatography and then distillation 
in 42% overall yield. 	This provided a more convenient route to the [(p- 
methoxybenzyloxy)methyl]-tri-n-butylstarinane 108 than that described by Parry"' 
(by avoiding the use of sulfur containing compounds). The attempted preparation of 
the [(pmethoxybenzyloxy)methyl]tri-n-butylstaflflafle 108 using a procedure 
analogous to that used for the preparation of [(methoxymethoxy)methyl]tri-n-
butylstannane 110 in which p-methoxybenzyl chloride was added to (tn-n-
butylstannyl)methanol 146 was unsuccessful and produced no desired product. 
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Lithiation of the [(p-methoxybenzyloxy)methyl]tri-n-butylstannane 108 gave the 
hydroxymethyl anion equivalent which added in a 1,2-fashion to the cyclopentenone 
61 to give the PMB-protected alcohol 125 in 73% yield. 
The protected alcohol 125 was then acetylated using acetic anhydride, pyridine 
and a catalytic amount of DMAP to give the ester 143 in 96% yield. 
As for the MOM-protected ester 136, the PMB-protected ester 143 underwent the 
palladium catalysed allylic rearrangement to give the acetate 144 in 63% yield. 
Examination of the 'H and '3C NMR spectra of the acetate 144 showed the presence 
of minor traces of the corresponding impurity that was present in the MOM-
protected acetate 137. 
The impure acetate 144 was deacetylated by treatment with anhydrous potassium 
carbonate in methanol to give the protected alcohol 145 in 61% yield. Unlike the 
MOM-protected alcohol 130, the PMB-protected alcohol 145 was obtained in pure 
form and contained none of the impurity that was present in the acetate 144 starting 
material. Therefore the oxidation-reduction sequence carried out for the MOM-
protected compounds did not need to be performed. 
The PMB group was then successfully selectively deprotected by treatment with 
DDQ to give the acetonide protected diol 129 in 38% yield. It was thought that the 
poor yield was a result of the desired product being very water-soluble and as a result 
extraction of the protected diol 129 from the aqueous layer during work-up was very 



















Scheme 3.11 Reagents and conditions: a. DDQ, CH2C12:H20 (20:1), 84%; b. NH3 sat. 
MeOH, 96%. 
Selective deprotection of the PMB group from the impure acetate 144 in the 
presence of the acetonide and acetate groups was achieved in 84% yield by treatment 
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with DDQ. The alcohol 148 obtained was pure and contained none of the impurity 
that was present in the acetate 144 starting material. 
The acetate group was then removed from the alcohol 148 by stirring in ammonia 
saturated methanol to give the acetonide protected diol 129 in 96% yield. The use 
of this reagent, which can simply be removed by evaporation under vacuum, meant 
that there was no problem with the desired product being lost during aqueous work-
up. 
The tetrol 83a, which has been used in the feeding studies as discussed in Section 
2.4, was subsequently obtained in 94% yield by deprotection of the acetonide group 
of 129 by treatment with trifluoroacetic acid. 
Having established a synthetic route to the cyclopentenol type compounds, the 
synthesis of the proposed phosphorylated intermediates was then investigated. 
3.3 	Synthesis of Phosphorylated Intermediates 
Monoalkyl phosphates are recognised to play important roles in many biological 
processes and as a result several chemical procedures have been developed for the 
conversion of alcohols into their corresponding phosphate esters.109 	One such 
procedure that has recently joined the p" phosphorylation strategies as a popular 
method for the preparation of phosphate monoesters is the use of P" 
phosphoramidite reagents in which the selection of the phosphate protecting group is 
of paramount importance."' 
In the synthesis of the desired phosphorylated intermediates the choice of 
phosphate protecting group is governed by the requirements that the protecting group 
must: 
be able to be deprotected under mild conditions without causing reduction of the 
double bond of the cyclopentene ring. 
be stable to the other reagents and conditions used in subsequent reactions in the 
synthetic pathway. 
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In the synthetic route to the 5-phosphate 83b recently reported by Parry,'°7 the 2-
(trimethylsilyl)ethyl protecting group was found to satisfy these conditions, its 
introduction being via the bis[2-(trimethylsilyl)ethyl]-N,N-diethylphosphorafflidite 
150. The 2-(trimethylsilyl)ethyl group can be cleaved by fluoride anion via a 
elimination mechanism to give ethene and the corresponding trimethylsilyl 
fluoride." 	Therefore, the use of this reagent and the 2-(trimethylsilyl)ethyl 
protecting group was employed in the synthesis of the desired phosphorylated 
intermediates. 
3.3.1 Preparation of phosphorylating agent 150 
Bis[2-(trimethylsilyl)ethyl] -N,N-diethylphosphoramidite 150 was prepared using 
the procedure reported by Parry'°7 which is outlined in Scheme 3.12. 
Et 	 Et 	CI 	Et 	0 
/  
N—H + PC13 
a 	N—P bft. N—P 	
SiMe3 
/ 
E/ 	 Et 	




149 	 150 
Scheme 3.12 Reagents and conditions: a. THF, <0°C to room temperature, 53%; b. 2-
(trimethylsilyl)ethanol, triethylamine, THF, 0°C to room temperature, 41%. 
N,N-Diethylphosphorochloridite 149 was prepared according to the procedure 
published by Perich and Johns'09  by the reaction of diethylamine with phosphorous 
trichioride. Treatment of the NN-diethylphosphorochloridite 149 with 2 equivalents 
of 2-(trimethylsilyl)ethanol in the presence of triethylamine gave the desired bis[2-
(trimethylsilyl)ethyl]-N,N-diethylphosphoramidite 150 in 41% yield. This reagent 
which has also been prepared in an alternative synthesis reported by Freeman et al."° 
is stable for over 12 months when stored at <0°C. 
3.3.2 Synthesis of 1-phosphate 152 
(a) 	Synthesis via methoxymethyl-protected compounds 
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In order to establish the viability of the synthetic procedures and experimental 
techniques used, the MOM-protected alcohol 130 was firstly converted to the 1-
phosphate 152 as shown in Scheme 3.13. Although the 1-phosphate 152 is not a 
proposed intermediate on the biosynthetic pathway it was viewed as a useful 
substrate in feeding studies. 
MOM "\ ç 7 	MoM\ç 7 
xo °X 
	
11/ 	 b, OP\ c 
OCH2CH2SiMe3  
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HO H ONa 	 HO oH ONa 
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Scheme 3.13 Reagents and conditions: a. i. (Me3SiCH2CH20)2PNEt2 150, 1H-tetrazole, 
THF; ii. MCPBA, CH2C12, -40°C to room temperature, 55%; b. 48-51% HF:MeCN:H20 
(10:85:15); c. 1 M NaOH, H20. 
The secondary hydroxyl group of the MOM-protected alcohol 130 was 
phosphorylated using bis[2-(trimethylsilyl)ethyl]-NN-diethylphosphoramidite 150 in 
the presence of 1H-tetrazole. Without isolation, the intermediate phosphite ester 
formed was oxidised by the addition of MCPBA to give the 2-(trimethylsilyl)ethyl 
protected phosphate triester 151 in 55% yield. 
The final step in the synthesis, which involved the deprotection of the protecting 
groups and subsequent formation of the sodium salt of the phosphate ester, caused 
problems in the synthesis. 
Preparation of the sodium salt of the deprotected phosphate using the literature 
procedure described by Parry'°7 did not result in the sodium salt being formed. 
Model studies on sodium salt formation were carried out using the commercially 
available a-D-glucose-1-phosphate, which is purchased as its disodium salt. The 
disodium salt was firstly converted to the acid form by stirring in AG 50W-X2 resin 
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for two hours. Confirmation that the acid form had indeed been prepared was 
obtained by the 31P NMR spectrum (ö,, of disodium salt = 3.20, 8, of acid form = 
0.08). It was then attempted to convert the acid form to the sodium salt using AG 
50W-X2 resin, sodium form and Amberlite IR 120, sodium form using both a 
column method and by stirring in the resin, however none of these methods resulted 
in the sodium salt being formed. 
The preparation of the sodium salt could however be achieved by careful titration 
of the acid form with sodium hydroxide. 
As an alternative to the preparation of a disodium salt the formation of the 
di(cyclohexylammonium) salt was successfully achieved by stirring the acid form in 
cyclohexylamine. 
The protected phosphate 151 was then deprotected by treatment with 48-51% 
HF:MeCN:H20 (10:85:15) stirring for 24 hours before conversion to the disodium 
salt by titration with 1 M NaOH. 	However, 'H, '3C, 3'P NMR and mass 
spectrometry showed that the product of this reaction was a mixture of the desired 
fully deprotected phosphate (disodium salt) 152 and the MOM-protected phosphate 
(disodium salt) 153. Attempts to deprotect the MOM protecting group by stirring in 
Amberlite JR 120 (H) and trifluoroacetic acid were unsuccessful and resulted in the 
decomposition of the phosphorylated compound. 
(b) 	Synthesis via para-methoxybenzyl-protected compounds 
As the MOM group could not be deprotected without decomposition taking place 
it was decided to prepare the 1-phosphate 152 via the PMB-protected compounds. 
The desired 1-phosphate 152 was prepared from the PMB-protected alcohol 145 
as shown in Scheme 3.14. 
As for the MOM-protected alcohol 130, the secondary hydroxyl group of the 
PMB-protected alcohol 145 was phosphorylated using bis[2-(trimethylsilyl)ethyl]-
N,N-diethylphosphoramidite 150 in the presence of 1H-tetrazole. The intermediate 
phosphite ester formed was oxidised using MCPBA to give the protected phosphate 
154 in 83% yield. 
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Scheme 3.14 Reagents and conditions: a. i. (Me3SiCH2CH2O)2PNEt2  150, 1H-tetrazole, 
THF; ii. MCPBA, CH2C12, -70°C to room temperature, 83%; b. DDQ, CH2CL2:H20 (20:1), 
94%; c. 48-51% HF:MeCN:H20 (10:85:15); d. 0.1 M NaOH, H20; e. Ion-exchange 
chromatography, 60%. 
The PMB group of the protected phosphate 154 was then selectively deprotected 
using DDQ to give the protected phosphate 155 in 94% yield. 
Deprotection of the protected phosphate 155 by stirring in a solution of 48-51% 
HF:MeCN:H20 (10:85:15) for 7 hours and then conversion to the sodium salt by 
titration with sodium hydroxide gave a mixture of the desired fully deprotected 
phosphate 152 and the phosphate with one 2-(trimethylsilyl)ethyl group still attached 
156. 	This was contrary to the literature procedure described by Parry 
117 who 
successfully deprotected both 2-(trimethylsilyl)ethyl groups by stirring in a solution 
of 48% HF:MeCN:H20 (5:85:15) for 5 hours. 
Freeman et al.11°  reported that both 2-(trimethylsilyl)ethyl protecting groups could 
be deprotected by stirring the protected phosphate triester in hydrofluoric acid for 24 
hours. 	However stirring the acetonide protected phosphate 155 in 48-51% 
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HF:MeCN:H20 for 24 hours resulted in cleavage of the phosphate group taking 
place. When the MOM-protected phosphate 151 was subjected to these conditions 
cleavage of the phosphate group did not appear to occur, the reason for this is 
unknown however it may be a result of the differing solubilities of the compounds. 
In the literature it was reported that the use of alternative fluoride anion sources 
such as tetrabutylammonium fluoride, lithium tetrafluoroborate, ammonium fluoride 
and trifluoroacetic acid resulted in either the deprotection reaction being 
unsuccessful or only one 2-(trimethylsilyl)ethyl protecting group being removed."' 
Therefore the use of these methods for the deprotection of the protected phosphate 
155 was not attempted. 
The hydrofluoric acid deprotection reaction was carried out under a variety of 
conditions, the optimum of which was determined to be stirring in a solution of 48-
51% HF:MeCN:H20 (5-10:85:15) for 6 to 7 hours which gave a mixture of the fully 
deprotected phosphate 152 and the phosphate with one 2-(trimethylsilyl)ethyl group 
156 still attached. These compounds could however be easily separated by ion-
exchange chromatography using triethylammonium bicarbonate buffer to give the 
desired 1-phosphate 152 as its triethylammonium salt in 60% yield. 
3.3.3 Synthesis of 5-phosphate 83b 
Having established a synthetic route to the 1-phosphate 152, the 5-phosphate 83b 
was prepared from the PMB-protected acetate 144 using a similar synthetic pathway, 
as shown in Scheme 3.15. 
The PMB protecting group of the PMB-protected acetate 144 was selectively 
deprotected in the presence of the acetate and acetonide protecting groups by 
treatment with DDQ. 
The primary hydroxyl group of the resulting acetonide protected acetate 148 was 
then phosphorylated using bis[2-(trimethylsilyl)ethyl]-NN-diethylphosphoramidite 
150 in the presence of 1H-tetrazole. As for the previous syntheses the intermediate 
phosphite ester was oxidised using MCPBA to give the protected phosphate 157 in 
85% yield. 
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Exposure of the protected phosphate 157 to ammonia saturated methanol resulted 
in deprotection of the acetate group and formation of the protected alcohol 158 in 
73% yield. 
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Scheme 3.15 Reagents and conditions: a. DDQ, CH2C12:H20 (20:1), 84%; b. i. 
(Me3SiCH2CH20)2PNEt2 150, 1H-tetrazole, THF; ii. MCPBA, CH2Cl2, -60°C to room 
temperature, 85%; c. NH3 sat. MeOH, 73%; d. 48-51% HF:MeCN:H20 (5:85:15); e. 1 M 
NaOH; f. Ion-exchange chromatography, 53%. 
Deprotection of the protected alcohol 158 by stirring in a solution of hydrofluoric 
acid followed by conversion to the sodium salt led to a mixture of the desired fully 
deprotected phosphate 83b and the phosphate with one 2-(trimethylsilyl)ethyl group 
still attached 159. Purification of this mixture by ion-exchange chromatography 
gave the desired 5-phosphate 83b in 53% yield. 
The desired 5-phosphate 83b was also prepared by conversion to the 
di(cyclohexylammonium) salt as opposed to the disodium salt in approximately 50% 
yield. 
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3.4 	Summary of Chapter 3 
The syntheses of the 1-phosphate 152 and the 5-phosphate 83b have been 
successfully achieved from the synthetically useful cyclopentenone 61. 	This 
compound was prepared either from D-ribose 126 as outlined in Scheme 3.4 or from 
cyclopentadiene 36 as shown in Scheme 2.12. 
Unfortunately due to time constraints the synthesis of the pyrophosphorylated 
intermediate 84b and feeding studies with these compounds could not be carried out. 
3.5 	Future Work 
3.5.1 Preparation of pyrophosphorylated intermediate 84b 
Two approaches to the synthesis of the pyrophosphorylated intermediate 84b 
could be examined. 
(a) 	Synthetic approach 
The pyrophosphorylation of the 5-phosphate 83b could be investigated using the 
conditions shown in Figure 3.3, which have been reported for the preparation of the 
saturated analogue of the pyrophosphate in which the double bond is absent. 112,113 
0P032- 	 0P032- 	 0P032- 
bH 	a, b, c, d 	:C 
	
, \-?'bP206 3- 206 
O 	 0/0 	 HO bH X/\ 
Reagents and conditions: a. bis(morpholino)-2-cyanoethylphosphite, 1H-tetrazole, THF; b. 
MCPBA; c. i. NH3, MeOH; ii. Amberlite JR 120, sodium form; d. (n-Bu)3NH H2PO4 , 
C5H5N; e. H, H20. 
Figure 3.3 Proposed synthesis of pyrophosphate 84b 
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(b) Enzymatic approach 
The alternative approach to the synthesis of the pyrophosphate 84b could be 
















Figure 3.4 Proposed enzymatic synthesis of pyrophosphate 84b 
This approach to the synthesis of the pyrophosphate 84b has the advantage that 
the mild conditions are commensurate with the anticipated instability of the 
pyrophosphate 84b. However, studies carried out by Parry et al. 
107 found that the 5-
phosphate 83b was an inhibitor, rather than a substrate for 5-phosphoribosyl a-i-
pyrophosphate synthetases of both bacterial and human origin. This result suggests 
that the preparation of the pyrophosphate 84b via this procedure may be difficult. 
3.5.2 Feeding studies 
The phosphorylated compounds cannot pass through the cell wall. Therefore the 
feeding experiments cannot be carried out by simply feeding these substrates to the 
CC940 mutant of Streptomyces citricolor grown on GAM 6:6 medium, as described 
for the tetrol and keto-tetrol compounds in Section 2.4. 
Therefore, in order to establish that the phosphate 83b and the pyrophosphate 84b 
are intermediates on the biosynthetic pathway, cell-free extracts of Streptomyces 
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citricolor will be required. These cell-free extracts could be obtained by adapting a 
procedure developed by Parry et al.87  to obtain a cell-free enzyme extract that is able 
to convert tetrol 83a to neplanocin A and aristeromycin. 	Using this cell-free 
enzyme extract the phosphate 83b and the pyrophosphate 84b will be assessed as 
intermediates on the biosynthetic pathway. 
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4 	Future Work - Exploitation of the Biosynthetic Pathway for the 
Preparation of Novel Carbocyclic Compounds 
Many further investigations must be carried out in order to obtain a complete 
understanding of the biosynthesis of aristeromycin and neplanocin A from D-glucose 
by the organism Streptomyces citricolor. However, an important consequence of 
understanding the biosynthetic pathway in detail is that it should be possible to 
exploit the enzymes involved for the conversion of unnatural substrates thereby 
generating novel chiral products and unnatural carbocyclic nucleoside analogues that 
would be difficult to prepare by alternative chemical procedures. 	These 
investigations would include: 
feeding analogues of D-glucose in which the 3-OH group is replaced by F, N3, H 
etc. For these experiments, in addition to the wild-type strain, a mutant of 
Streptomyces citricolor could be used. For example, the secretor mutant CC9 14 
which produces tetrol 83a when supplied with glucose, would yield the 
corresponding analogues of tetrol 83a as shown in Scheme 4.1. 
	
OH 	 OH 
HQ 	6 OH 
Streptomyces citricolor 
x OH X=F,N3,H 	) OH 
Scheme 4.1 
synthesising analogues of the keto-tetrol 95, enone 82a and tetrol 83a and then 
feeding these to the converter mutant CC940 to obtain modified carbocyclic 
structures and novel carbocyclic nucleoside analogues. 
replacing adenine with alternative purine precursors to obtain novel analogues of 




5.1 	General Experimental 
5.1.1 Instrumentation 
'H, '3C and 31P NMR spectra were recorded on either a Varian Gemini 200, 
Bruker AC 250, Bruker WH 360 or Varian UNITY NOVA 600 instrument. 
Chemical shifts (oH, 8c, 8,) are reported in parts per million (ppm) and coupling 
constants (J) are reported in Hertz (Hz) and quoted to the nearest 0.5 Hz. 
Electron Impact (El) mass spectrometry was carried out on a Finnegan 4500 or a 
Finnegan 4600 instrument and Fast Atom Bombardment (FAB) mass spectrometry 
was performed using a Kratos MS50TC instrument. Electrospray (ES) and 
Atmospheric Pressure Chemical lonisation (APCI) mass spectrometry was carried 
out on a Micromass Platform II instrument. 
Infrared spectra were recorded on a Biorad FTS-7 or a Perkin Elmer Paragon 
1000 FT-JR spectrometer with the frequencies (v) being measured in wavenumbers 
(cm-'). Samples were recorded as thin films using either sodium chloride plates or 
disposable IR cards (3M, type 61, polyethylene 19 mm aperture), as nujol mulls or in 
solution. 
Optical rotations were measured on an Optical Activity AA-1000 polarimeter 
with a cell path length of 1 dm and concentrations (c) quoted in g/100 ml (sodium 
589 nm detection). [a]DT values are given in 10' deg cm2 g'. 
Elemental analysis was performed using a Perkin-Elmer 2400 CHN Elemental 
Analyser. 
Melting points were obtained on a Gallenkamp melting point apparatus and are 
given in (°C) uncorrected. 
Chiral gas chromatography was carried out on a Shimadzu GC-17A Gas 
Chromatograph with Shimadzu C-R6A Chromatopac recorder. A Supelco 13-dex 
120 column (30 m x 0.25 mm) was used with a column temperature of 125°C, 
injector temperature of 260°C, detector temperature of 300°C and helium as the 




Analytical thin layer chromatography (TLC) was carried out on Merck aluminium 
backed plates coated with silica gel 60 F254  and components were identified using p-
anisaldehyde, ammonium molybdate and potassium permanganate dips. 
Flash column chromatography was carried out using the appropriately sized 
parallel-sided column filled with silica gel 60 (Merck 9385, particle size 0.04-0.063 
mm). 
Phosphate esters were purified by ion-exchange chromatography using the 
following procedure: 
1 M triethylammonium bicarbonate buffer solution was prepared by bubbling 
carbon dioxide through an immiscible mixture of freshly distilled triethylamine (139 
ml) and deionized water (861 ml) until the triethylamine had dissolved and a pH of 8 
was obtained. 
AG 1-X2 resin (Biotechnology grade, 200-400 mesh, hydroxide form, strongly 
basic anion exchange resin, approximately 0.5 g), made into a slurry with deionized 
water, was pipetted into a small parallel-sided column (diameter = 8 mm) to give a 
resin bed of approximately 6 cm. A piece of cotton-wool was placed on top and the 
resin was then washed with deionized water before being converted to the 
bicarbonate form by washing with 1 M triethylammonium bicarbonate buffer 
solution (final pH = 8). When converted the resin was washed repeatedly with 
deionized water (final pH = 6). 
The mixture containing the phosphate ester (approximately 20 mg) was dissolved 
in the minimum amount of deionized water and the resulting solution applied to the 
top of the resin bed. The phosphates were then eluted with portions (20 ml) of 
increasing concentration of triethylammonium bicarbonate buffer solution, starting 
with water then increasing by 5 mM to 50 mM. 
5.1.3 Solvents and reagents 




Where a solvent has been described as anhydrous, it was either purchased as 
anhydrous grade or was distilled prior to use. Dichloromethane was distilled from 
calcium hydride and tetrahydrofiran was distilled from sodium benzophenone ketyl. 
DBU, diethylamine, diisopropylamine, dimethyl methylphosphonate, phosphorous 
trichloride, trichioroacetonitrile and triethylamine were distilled before use. 
Petroleum ether refers to the fraction bp 45-60°C. 
Novozyme® was received as a gift from Novo-Nordisk. 
n-BuLi was titrated against N-pivaloyl-o-toluidine 5  or diphenylacetic acid before 
use. Sodium hydride (60% dispersion in mineral oil) was washed under an 
atmosphere of nitrogen with anhydrous petroleum ether before use. 
Amberlite IR 120 (H) ion-exchange resin was activated by stirring in 2 M HCI for 
30 min then washing with water until the washings were neutral pH. 
Cyclopentadiene was obtained by heating dicyclopentadiene in distillation 
apparatus equipped with a 30 cm vigreux column. The cyclopentadiene was 
distilled at 40-44°C at a rate of approximately 0.5 g/min, and collected in a receiver 
flask cooled in an ice bath. Excessive heating was avoided in order to minimise 
distillation of the dimer. 
Jones reagent (1.34 M) was prepared by dissolving chromium trioxide (13.40 g, 
0.13 mol) in concentrated sulfuric acid (12 ml) and then diluting to 100 ml with 
distilled water. 93 
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5.2 	Experimental Procedures for Chapter 2 
5.2.1 Synthesis of ent-keto-tetrol ent-95 
(a) 	2,3-0-Isopropylidene-D-ribonolactone ent-103 
A solution of D-(+)-ribonic acid-?-lactone (10.32 g, 69.7 mmol, 1.0 eq) and p-
toluenesulfonic acid (1.05 g, 5.52 mmol, 0.08 eq) in acetone (400 ml) was stirred at 
room temperature under nitrogen for 18 h. Sodium bicarbonate was then added until 
a pH = 6 was obtained and the mixture was stirred for 1 h before being filtered 
through a pad of silica. The silica was washed with ethyl acetate (500 ml) and the 
filtrate was concentrated to give the protected ribonolactone enl-103 as a white solid 
(12.98 g, 99%); mp 134-138°C (lit.  116 mp 134-1370C); (Found: C, 51.19; H, 6.71. 
C8H1205 requires C, 51.06; H, 6.43%); Rf 0.74 (EtOAc); [a]D24 —69.9 (c 0.81 in 
CHC13); vmax(flujol)/cm' 3463 (OH), 1764 (C=O), 1383 (CMe2), 1224 (CO); 54250 
MHz; CDC13) 4.79 (2H, 2d, J 5.5 and 5.5, 2-H and 3-H), 4.62 (1H, t, J 2.0, 4-H), 
3.98 (1H, br d, J 12.0, CH2), 3.77 (1H, br d, J 12.0, CR2), 2.84 (1H, br s, OH), 1.46 
(3H, s, CCH3), 1.36 (3H, s, CCH3); 8(63 MHz; CDC13) 175.2 (CO), 113.1 (CMe2), 
82.9 (CH), 78.3 (CH), 75.6 (CH), 61.8 (CH2), 26.7 (CH3), 25.4 (CH3); m/z (FAB) 189 




(b) 	5-0-(p-Toluenesufonyl)-2,3-0-isopropylidene-D-ribonolactofle ent-104 
-O-EH°' 
dXo 
A mixture of the protected ribonolactone ent-103 (12.90 g, 68.6 mmol, 1.0 eq), p-
toluenesulfonyl chloride (23.45 g, 0.12 mol, 1.8 eq) and pyridine (15.00 ml, 0.19 
mol, 2.7 eq) in chloroform (100 ml) was stirred at room temperature under nitrogen 
for 19 h. Water (15 ml) was added and the mixture was stirred for a further 30 mm. 
The mixture was diluted with dichloromethane (250 ml) and then poured over 1 M 
citric acid (2 x 250 ml). The organic portion was washed with brine (300 ml), dried 
over sodium sulfate, filtered and concentrated. Diethyl ether (100 ml) was added to 
the resulting yellow oil and after slight swirling a white solid crystallised out. The 
solid was collected by filtration to give the tosylate ent-104 as an off-white solid 
(18.72 g, 80%); mp 117°C (lit.  117 mp 117.5-1180C); (Found: C, 52.64; H, 5.46. 
C15H1807S requires C, 52.62; H, 5.30%); Rf 0.56 (EtOAc:hexane, 1:1); [a]D24 —15.2 
(c 1.05 in CHCI3); vmax(nUjol)/cm' 1784 (C0), 1594 (C=Car), 1373 (CMe2), 1215 
(CO), 1175 (S02-0); 64200 MHz; CDC13) 7.74 (2H, d, J 8.5, 2 X Har), 7.37 (2H, d, J 
8.5,2 x Har), 4.75 (2H, 2d, J5.5 and 5.5, 2-H and 3-H), 4.67 (1H, t, J2.0, 4-H), 4.33 
(1H, dd, J 2.0 and 11.0, CH2), 4.16 (1H, dd, J 2.0 and 11.0, CH2), 2.45 (3H, s, 
PhCH3)1  1.44 (3H, s, CCH3), 1.37 (3H, s, CCH3); 8(63 MHz; CDC13) 173.1 (C=O), 
145.9 (Car), 131.5 (Car), 130.2 (2 x CHar), 127.9 (2 x CHar), 113.8 (CMe2), 79.0 (CH), 
77.3 (CH), 75.0 (CH), 68.2 (CH2), 26.6 (CH3), 25.5 (CH3), 21.7 (PhCH3); m/z (FAB) 
343 (MH, 19%), 155 (CH3C6H4SO2, 8), 91 (CH3C6H4, 100); [Found: MH, 




A stirred solution of the tosylate ent-104 (17.74 g, 51.8 mmol, 1.0 eq) and sodium 
iodide (15.54g, 0.10 mol, 2.0 eq) in acetone (250 ml) was heated at reflux for 18 h 
before being allowed to cool to room temperature. The mixture was then filtered 
through Celite and the filtrate was concentrated under reduced pressure. 	The 
concentrated residue was dissolved in ethyl acetate (300 ml) and the solution was 
washed with saturated aqueous sodium thiosulfate (250 ml). The organic portion 
was dried over sodium sulfate, filtered and concentrated to give a pale yellow solid. 
Recrystallisation of the solid from ethyl acetate-hexane gave the iodide ent-105 as 
white needle-like crystals (13.14 g, 85%); mp 93-94°C (lit." mp 95-970C); (Found: 
C, 32.32; H, 3.75. C8H11104 requires C, 32.24; H, 3.72%); Rf 0.36 (EtOAc:hexane, 
1:3); [a]D24 —35.1 (c 1.10 in CHC13); vma (nujol)/Cm 1  1778 (C0), 1371 (CMe2), 
1216 (CO); 84250 MHz; CDCI3) 4.97 (1H, d, J 6.0, 2-H), 4.63 (1H, in, 4-H), 4.60 
(1H, d, J6.0, 3-H), 3.40 (2H, in, CH2), 1.46 (3H, s, CCH3), 1.38 (3H, s, CCH3); 6 (63  
MHz; CDC13) 172.9 (C=O), 113.9 (CMe2), 80.7 (CH), 80.2 (CH), 75.1 (CH), 26.4 
(CH3), 25.3 (CH30.5 (CH2); m/z (FAB) 299 (MH, 41%); [Found: MH, 298.97853. 










DBU (1.02 ml, 6.84 mmol, 1.0 eq) was added dropwise to a solution of the iodide 
ent-105 (2.04 g, 6.84 mmol, 1.0 eq) in anhydrous THF (15 ml) to give a pale yellow 
solution containing a white solid, which was stirred at room temperature under 
nitrogen for 40 mm. The mixture was cooled to -78°C and the solution was then 
separated from the solid by filter cannulation of the solution into a round-bottomed 
flask under nitrogen. The resulting pale brown solution of enol-lactone ent-99 was 
then cooled to -78°C. 
A solution of [(p-methoxybenzyloxy)methyl]tri-n-butylstanflafle 108 (3.07 g, 6.96 
mmol, 1.02 eq) in anhydrous THF (29 ml) was cooled to -78°C. n-BuLi (1.57 M 
solution in hexanes, 4.36 ml, 6.84 mmol, 1.0 eq) was then added dropwise over 2 
min to give a pale yellow solution which was stirred at -78°C for 5 mm. The cooled 
enol-lactone ent-99 solution was then added quickly via nitrogen pressure transfer 
through a double tipped needle. The resulting yellow solution was stirred at -78°C 
for 17 min after which time the reaction mixture was quenched by the addition of 
saturated aqueous ammonium chloride (20 ml). The mixture was then allowed to 
warm to room temperature before being poured into ethyl acetate (20 ml) and 
saturated aqueous ammonium chloride (10 ml). The organic layer was separated 
and the aqueous portion was extracted with ethyl acetate (3 x 75 ml). The combined 
organic portions were washed with water (150 ml) and brine (150 ml), dried over 
sodium sulfate, filtered and concentrated. The resulting colourless liquid containing 
a yellow oil was purified by flash column chromatography using ethyl acetate-
hexane (3:7) as the eluent to give the PMB -protected /Jhydroxycyclopentanone ent-
106 as a pale yellow oil (762 mg, 35%); Rf O.49 (EtOAc:hexane, 1:1); [aID24  +97.2 (c 
1.04 in CHC13); vm (neat)/cm 1 3460 (OH), 2988, 2936, 2866 and 2838 (CH), 1760 
(C=O), 1612 (CCar), 1514 (CCar), 1374 (CMe2), 1248 (CO); 84250 MHz; CDC13) 
7.26 (2H, d, J 8.5, 2 x Har), 6.89 (2H, d, J 8.5, 2 x Har), 4.61-4.38 (4H, m, PhCH2, 2-H 
and 3-H), 3.81 (3H, s, OCH3), 3.75 (1H, d, J9.5, CH20), 3.55 (1H, d, J9.5, CH20), 
2.91 (1H, br s, OH), 2.54 (1H, d, J 18.0, C-6-H2fldO), 2.24 (1H, dt, J 1.5 and 18.0, C-
6-H20), 1.39 (3H, s, CCH3), 1.35 (3H, s, CCH3); 6(63 MHz; CDCI3) 211.0 (C=O), 
159.3 (Ca), 129.5 (Ca), 129.3 (2 x CHar), 113.8 (2 x CHar), 113.1 (CMe2), 81.2 (CH), 
79.3 (CH), 75.0 (C-4), 73.2 (CH2), 71.0 (CH2), 55.2 (OCH3), 43.5 (C-6H2), 26.8 
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(CH3), 24.9 (CH3); m/z (El) 322 (M, 1%), 201 (M-CH30C6H4CH2, 3), 137 
(CH30C6H4CH20, 19),121 (CH30C6H4CH2, 100); [Found: M, 322.14186. C17H2206 







Palladium on activated charcoal (10% Pd, 198 mg, 0.018 g of Pd, 0.186 mmol, 0.5 
e 	was added to a solution of the PMB-protected 3-hydroxycyc1opentanone ent-106 
(120 mg, 0.372 mmol, 1.0 eq) in anhydrous THF (4 ml) and the mixture was 
vigorously stirred for 3 h under an atmosphere of hydrogen. The catalyst was then 
removed by filtering through Celite. The Celite was washed repeatedly with ethyl 
acetate and the filtrate was concentrated under reduced pressure. The resulting pale 
yellow oil was purified by flash column chromatography using ethyl acetate-hexane 
(4:1) as the eluent to give the acetonide-protected /3-hydroxycyclopentanone ent-107 
as a colourless oil (51 mg, 68%); Rf 0.49 (EtOAc); lab 22 +171.1 (c 1.03 in CHC13); 
vm (fleat)/cm 1 3437 (OH), 2988, 2938 and 2879 (CH), 1760 (C=O), 1376 (CMe2), 
1213 (CO); 11(250 MHz; CDC13) 4.55 (1H, dd, J 1.5 and 5.0, 3-H), 4.43 (1H, ddd, J 
1.0, 1.5 and 5.0, 2-H), 3.93 (1H, d, J 11.0, CH20H), 3.74 (1H, d, J 11.0, CH20H), 
3.28 (1H, br s, C-4-OH), 2.63 (1H, dd, J 1.0 and 18.0, C6H2efldo), 2.25 (1H, dt, J 1.5 
and 18.0, C-6-H20), 1.41 (3H, s, CCH3), 1.34 (3H, s, CCH3); 5(63 MHz; CDC13) 
211.0 (C=O), 113.4 (CMe2), 81.1 (CH), 79.3 (CH), 75.9 (C-4), 64.5 (CH20H), 43.2 
(C-6H2),26.7 (CH3), 24.8 (CH3); m/z (FAB) 203 (MH, 100%), 185 (M-OH, 6),171 
(M-CH20H, 2); [Found: MH, 203.09205. C9H1405 requires MH, 203.09195]. 
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(1) 	(2S,3R,45)-4-Hydroxymethyl-2,3,4-trihydroxy-cyClOPefltafl-1-Ofle ent-95 
OH 
O /OH 
Trifluoroacetic acid (0.5 ml) was added to a solution of the protected 0-
hydroxycyclopentanone ent-107 (108 mg, 0.534 mmol, 1.0 eq) in anhydrous 
dichioromethane (2 ml). The resulting pale yellow solution was stirred at room 
temperature for 3 min before being concentrated under reduced pressure to give a 
brown oil. The brown oil was purified by flash column chromatography using 
methanol-chloroform (2:8) as the eluent to give the desired keto-tetrol ent-95 as a 
colourless foam (23 mg, 26%). 'H, '3C NMR and mass spectrometry showed that 
the keto-tetrol ent-95 was contaminated with minor traces of the eliminated enone 
ent-82a (47:1), determined by 250 MHz 'H NMR analysis. 
(2S, 3R, 4S)-4-Hydroxymethyl-2, 3, 4-trihydroxy-cyclopentan-] -one ent-95 
Rf 0.38 (MeOH:CHC13, 3:7); 84250 MHz; D20) 4.66 (1H, d, J4.5, 2-H), 4.15 (1H, 
d, J4.5, 3-H), 3.77 (1H, d, J 12.0, CH20H), 3.65 (1H, d, J 12.0, CH20H), 2.34 (2H, 
s, C-6-H2); 8(63 MHz; D20) 215.4 (CO), 73.9 (CH), 73.6 (C-4), 70.7 (CH), 61.5 
(CH20H), 39.6 (C-6H2); m/z (FAB) 163 (MH, 2%),131 (M-CH20H, 60). 
(2S, 3S)-4-Hydroxymethyl-2, 3-dihydroxy-cyclopent-4-en-1-one ent-82a 
R1  0.44 (MeOH:CHC13, 3:7); m/z (FAB) 145 (MW, 3%), 113 (M-CH20H, 5). Peaks 
in 'H and '3C NMR spectra were too small to measure. 
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DBU (1.02 ml, 6.84 mmol, 1.0 eq) was added dropwise to a solution of the iodide 
105, prepared from L-ribose by I. V. J. Archer (2.04 g, 6.84 mmol, 1.0 eq) in 
anhydrous THF (15 ml) to give a pale yellow solution containing a white solid, 
which was stirred at room temperature under nitrogen for 40 mm. The mixture was 
then cooled to -78°C and the solution was separated from the solid by filter 
cannulation of the solution into a round-bottomed flask under nitrogen. 	The 
resulting pale brown solution of enol-lactone 99 was then cooled to -78°C. 
A solution of [(p-methoxybenzyloxy)methyl]tri-n-butylstannane 108 (3.07 g, 6.96 
mmol, 1.02 eq) in anhydrous THF (29 ml) was cooled to -78°C. n-BuLi (1.53 M 
solution in hexanes, 4.47 ml, 6.84 mmol, 1.0 eq) was then added dropwise over 2 
min to give a pale yellow solution which was stirred at -78°C for 5 mm. The cooled 
enol-lactone 99 solution was then added quickly via nitrogen pressure transfer 
through a double tipped needle and the resulting yellow solution was stirred at -78°C 
for 15 min after which time the reaction mixture was quenched by the addition of 
saturated aqueous ammonium chloride (15 ml). The mixture was allowed to warm 
to room temperature before being poured into ethyl acetate (20 ml) and saturated 
aqueous ammonium chloride (10 ml). The organic layer was separated and the 
aqueous portion was extracted with ethyl acetate (2 x 100 ml). The combined 
organic portions were washed with water (175 ml) and brine (175 ml), dried over 
sodium sulfate, filtered and concentrated. The resulting colourless liquid containing 
a yellow oil was purified by flash column chromatography using ethyl acetate- 
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hexane (7:13) as the eluent to give the PMB -protected ,&hydroxycyclopentanone 106 
as a pale yellow oil (1.21 g, 55%); Rf 0.55 (EtOAc:hexane, 1:1); [aJD24  —92.0 (c 0.97 
in CHC13); vmax(fleat)/Cm '  3464 (OH), 2989, 2937 and 2866 (CH), 1761 (C=O), 1613 
(CCar), 1514 (C=Car), 1376 (CMe2), 1250 (CO); 64250 MHz; CDC13) 7.26 (2H, d, J 
9.0, 2 x Ha),  6.89 (2H, d, J 9.0, 2 X Ha), 4.61-4.37 (4H, in, PhCH2, 2-H and 3-H), 
3.80 (3H, s, OCH3), 3.75 (1H, d, J 9.5, CH20), 3.55 (1H, d, J 9.5, CH20), 2.93 (1H, 
br s, OH), 2.54 (1H, d, J 18.0, C-6-H20), 2.24 (1H, dt, J 1.5 and 18. 0, C6H2efldo), 
1.39 (3H, s, CCH3), 1.34 (3H, s, CCH3); 5(63 MHz; CDC13)  211.0 (C0), 159.3 
(Ca), 129.5 (Ca), 129.3 (2 X CHar), 113.8 (2 x CHar), 113.1 (CMe2), 81.2 (CH), 79.3 
(CH), 75.0 (C-4), 73.2 (CH2), 71.0 (CH2), 55.2 (OCH3), 43.5 (C-6H2), 26.8 (CH3), 
24.9 (CH3); m/z (El) 322 (M, 1%), 201 (M-CH30C6H4CH2, 3), 137 
(CH3OC6H4CH20, 12), 121 (CH30C6H4CH2, 100); [Found: W, 322.14213. C17H2206 
requires M, 322.14 164]. 
(b) (2R,3S,4R)2,3(Isopropylidenedioxy)-4-hydroxyfflethY1-4-hYdrOXY-
cyclopentan-1-one 107 
Palladium on activated charcoal (10% Pd, 867 mg, 0.087 g of Pd, 0.814 mmol, 0.5 
eq) was added to a stirred solution of the PMB-protected -hydroxycyclopentanone 
106 (525 mg, 1.63 mmol, 1.0 eq) in anhydrous THF (16 ml). The mixture was then 
vigorously stirred under an atmosphere of hydrogen for 2 h 20 mm. The mixture 
was filtered through Celite, the Celite was washed repeatedly with ethyl acetate, and 
the filtrate was concentrated under reduced pressure. The resulting pale yellow oil 
was purified by flash column chromatography using ethyl acetate-hexane (4:1) as the 
eluent to give the acetonide-protected ,8-hydroxycyclopentanone 107 as a colourless 
oil (188 mg, 57%); R f O.S3 (EtOAc) [a]D24 —163.1 (c 1.17 in CHC13); vm (neat)/cm' 
3437 (OH), 2989, 2938 and 2879 (CH), 1760 (C=O), 1378 (CMe2), 1213 (CO); 
811(250 MHz; CDC13) 4.55 (1H, dd, J 1.5 and 5.0, 3-H), 4.43 (1H, ddd, J 1.0, 1.5 and 
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5.0, 2-H), 3.93 (1H, d,J 1.1.0, CH20H), 3.73 (1H, d,J 11.0, CH20H), 3.14 (1H, br s, 
C-4-OH), 2.62 (1H, dd, J 1.0 and 18.0, C-6-H20), 2.48 (1H, br s, OH), 2.25 (1H, dt, 
J 1.5 and 18.0, C6H2endo), 1.41 (3H, s, CCH3), 1.35 (3H, s, CCH3); 6(63 MHz; 
CDC13) 210.8 (C0), 113.4 (CMe2), 81.2 (CH), 79.3 (CH), 75.8 (C-4), 64.5 
(CH20H), 43.1 (C-6H2), 26.7 (CH3), 24.8 (CH3); m/z (FAB) 203 (MH, 100%), 185 
(M-OH, 2), 171 (M-CH20H, 4); [Found: MH, 203.09265. C9H1405 requires MH, 
203.09 195]. 
(c) 	(2R,3S,4R)-4-Hydroxymethyl-2,3,4-trihydroxy-cyClOPefltaIl-1-Ofle 95 
Trifluoroacetic acid (0.7 ml) was added to a solution of the protected 3-
hydroxycyclopentanone 107 (150 mg, 0.742 mmol, 1.0 eq) in anhydrous 
dichioromethane (2.8 ml). The resulting pale yellow solution was stirred at room 
temperature for 3 min before being concentrated under reduced pressure to give a 
brown oil. The brown oil was purified by flash column chromatography using 
methanol-chloroform (1:4) as the eluent to give the desired keto-tetrol 95 as a 
colourless oil (48 mg, 40%). 'H, 13C NIVIR and mass spectrometry showed that the 
keto-tetrol 95 was contaminated with minor traces of the eliminated enone 82a 
(10:1), determined by 600 MHz 1H NMR analysis. 
(2R, 3S, 4R) -4-Hydroxymethyl-2 , 3, 4-trihydroxy-cyclopentan-1-one 95 
R f 0.32 (MeOH:CHC13, 3:7); 611(600 MHz; D20) 4.74 (1H, d, J 4.5, 2-H), 4.24 (1H, 
d, J4.5, 3-H), 3.86 (1H, d, J 12.0, CH20H), 3.73 (1H, d, J 12.0, CH20H), 2.43 (2H, 
s, C-6-H2); 5(91 MHz; D20) 218.4 (C=O), 76.9 (CH), 76.6 (C-4), 73.6 (CH), 64.5 
(CH20H), 42.6 (C-6H2); m/z (FAB) 163 (MH, 2%),131 (M-CH20H, 77). 
(2R. 3R)-4-Hydroxymethyl-2, 3-dihydroxy-cyclopent-4-en-1-one 82a 
R f 0.39 (MeOH:CHC13, 3:7); 6H(600 MHz; D20) 6.33 (1H, t, J 2.0, =CH), 4.79 (1H, 
obscured by D20 residual peak, 2-H), 4.68 (1H, dd, J 2.0 and 19.0, CH20H), 4.54 
113 
Experimental 
(1H, dd, J 2.0 and 19.0, CH20H), 4.34 (1H, d, J 6.0, 3-H); 6(91  MHz; D20) 209.6 
(C=O), 179.6 (C-4), 126.5 (=CH), 72.5 (CH), 69.0 (CH), 60.5 (CH20H); m/z (FAB) 
145 (MH, 3%),113 (M-CH20H, 5). 
(d) 	(2R,3R)-4-Hydroxymethyl-2,3-dihydroxy-cyclopent-4-en-1-ofle 82a 
Trifluoroacetic acid (1 ml) was added to a stirred solution of the keto-tetrol 95 and 
enone 82a (30 mg) in dichioromethane (2 ml) and methanol (0.5 ml). The resulting 
yellow solution was stirred at room temperature for 1 h after which time further TFA 
(1 ml) was added and the solution was stirred for a further 3 h 45 mm. TLC showed 
that the keto-tetrol was still present therefore additional TFA (1 ml) was added and 
the solution was stirred at room temperature for 18 h. The brown solution was then 
concentrated under reduced pressure and the resulting brown oil was purified by 
flash column chromatography using methanol-chloroform (1:4) as the eluent to give 
the enone 82a as a yellow oil (12 mg, 45%); Rf 0.39 (MeOH:CHC13, 3:7); 
vmax(fleat)/Cm 1 3368 (OH), 2989, 2921 and 2853 (CH), 1755 (C=O), 1682 (C=C), 
1212 (CO); 84600 MHz; D20) 6.28 (1H, s, =CH), 4.80 (1H, obscured by D20 
residual peak, 2-H), 4.63 (1H, d, J 19.0, CH20H), 4.49 (1H, d, J 19.0, CH20H), 4.29 
(1H, d, J 5.5, 3-H); 5J91 MHz; D20) 209.6 (C=O), 179.6 (C-4), 126.5 (CH), 72.5 
(CH), 68.9 (CH), 60.5 (CH20H); m/z (FAB) 145 (MH, 4%),113 (M-CH20H, 10); 
[Found: MH, 145.05 101. C6H804 requires MH, 145.05008]. 
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Sodium acetate (12.00 g) was added to peracetic acid (36-40% wt. solution in 
acetic acid, 196 ml, 1.05 mol, 0.72 eq) and the mixture was set aside until dissolution 
was complete. 
Cyclopentadiene 36 (96.12 g, 1.45 mol, 1.0 eq) was added to a mechanically 
stirred mixture of sodium carbonate (483 g) in dichioromethane (820 ml) cooled to 
0°C. The buffered peracetic acid solution was then added dropwise via a dropping 
funnel. After approximately 10 min carbon dioxide gas was given off and the rate 
of addition was controlled by monitoring the rate of carbon dioxide passing through 
a bubbler. After 1 h, when the addition was complete, the cooling bath was 
removed and the mixture was stirred at room temperature for 1 h 30 mm. A sample 
was removed and dropped into saturated aqueous sodium iodide (brown colour in 
presence of oxidant) no colour was observed therefore the reaction was deemed to be 
complete. 	The mixture was filtered and the filtrate concentrated under slight 
vacuum. Distillation at 160 mmHg (64°C) (lit.  118 bp 39-41°C at 46 mm) gave the 
cyclopentadiene monoepoxide 121 as a yellow liquid (28.13 g, 24% based on 
cyclopentadiene); vmax(neat)/cm' 3050 (epoxide CH), 2910 (CH), 1673 (C=C), 1283 
(CO), 913 and 813 (epoxide CO); 84200 MHz; CDC13) 6.13 (1H, in, =CH), 6.00 
(1H, in, =CH), 3.90 (1H, in, CHO), 3.80 (1H, in, CHO), 2.67-2.31 (2H, in, CR2); 
5(63 MHz; CDCI3) 137.7 (=CH), 131.1 (=CH), 59.1 (CHO), 56.7 (CHO), 35.4 
(CH2); m/z (FAB) 83 (MH, 100%), 66 (M-0, 34); [Found (El): M, 82.04 156. 
C5H60 requires M, 82.04186]. 
(b) 	cis-1,4-Diacetoxycyclopent-2-ene 48' 
AcO4yOAC 
A solution of cyclopentadiene monoepoxide 121 (25.00 g, 0.31 mol, 1.0 eq) in 
anhydrous THF (50 ml) was added dropwise over 10 min to an ice-cooled, stirred 
solution of tetrakis(triphenylphosphine)palladium(0) (1.76 g, 1.53 mmol, 0.5 mol %) 
and acetic anhydride (30 ml, 0.32 mol, 1.04 eq) in anhydrous THF (250 ml). After 
stirring at 0°C for 10 min the mixture was filtered through silica, the silica was 
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washed with diethyl ether (200 ml) and the filtrate was concentrated. The resulting 
brown oil was purified by flash column chromatography using ethyl acetate-hexane 
(3:17) as the eluent to give the diacetate 48 as an orange/brown oil (33.11 g, 59%); 
Rf 0.69 (EtOAc:hexane, 1:1); vmax(neat)/Cm ' 3075 (C=C-H), 2992 and 2951 (CH), 
1737 (C0), 1234 (CO); 54250 MHz; CDC13) 6.07 (2H, d, J 1.0, 2-H and 3-H), 5.52 
(2H, ddd, J 1.0, 4.0 and 7.5, 1-H and 4-H), 2.85 (1H, dt, J 7.5 and 15.0, C-S -H 2endo), 
2.03 (6H, s, 2 x CH3), 1.71 (1H, dt, J 4.0 and 15.0, C-5-H20); 8(63 MHz; CDC13) 
170.6 (2 x C0), 134.4 (2 x =CH), 76.4 (2 x CHO), 36.9 (CH2), 21.0 (2 x CH3); m/z 
(FAB) 185 (MH, 9%), 141 (M-CH3CO, 2), 125 (M-CH3C(0)O, 100), 43 (CH3CO, 
48); [Found: MH, 185.08163. C9H1204 requires MH, 185.08138]. Spectroscopic 




The diacetate 48 (9.94 g, 54.0 mmol, 1.0 eq) was added to a suspension of 
Novozyme®  SP435 (2.0 g) in 50 mM phosphate buffer (1H = 8) (600 ml) and the 
resulting yellow mixture was stirred at room temperature for 4 h. The mixture was 
filtered to remove the catalyst, which was rinsed with ethyl acetate (50 ml). The 
filtrate was then saturated with sodium chloride and extracted with ethyl acetate (3 x 
500 ml). 	The organic portions were dried over sodium sulfate, filtered and 
concentrated under reduced pressure. The resulting yellow oil was purified by flash 
column chromatography using ethyl acetate-hexane (1:1) as the eluent to give the 
monoacet ate 49 as an off-white solid (4.97 g, 85% based on recovered starting 
material); mp 45-48°C (lit. 96  mp 46-48.5°C); (Found: C, 58.86; H, 6.94. C7H1003 
requires C, 59.14; H, 7.09%); Rf 0.42 (EtOAc:hexane, 1:1); Optical purity >99% e.e. 
(determined by chiral GC); [aID24 +67.4 (c 1.12 in CHCI3); v(nujol)/cm' 3328 
(OH), 1726 (C=O), 1243 (CO); 6H(200 MHz; CDC13) 6.09 (1H, ddd, J 1.0, 2.0 and 
5.5, 3-H), 5.96 (1H, ddd, J 1.0, 2.0 and 5.5, 2-H), 5.48 (1H, m, 4-H), 4.69 (1H, in, 1-
H), 2.78 (1H, dt, J7.5 and 14.5, C5H2endo), 2.03 (3H, s, CH3), 1.92 (1H, br s, OH), 
1.63 (1H, dt, J 4.0 and 14.5, C-5-H20); 8(50 MHz; CDC13) 170.7 (CO), 138.4 
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(=CH), 132.4 (=CH), 76.9 (CHO), 74.7 (CHO), 40.4 (CH2), 21.1 (CH3); m/z (FAB) 
143 (MH, 37%), 125 (M-OH, 43), 99 (M-CH3CO, 3), 83 (M-CH3C(0)0, 37), 43 
(CH3CO, 19); [Found: MH, 143.07041. C7H,003 requires MH, 143.070821. 
(d) (1S,2R,3R,4R)-4-Acetoxy-cyclopentan-1,2,3-triol 122 
HO 	 Ac 
Acetone (60 ml) and water (21 ml) were added to a solution of the monoacetate 
49 (15.30 g, 0.11 mol, 1.0 eq) in THF (150 ml). NMO (24.00 g, 0.18 mol, 1.6 eq) 
followed by osmium tetroxide (4 wt. % solution in water, 0.69 ml, 0.109 mmol, 0.1 
mol %) were then added and the resulting yellow solution was stirred at room 
temperature for 19 h. Sodium bisulfite (1.65 g) was added to the solution, which 
was then concentrated under reduced pressure. The resulting brown oil was purified 
by flash column chromatography using methanol-ethyl acetate (1:19) as the eluent to 
give the triol 122 as a yellow oil, which formed an off-white oily solid when stored 
in the freezer (16.62 g, 88%); Rf 0.57 (MeOH:EtOAc, 1:9); lab 24 —41.4 (c 1.00 in 
MeOH) lit."' lab 25 —44.3 (c 1.30 in MeOH); vma (nujol)/cm' 3370 (OH), 1715 
(C=O), 1263 (CO); 84250 MHz; D20) 4.87 (1H, dt, J5.0 and 8.0, 4-H), 4.14 (1H, t, 
J 5.0, 3-H), 4.06 (1H, dt, J 5.0 and 8.0, 1-H), 3.92 (1H, t, J 5.0, 2-H), 2.64 (1H, dt, J 
8.0 and 15.0, C5H2efldo), 2.07 (3H, s, CH3), 1.49 (1H, dt, J5.0 and 15.0, C-5-H20); 
(63  MHz; D20) 173.9 (C=O), 77.8 (CH), 76.6 (CH), 75.0 (CH), 73.8 (CH), 35.1 
(CH2), 20.5 (CH3); m/z (FAB) 177 (MH, 100%), 159 (M-OH, 9), 117 (M-




(e) 	(1S,2R,3R,4R)-2,3-(Isopropylidenedioxy)-4-acetoxy-cyclOPefltafl-1-01 117 
A solution of the trio! 122 (15.50 g, 88.0 mmol, 1.0 eq) and p-toluenesulfonic acid 
(300 mg, 1.58 mmol, 0.02 eq) in acetone (300 ml) was stirred at room temperature 
for 19 h. Calcium hydroxide was then added until a pH = 7 was obtained and the 
mixture was stirred at room temperature for 10 min before being filtered and the 
filtrate concentrated under reduced pressure to give the acetonide-protected diol 117 
as a yellow oil (17.64 g, 93%); Rf 0.68 (MeOH:EtOAc, 1:9); lab 24 —12.4 (c 1.05 in 
CHC13) lit.93 [aID25  —12.7 (c 0.95 in CHC13); vmax(neat)/cm 1 3464 (OH), 2988 and 
2938 (CH), 1736 (C=O), 1376 (CMe2), 1245 (CO); 84250 MHz; CDC13) 5.11 (1H, 
d, J 5.0, 3-H), 4.60 (1H, dd, J 1.5 and 5.0, 4-H), 4.56 (1H, dd, J 1.5 and 5.0, 1-H), 
4.20 (1H, d, J 5.0, 2-H), 2.31 (1H, dt, J 5.0 and 15.0, C5H 2efldo), 2.05 (3H, s, 
OC(0)CH3), 1.83 (1H, dt, J 1.5 and 15.0, C-5-H20), 1.39 (3H, s, CCH3), 1.25 (3H, s, 
CCH3); 8(63  MHz; CDC13) 169.5 (C=O), 110.6 (CMe2), 86.1 (CH), 84.1 (CH), 79.5 
(CH), 76.7 (CH), 36.1 (CH2), 26.1 (CH3), 23.7 (CH3), 21.0 (OC(0)CH3); m/z (FAB) 
217 (MH, 67%), 201 (M-CH3, 44), 157 (M-CH3C(0)0, 35), 59 (CH3C(0)0, 36), 43 
(CH3CO, 100); [Found: MH, 217.10782. C10H1605 requires MH, 217.10760]. 
(1) 	(2S,3R,4R)_2,3-(Isopropylidenedioxy)-4-acetoxy-cyclOPefltafl-1-Ofle 118 
OAc 
°X°  
A solution of the acetonide-protected diol 117 (3.25 g, 15.0 mmol, 1.0 eq) in 
acetone (170 ml) was cooled to 0°C. Jones reagent (8.64 ml, 11.6 mmol, 0.77 eq) 
was added dropwise and the solution was stirred at 0°C for 15 min after which time 
the cooling bath was removed and the mixture was stirred at room temperature for 3 
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h. Sodium bicarbonate (0.4 g) and sodium bisulfite (0.4 g) were then added and the 
mixture was filtered and the filtrate concentrated under reduced pressure. The 
concentrated residue was dissolved in ethyl acetate (80 ml) and the solution was 
washed with brine (70 ml). The aqueous portion was further extracted with ethyl 
acetate (2 x 50 ml) and the combined organic portions were dried over sodium 
sulfate, filtered and concentrated to give a pale yellow solid. Recrystallisation of the 
solid from diethyl ether gave the /3-acetoxycyclopentanone 118 as a white solid (1.92 
g, 60%); mp 74-77°C; (Found: C, 55.94; H, 6.58. C10 H1405 requires C, 56.07; H, 
6.59%); R.f  0.63 (EtOAc:hexane, 1:1); [a]D24  +156.4 (c 1.04 in CHC13); 
vma (nujol)/cm' 1757 (C0), 1730 (COacetate), 1378 (CMe2 ), 1257 (CO); 84250 
MHz; CDC13) 5.26 (1H, dt, J 1.5 and 6.5, 4-H), 4.67 (1H, d, J 5.5, 2-H), 4.36 (1H, 
dd, J 1.5 and 5.5, 3-H), 2.96 (111, dd, J6.5 and 19.0, C5H2efldo), 2.35 (1H, dd, J 1.5 
and 19.0, C-5-H20), 2.05 (3H, s, OC(0)CH3), 1.42 (3H, s, CCH3), 1.34 (3H, s, 
CCH3); 6(63  MHz; CDC13) 210.2 (C0), 169.8 (COacetate), 112.9 (CMe2 ), 80.2 
(CH), 78.0 (CH), 71.0 (CH), 40.1 (CH2 ), 26.5 (CH3), 24.5 (CH3), 20.7 (OC(0)CH3); 
m/z (FAB) 215 (MH, 42%), 155 (M-CH3C(0)O, 12), 43 (CH3CO, 74); [Found: 
MH, 215.09207. C10H1405 requires MH, 215.09195]. 
(g) 	(4S,5S)-4,5-(Isopropylidenedioxy)-cyclopeJIt-2-efl-1-Ofle 61 
oz::2 
°X°  
DBU (0.5 ml, 3.34 mmol, 0.65 eq) was added to a stirred solution of the 13-
acetoxycyclopentanone 118 (1.10 g, 5.13 mmol, 1.0 eq) in diethyl ether (10 ml). 
The mixture was then stirred at room temperature for 30 min before being filtered 
through a pad of silica and the filtrate concentrated under reduced pressure. The 
resulting oily white solid was purified by flash colunm chromatography using ethyl 
acetate-hexane (1:3) as the eluent to give the enone 61 as a white solid (723 mg, 
91%); mp 67-68°C (lit." mp 68-69°C); Rf O.S7 (EtOAc:hexane, 1:1). Spectroscopic 
data was consistent with that for procedure 5.3.1(d). 
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A solution of [(p-methoxybenzyloxy)methyl]tri-n-butylstannane 108 (5.48 g, 12.4 
mmol, 1.05 eq) in anhydrous THF (60 ml) was cooled to -78°C. n-BuLi (1.61 M 
solution in hexanes, 7.25 ml, 11.7 mmol, 1.0 eq) was then added dropwise over 2 
min to give a pale yellow solution which was stirred at -78°C for 5 mm. A solution 
of the J3-acetoxycyclopentanone 118 (2.53 g, 11.8 mmol, 1.0 eq) in anhydrous THF 
(38 ml) was then added via nitrogen pressure transfer through a double tipped 
needle. The resulting pale yellow solution was stirred at -78°C for 30 min after 
which time the reaction mixture was quenched by the addition of saturated aqueous 
ammonium chloride (60 ml). 	The mixture was allowed to warm to room 
temperature before being poured into ethyl acetate (100 ml). The organic layer was 
separated and the aqueous portion was extracted with ethyl acetate (3 x 100 ml). 
The combined organic portions were washed with water (250 ml) and brine (250 ml). 
The water portion was saturated with sodium chloride and then extracted with ethyl 
acetate (3 x 200 ml). The combined organic portions were dried over sodium 
sulfate, filtered and concentrated. 	The resulting colourless liquid containing a 
yellow oil was purified by flash column chromatography using ethyl acetate-hexane 
(1:3) as the eluent to give the PMB-protected acetate 120 as a yellow oil (822 mg, 
19%); R f 0.53 (EtOAc:hexane, 1:1); lab  24 +2.25 (c 1.02 in CHC13); vmax(neat)/cm '  
3513 (OH), 2988, 2937 and 2861 (CH), 1739 (C0), 1613 (C=Car), 1514 (CCa ), 
1374 (CMe2), 1246 (CO); 84250 MHz; CDC13) 7.25 (2H, d, J 8.5, 2 x Har), 6.87 (2H, 
d, J 8.5, 2 x Har), 5.08 (1H, dd, J 5.0 and 6.5, 1-H), 4.52 (2H, 2d, J 5.5 and 5.5, 2-H 
and 3-H), 4.47 (2H, s, PhCH20.79 (3H, s, OCH3), 3.39 (2H, s, CH20), 2.96 (1H, br 
s, OH), 2.23 (1H, dd, J6.5 and 14.5, C6H2efldo), 1.95 (3H, s, OC(0)CH3), 1.92 (1H, 
dd, J 5.0 and 14.5, C-6-H20), 1.52 (3H, s, CCH3), 1.32 (3H, s, CCH3); (63  MHz; 
CDC13) 169.7 (C=O), 159.2 (Ca), 129.9 (Car), 129.3 (2 x CHar), 113.7 (2 x CHar), 
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112.9 (CMe2), 84.4 (CH), 79.9 (CH), 78.1 (C-4), 76.4 (C-1H), 73.3 (CH), 73.1 
(CH2), 55.1 (0CH3), 39.3 (C-6H2), 26.1 (CH3), 24.4 (CH3), 20.8 (OC(0)CH3); m/z 
(El) 366 (M, 5%), 308 (M-CH3C(0)0, 4), 137 (CH30C6H4CH20, 35), 122 
(CH30C6H4CH3, 38), 59 (CH3C(0)0, 35), 43 (CH3CO1  100); [Found: M, 






A solution of the PMB-protected acetate 120 (558 mg, 1.52 mmol) in ammonia 
saturated methanol (50 ml) was stirred at room temperature for 18 h 30 min after 
which time the solution was concentrated under reduced pressure. The resulting 
yellow oil was purified by flash column chromatography using ethyl acetate-hexane 
(1:1) as the eluent to give PMB-protected alcohol 123 as a pale yellow oil (453 mg, 
92%); Rf 0.38 (EtOAc:hexane, 1:1); [()CID 14 +24.8 (c 1.20 in CHC13); vmax(neat)/cm' 
3445 (OH), 2987, 2936, 2864 and 2839 (CH), 1613 (CCar), 1515 (CCar), 1374 
(CMe2), 1248 (CO); 611(250 MHz; CDC13) 7.23 (2H, d, J 8.5, 2 X Ha), 6.88 (2H, d, J 
8.5, 2 X Ha), 4.51 (2H, s, PhCH2), 4.40 (2H, 2d, J 5.5 and 5.5, 2-H and 3-H), 4.04 
(1H, m, 1-H), 3.79 (3H, s, OCH3), 3.57 (1H, br s, C-i-OH), 3.53 (iH, d, J 8.5, 
CH20), 3.45 (1H, d, J 8.5, CH20), 3.14 (1H, br s, C-4-OH), 2.21 (1H, dd, J 6.0 and 
14.5, C6H2efldo)1  1.96 (iH, dd, J2.0 and 14.5, C-6-H20), 1.48 (3H, s, CCH3)1  1.32 
(3H, s, CCH3); 6(63 MHz; CDC13) 159.5 (Ca), 129.7 (2 X CH.), 128.5 (Ca), 113.9 
(2 x CH.), 111.7 (CMe2)1  87.7 (CH), 81.7 (CH), 77.9 (C-4), 75.1 (CH2), 73.5 (CH2), 
73.1 (C-1H), 55.1 (OCH3), 44.5 (C-6H2), 26.1 (CH3), 24.3 (CH3); m/z (El) 324 (Mt, 
9%), 203 (M-CH30C6H4CH2, 4), 137 (CH30C6H4CH20, 27), 121 (CH30C6H4CH21  








A mixture of IBX 141 (1.21 g, 4.32 mmol, 3.1 eq) in DMSO (8 ml) was stirred at 
room temperature for 25 min after which time the IBX had dissolved. The PMB-
protected alcohol 123 (453 mg, 1.40 mmol, 1.0 eq) dissolved in the minimum 
volume of THF was added to the IBX solution which was then stirred at room 
temperature for 6 h 30 mm. Water (16 ml) was added and the white solid that 
precipitated was filtered off. The filtrate was transferred to a separating funnel and 
the organic layer was separated. The aqueous portion was extracted with diethyl 
ether (3 x 70 ml) and the combined organic portions were dried over sodium sulfate, 
filtered and concentrated. The resulting yellow oil was purified by flash column 
chromatography using ethyl acetate-hexane (7:13) as the eluent to give the PMB-
protected fi-hydroxycyclopentanone 124 as a pale yellow oil (397 mg, 88%); Rf 0.42 
(EtOAc:hexane, 1:1); [aID24 —89.1 (c 1.14 in CHC13); vmax(neat)/cm' 3490 (OH), 
2988, 2936 and 2865 (CH), 1759 (C0), 1612 (C=Car), 1514 (C=Car), 1376 (CMe2), 
1248 (CO); 84250 MHz; CDC13) 7.15 (2H, d, J9.0, 2 x Ha), 6.86 (2H, d, J9.0, 2 x 
Ha), 4.52 (1H, d, J5.5, 3-H), 4.41 (2H, s, PhCH2), 4.35 (1H, ddd, J 1. 0, 1.5 and 5.5, 
2-H), 3.79 (3H, s, OCH3), 3.50 (1H, d, J 8.5, CH20), 3.42 (1H, d, J 8.5, CH20), 2.84 
(1H, br s, OH), 2.69 (1H, dd, J 1.0 and 18.0, C6H2efldo), 2.44 (1H, ddd, J 1.0, 1.5 
and 18.0, C-6-H20), 1.47 (3H, s, CCH3), 1.35 (3H, s, CCH3); 8(63 MHz; CDC13) 
208.2 (C=O), 159.3 (Ca), 129.3 (2 x CH), 128.9 (Cr), 113.8 (2 x CH), 112.8 
(CMe2), 81.7 (CH), 80.8 (CH), 74.1 (CH2), 73.3 (CH2), 73.2 (C-4), 55.1 (OCH3), 
46.1 (C-6H2), 26.5 (CH3), 24.8 (CH3); m/z (El) 322 (M, 10%), 201 (M-
CH30C6H4CH2, 4), 137 (CH30C6H4CH20, 7), 121 (CH30C6H4CH2, 100); [Found: 





Palladium on activated charcoal (10% Pd, 430 mg, 0.043 g of Pd, 0.404 mmol, 0.5 
eq) was added to a stirred solution of the PMB-protected -hydroxycyclopentanone 
124 (259 mg, 0.803 mmol, 1.0 eq) in anhydrous THF (8 ml). The mixture was then 
vigorously stirred under an atmosphere of hydrogen for 1 h 50 mm. The mixture 
was filtered through Celite, the Celite was washed repeatedly with ethyl acetate, and 
the filtrate was concentrated under reduced pressure. The resulting pale yellow oil 
was purified by flash column chromatography using ethyl acetate-hexane (17:3) as 
the eluent to give the protected /3-hydroxycyclopentanone 119 as a white solid (58 
mg, 36%); mp 120-124°C; (Found: C, 53.52; H, 7.41. C9H1405 requires C, 53.46; H, 
6.98%); Rf 0.41 (EtOAc); [a]D23  —140.1 (c 0.90 in CHC13); vmax(CHC13)/cm t 3429 
(OH), 2989, 2936 and 2880 (CH), 1759 (C=O), 1376 (CMe2), 1215 (CO); 6H(250 
MHz; CDC13) 4.67 (1H, d, J 6.0, 3-H), 4.40 (1H, ddd, J 1.0, 1.5 and 6.0, 2-H), 3.68 
(1H, d, J 10.5, CH20H), 3.56 (1H, d, J 10.5, CH20H), 3.06 (1H, br s, C-4-OH), 2.74 
(1H, dd, J 1.0 and 18.0, C6H2efldo), 2.47 (1H, br s, CH20II), 2.46 (1H, ddd, J 1.0, 
1.5 and 18.0, C-6-H20), 1.50 (3H, s, CCH3), 1.38 (3H, s, CCH3); 5J63 MHz; CDC13) 
208.7 (C=O), 113.5 (CMe2), 80.3 (CH), 80.2 (CH), 74.0 (C-4), 67.2 (CH20H), 45.7 
(C-6H2), 26.4 (CH3), 24.7 (CH3); m/z (FAB) 203 (MH, 45%); [Found: MH, 
203.09180. C9H1405 requires MH, 203.09195]. 





Trifluoroacetic acid (0.8 ml) was added to a solution of the protected 13-
hydroxycyclopentanone 119 (152 mg, 0.752 mmol, 1.0 eq) in anhydrous 
dichloromethane (3.8 ml). The resulting pale yellow solution was stirred at room 
temperature for 3 min before being concentrated under reduced pressure to give a 
yellow oil. The yellow oil was purified by flash column chromatography using 
methanol-chloroform (3:7) as the eluent to give the desired keto-tetrol 116 as a 
colourless oil (26 mg, 21%). 'H, 13C NMR and mass spectrometry showed that the 
keto-tetrol 116 was contaminated with minor traces of the eliminated enone 82a 
(8.6:1), determined by 600 MHz 'H NMR analysis. 
(2R, 3S, 4S) -4-Hydroxymethyl-2, 3, 4-trihydroxy-cyclopentan-] -one 116 
R f 0.36 (MeOH:CHC13, 3:7); 64600 MHz; D20) 4.52 (1H, dd, J 1.5 and 5.0, 2-H), 
4.25 (1H, d, J5.0, 3-H), 3.70 (2H, s, CH20H), 2.68 (1H, ddd, J 1.0, 1.5 and 19.5, C-
6-H20), 2.32 (1H, d, J 19.5, C6H2endo); (91 MHz; D20) 218.2 (C=O), 76.9 (CH), 
75.1 (C-4), 72.7 (CH), 66.0 (CH20H), 43.2 (C-6H2); m/z (FAB) 163 (MH, 1%), 131 
(M-CH20H, 100). 
(2R, 3R)-4-Hydroxymethyl-2, 3-dihydroxy-cyclopent-4-en-1-one 82a 
R f O.46 (MeOH:CHC13, 3:7); 84600 MHz; D20) 6.32 (1H, t, J 1.5, =CH), 4.79 (1H, 
obscured by D20 residual peak, 2-H), 4.68 (1H, dd, J 1.5 and 19.0, CH20H), 4.54 
(1H, dd, J 1.5 and 19.0, CH20H), 4.33 (1H, d, J 6.0, 3-H); 8J91 MHz; D20) 209.5 
(CO), 179.6 (C-4),126.5 (=CH), 72.5 (CH), 69.0 (CH), 60.5 (CH20H); m/z (FAB) 
145 (MH, 2%), 113 (M-CH20H, 7). 
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5.2.4 Feeding studies 
(a) 	General techniques 
Strain used 
Streptomyces citricolor mutant: CC940 
Preparation of liquid medium 
Arkosoy 50 	60 g1' 
MOPS buffer 	21 g1' 
Made up in tap water to 800 ml and pH adjusted to 7.0 with 10 M NaOH. 
After autoclaving the following ingredients were added: 
Glucose 	 60 g1' 
Uracil 	 25 mgl' 
HPLC conditions for detecting aristeromycin and neplanocin A 
HPLC analysis was carried out using a Waters 486 Tuneable Absorbance Detector 
and a Waters 600E Pump and Controller. Waters Millennium Chromatography 
Manager software package was used to analyse the results. 
Column: 	 Phenomenex sphereclone 5 t ODS (2) C 18 reverse phase 
250 x 4.6 mm 
Mobile Phase: 	97% 50 mM ammonium formate buffer (pH = 3.0) 
3% acetonitrile 
Flow rate: 	lml min' 
Injection: 	 via 50 il injection loop 
Detector: 	UV at 260 nm 
Retention times: 	Neplanocin A 	6.51 mm 
Aristeromycin 	9.72 mm 
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(b) 	General procedure for running a feeding experiment 
All bacteriological procedures were carried out in a SterilGard Class II Type 
A/B3 biological safety cabinet (Baker Company). The GAM 6:6 medium (without 
glucose) was sterilised by autoclaving at 12 1°C for 20 mm. In order to prevent 
caramelisation, glucose was subsequently added to the cooled medium from a filter 
sterilised stock solution (50% w/v). 
Streptomyces citricolor CC940 mutant was maintained as a vegetative mycelium 
in 20% (v/v) glycerol at -20°C. A 50 tl aliquot of mycelium was used to inoculate a 
250 ml conical flask containing 60 ml of GAM 6:6 medium. The flask was fitted 
with a stainless steel spring to ensure the culture was sufficiently aerated and well 
dispersed. Following 3 days of growth at 30°C, 270 rpm, 5 ml aliquots of culture 
broth was transferred to two sterile 100 ml conical flasks fitted with steel coils. The 
substrate (20 mg) was dissolved in distilled water (1 ml) and using a sterile pipette, 
250 il of this substrate solution was transferred into one of the conical flasks. The 
second flask was used as a control. The flasks were then incubated at 30°C, 270 
rpm and the transformation was monitored by HPLC. 
At regular intervals, using sterile techniques, 430 tl was removed from each flask 
and placed in an eppendorf tube. This was then centrifuged at 14,000 rpm for 5 
mm. The supernatant was removed using a 1 ml disposable plastic syringe and the 
sample was filtered through a 0.2 jiM syringe filter before being injected into the 
HPLC under the conditions outlined above. 
The above procedure was used to carry out the following feeding experiments: 
Feeding Experiment 1 
Substrate used: 	 Tetrol 83a 	 5 mg in 5 ml of media. 
Four samples removed. Final sample removed after incubation for 47 h. 
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Conversion after 47 h: 	Neplanocin A 4.3% 
Aristeromycin 1.2% 
Total conversion 5.5% 
The fraction corresponding to neplanocin A was collected and subjected to mass 
spectrometry: m/z (ES+) 263.8 (MH, 30%), 285.9 (M+Na, 50). 
Feeding Experiment 2 
Substrates used: 	 Tetrol 83a 	 5 mg in 5 ml of media 
2R,3S,4R Keto-tetrol 95 	5 mg in 5 ml of media 
2S,3R,4S Keto-tetrol ent-95 5 mg in 5 ml of media 
Four samples removed. Final sample removed after incubation for 47 h. 
Tetrol 83a: 
Conversion after 47 h: 	Neplanocin A 	 22.6% 
Aristeromycin 	 9.4% 
Total conversion. 	32.0% 
2R,3S,4R Keto-tetrol 95: 
Conversion after 47 h: 	Neplanocin A 	 23.7% 
Aristeromycin 	 9.0% 
Total conversion 	32.7% 
The fraction corresponding to neplanocin A was collected and subjected to mass 
spectrometry: m/z (ES+) 263.6 (MH, 60%), 285.7 (M+Na, 10). 
The fraction corresponding to aristeromycin was collected and subjected to mass 
spectrometry: m/z (ES+) 265.8 (MH, 50%), 287.8 (M+Na, 20). 
2S,3R,4S Keto-tetrol ent-95: 
Shows no conversion to neplanocin A or aristeromycin. 
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Feeding Experiment 3 
Substrates used: 	 Tetrol 83a 	 5 mg in 5 ml of media 
2R,3S,4R Keto-tetrol 95 	5 mg in 5m1 of media 
2R,3S,4S Keto-tetrol 116 	5 m in 5 ml of media 
Seven samples removed. Final sample removed after incubation for 71 h. 
Tetrol 83a: 
Conversion after 71 h: 	Neplanocin A 	 24.6% 
Aristeromycin 	 10.0% 
Total conversion 	34.6% 
2R,3S,4R Keto-tetrol 95: 
Conversion after 71 h: 	Neplanocin A 	 26.7% 
Aristeromycin 	 10.2% 
Total conversion 	36.9% 
2R,3S,4S Keto-tetrol 116: 
Conversion after 71 h: 	Neplanocin A 	 13.4% 
Aristeromycin 	 7.7% 
Total conversion 	21.1% 
Feeding Experiment 4 
Substrates used: 	 Tetrol 83a 	 15 mg in 15 ml of media 
2R,3S,4R Keto-tetrol 95 	15 mg in 1 5m1 of media 
2R,3S,4S Keto-tetrol 116 	15 mg in 15 ml of media 
Fifteen samples removed. Final sample removed after incubation for 143 h. 
Tetrol 83a: 
Conversion after 143 h: Neplanocin A 29.7% 
Aristeromycin 26.7% 
Total conversion 56.4% 
128 
Experimental 
2R,3S,4R Keto-tetrol 95: 
Conversion after 143 h: 	Neplanocin A 	 8.0% 
Aristeromycin 	 11.6% 
Total conversion 	19.6% 
2R,3S,4S Keto-tetrol 116: 
Conversion after 143 h: 	Neplanocin A 	 8.2% 
Aristeromycin 	 11.1% 
Total conversion 	19.3% 
Feeding Experiment 5 
Substrates used: 	 Tetrol 83a 	 5 mg in 5 ml of media 
Enone 82a 	 5 mg in 5m1 of media 
2R,3S,4R Keto-tetrol 95 	5 mg in 5 ml of media 
Five samples removed. Final sample removed after incubation for 89 h. 
Tetrol 83a: 
Conversion after 89 h: 	Neplanocin A 	 25.7% 
Aristeromycin 	 11.5% 
Total conversion 	37.2% 
Enone 82a: 
Conversion after 89 h: 	Neplanocin A 	 22.6% 
Aristeromycin 	 6.0% 
Total conversion 	28.6% 
2R,3S,4R Keto-tetrol 95: 
Conversion after 89 h: 	Neplanocin A 	 15.2% 
Aristeromycin 	 7.0% 
Total conversion 	37.2% 
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After incubation for 93 h 30 min a further 5 mg of the 2R,3S,4R keto-tetrol 95 was 
added to the media and after incubating for a further 43 h 30 min a further sample 
was taken. 
Conversion after 137 h: 	Neplanocin A 	 25.0% 
Aristeromycin 	 12.6% 
Total conversion 	37.6% 
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5.3 	Experimental Procedures for Chapter 3 
5.3.1 Synthesis of tetrol 83a via methoxymethyl-protected compounds 
(a) 	Methyl 2,3-0-isopropy1idene-3-D-ribofuranoside 13163 
HO '4\ç''( 
Xo 
A solution of D-ribose 126 (52.11 g, 0.35 mol, 1.0 eq) and 2,2-dimethoxypropane 
(100 ml, 0.81 mol, 2.3 eq) in acetone (400 ml) was cooled to 0°C and perchloric acid 
(70%, 4 ml) was added dropwise. On complete addition the cooling bath was 
removed and the contents were stirred at room temperature for 14 h. Methanol (70 
ml) was added and the reaction mixture was stirred at room temperature for a further 
2 h, before being cooled to 0°C and neutralised with cold saturated aqueous sodium 
carbonate (90 ml) at which point a white solid precipitated. The solid was removed 
by filtering through Celite and the filtrate was concentrated under reduced pressure. 
The concentrated residue was dissolved in diethyl ether (300 ml) and washed with 
water (2 x 100 ml) then brine (100 ml). The aqueous layer was saturated with 
sodium chloride and extracted with diethyl ether (5 x 200 ml). The combined 
organic layers were dried over sodium sulfate, filtered and concentrated to give a 
yellow oil. Distillation at 0.03 mmHg (60°C) gave the protected ribose 131 as a 
pale yellow oil (57.20 g, 81%); Rf 0.40 (EtOAc:PE, 1:1); [0C]D24  —78.6 (c 1.50 in 
CHC13) lit.  120 10CiD25 —82.2 (c 2.00 in CH03); vm (neat)/cm 1 3458 (OH), 2988 and 
2918 (CH), 1380 (CMe2), 1241 (CO); 5H(200 MHz; CDC13) 4.96 (lH, s, 1-H), 4.82 
(1H, d, J 6.0, 2-H), 4.57 (1H, d, J 6.0, 3-H), 4.41 (1H, t, J 3.0, 4-H), 3.64 (2H, m, 
CH2), 3.42 (3H, s, OCH3), 3.26 (1H, br s, OH), 1.47 (3H, s, CCH3), 1.30 (3H, s, 
CCH3); 8(63 MHz; CDC13) 111.9 (CMe2)1  109.7 (CH), 88.0 (CH), 85.5 (CH), 81.3 
(CH), 63.7 (CR2), 55.2 (OCH3), 26.1 (CH3), 24.5 (CH3); m/z (FAB) 205 (MW, 40%), 
173 (M-CH20H, 100); [Found: MH, 205.10785. C9H1605 requires MH, 205.10760]. 
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Method 1: Preparation of iodide using iodine, imidazole and triphenyiphosphine. 
Iodine (77.69 g, 0.31 mol, 1.2 eq) was added in small portions to a stirred solution 
of the protected ribose 131 (51.45 g, 0.25 mol, 1.0 eq), imidazole (21.99 g, 0.32 mol, 
1.3 eq) and triphenylphosphine (79.38 g, 0.30 mol, 1.2 eq) in diethyl 
ether:acetonitrile (3:1) (930 ml). The mixture was stirred for 15 h before being 
filtered through Celite. The filtrate was then concentrated under reduced pressure to 
give the crude iodide 132. 
The crude iodide 132 was dissolved in anhydrous THF (600 ml) and DBU (60 ml) 
was added. The mixture was heated at reflux under nitrogen for 16 h before being 
allowed to cool to room temperature. The reaction mixture was filtered through 
Celite and the filtrate was concentrated. The residue was dissolved in diethyl ether 
(300 ml) and washed with water (2 x 250 ml) and saturated aqueous sodium 
thiosulfate (150 ml). The organic portion was then dried over magnesium sulfate, 
filtered and concentrated to give a yellow oil. Distillation at 0.03 mmHg (28-30°C) 
gave the enol ether 133 as a colourless oil (29.82 g, 64% from protected ribose 131); 
Rf 0.58 (EtOAc:PE, 1:3); [a]D24  +62.1 (c 1.00 in CHC13) lit.97 [0t]D27 +60.2 (c 1.22 in 
CHC13); vm (neat)/cm 1 2989 and 2918 (CH), 1672 (C=C), 1383 (CMe2)1  1258 (CO); 
64200 MHz; CDC13) 5.13 (11-1, s, 1-H), 5.04 (1H, d, J 6.0, =CHH), 4.62 (1H, in, 2-
H), 4.52 (1H, d, J 6.0, =CHH), 4.40 (111, in, 3-H), 3.43 (311, s, OCH3), 1.49 (311, s, 
CCH3), 1.37 (3H, s, CCH3); 6(63 MHz; CDC13) 161.0 (=C), 112.9 (CMe2)1  108.1 
(CH), 88.4 (CH2), 82.4 (CH), 78.5 (CH), 55.4 (OCH3), 26.5 (CH3), 25.4 (CH3); m/z 




Method 2: Preparation of iodide via tosylate. 
p-Toluenesulfonyl chloride (16.88 g, 88.5 mmol, 2.5 eq) and anhydrous pyridine 
(7.80 ml, 96.4 mmol, 2.7 eq) were added to a solution of the protected ribose 131 
(7.17 g, 35.1 mmol, 1.0 eq) in chloroform (77 ml) at 0°C. The cooling bath was 
removed and the reaction mixture was stirred at room temperature for 30 min after 
which time DMAP (50 mg, cat.) was added. The resulting pale yellow solution was 
stirred at room temperature for 18 h before further DMAP (50 mg, cat.), p-
toluenesulfonyl chloride (6.69 g, 35.1 mmol, 1.0 eq) and anhydrous pyridine (2.80 
ml, 34.6 mmol, 1.0 eq) were added. Stirring was continued for 3 h and then water 
(50 ml) was added and the mixture was stirred for 15 mm. The reaction mixture 
was poured into diethyl ether (200 ml) and washed with water (2 x 125 ml). The 
aqueous portions were saturated with sodium chloride and extracted with diethyl 
ether (150 ml). The combined organic layers were dried over magnesium sulfate, 
filtered and concentrated. 	Excess pyridine was then removed by azeotropic 
distillation with toluene (2 x 50 ml) to give the crude tosylate 139 as a yellow oil 
(22.97 g). 
A solution of the crude tosylate 139 (22.97 g, 64.1 mmol, 1.0 eq) and sodium 
iodide (31.67 g, 0.21 mol, 3.3 eq) in acetone (250 ml) was heated at reflux for 16 h. 
TLC examination after this time showed that starting material remained, therefore 
further sodium iodide (30.42 g, 0.20 mol, 3.2 eq) was added and the mixture was 
heated at reflux for 2 days. The mixture was then cooled to room temperature 
before being concentrated under vacuum. Diethyl ether (100 ml) was added to the 
residue, which was then filtered through Celite, and the filtrate concentrated. The 
concentrated residue was dissolved in ethyl acetate (500 ml) and washed with 
saturated aqueous sodium thiosulfate (200 ml) and water (200 ml). The organic 
portion was dried over sodium sulfate, filtered and concentrated to give the crude 
iodide 132 as a yellow oil (16.14 g). 
The crude iodide 132 (16.14 g, 51.4 mmol, 1.0 eq) was dissolved in anhydrous 
THF (200 ml) and DBU (17.00 ml, 0.11 mol, 2.2 eq) was added. The mixture was 
heated at reflux under nitrogen for 19 h before being allowed to cool to room 
temperature. The reaction mixture was filtered through Celite and the filtrate was 
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concentrated. The residue was dissolved in diethyl ether (250 ml) and washed with 
water (3 x 200 ml). The aqueous portions were then further extracted with diethyl 
ether (2 x 200 ml). The combined organic portions were dried over magnesium 
sulfate, filtered and concentrated to give a yellow oil. Distillation at 0.08 mmHg 
(32°C) gave the enol ether 133 as a colourless oil (2.93 g, 45% from protected ribose 
131). Spectroscopic data was consistent with that synthesised in Method 1. 
(c) 	(2S,3R,4R)-2,3-(Isopropylidenedioxy)-4-methoxybutyrolactone 134 
y OCH3  
Sodium periodate (72.62 g, 0.34 mol, 2.1 eq) was added in small portions over a 
period of 7 h to a stirred solution of enol ether 133 (29.79 g, 0.16 mol, 1.0 eq) and 
osmium tetroxide (4 wt. % solution in water, 2.0 ml, cat.) in a mixture of THF (490 
ml) and water (122 ml) at 0°C. The mixture was stirred at 0°C for 15 h after which 
time a further portion of sodium periodate (17.11 g, 80.0 mmol, 0.5 eq) was added 
and the mixture was allowed to warm to room temperature. After stirring at room 
temperature for 23 h an additional portion of sodium periodate (17.11 g, 80.0 mmol, 
0.5 eq) was added and the mixture was stirred at room temperature for a further 4 h. 
The mixture was then filtered through Celite and the filtrate was concentrated. The 
residue was poured into ethyl acetate (500 ml), which was washed with brine (3 x 
250 ml), water (250 ml) and saturated aqueous sodium metabisulfite (200 ml). The 
aqueous brine and water portions were extracted with ethyl acetate (2 x 200 ml) then 
the organic layers were washed with saturated aqueous sodium metabisulfite (200 
ml). The combined organic layers were dried over sodium sulfate, filtered and 
concentrated to give an off-white solid. 	Recrystallisation of the solid from 
petroleum ether-diethyl ether gave the lactone 134 as white needles (20.11 g, 67%); 
mp 72-74°C (lit.63 mp 75-76°C); (Found: C, 50.80; H, 6.34. C8H1205 requires C, 
51.06; H, 6.43%); R1  0.37 (EtOAc:PE, 1:3); lab 24  —58.3 (c 1.09 in MeOH); Vm 
(nujol)/cm' 2947 and 2919 (CH), 1782 (C=O), 1382 (CMe2), 1255 (CO); 5H(200 
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MHz; CDC13) 5.27 (1H, s, 4-H), 4.74 (1H, d, J 5.5, 2-H), 4.48 (1H, d, J 5.5, 3-H), 
3.47 (3H, s, OCH3), 1.39 (3H, s, CCH3), 1.32 (3H, s, CCH3); (63  MHz; CDC13) 
173.5 (CO), 114.3 (CMe2), 104.9 (CH), 79.1 (CH), 74.3 (CH), 56.9 (OCH3), 26.5 
(CH3), 25.5 (CH3); m/z (FAB) 189 (MH, 43%); [Found: MH, 189.07579. C8H,205 
requires MH, 189.07630]. 
(d) 	(4S,58)-4,5-(Isopropylidenedioxy)-cyclopent-2-en-1-one 61 
A solution of dimethyl methyiphosphonate (3.50 ml, 32.3 mmol, 1.0 eq) in 
anhydrous THF (150 ml) was cooled to -78°C. n-BuLi (1.57 M solution in hexanes, 
20.30 ml, 31.9 mmol, 1.0 eq) was then added dropwise to the solution over 12 min so 
that the temperature did not rise above -78°C. The solution was stirred at -78°C 
under nitrogen for 30 mm, after which time a solution of the lactone 134 (6.02 g, 
32.0 mmol, 1.0 eq) in anhydrous THF (20 ml) was added via nitrogen pressure 
transfer through a double tipped needle. The solution was stirred at -78°C for a 
further 2 h 30 min after which time the acetone/dry ice bath was replaced by an 
ice/brine bath and the solution was allowed to warm up to approximately -10°C. 
The reaction mixture was poured into ice-cold brine (150 ml) and diethyl ether (250 
ml) was added. After removal of the organic phase, the aqueous layer was extracted 
with diethyl ether (2 x 100 ml). The combined organic layers were washed with 
brine (200 ml), dried over sodium sulfate, filtered and concentrated to give the enone 
61 as a yellow oil which formed an off-white crystalline solid when concentrated 
under vacuum (2.41 g, 49%); mp 66-68°C (lit. 63  mp 66-67°C); (Found: C, 62.57; H, 
6.60. C8H1003 requires C, 62.33; H, 6.54%); Rf 0.54 (EtOAc:PE, 1:1); [ct]D24 +65.4 (c 
1.02 in CHC13); v(nujol)/cm 1 2979 and 2918 (CH), 1756 (C0), 1584 (C=C), 
1377 (CMe2), 1240 (CO); 84200 MHz; CDC13) 7.60 (1H, dd, J 2.0 and 6.0, 3-H), 
6.22 (1H, d, J 6.0, 2-H), 5.27 (1H, dd, J 2.0 and 5.5, 4-H), 4.47 (1H, d, J 5.5, 5-H), 
1.41 (6H, s, CH3CCH3); 8(63 MHz; CDC13) 202.9 (C0), 159.5 (=CH), 134.2 
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(=CH), 115.4 (CMe2), 78.4 (CH), 76.4 (CH), 27.2 (CH3), 26.0 (CH3); m/z (FAB) 155 
(MH, 18%); [Found: MH, 155.07058. C8H1003 requires MH, 155.07082]. 





A solution of dimethyl methyiphosphonate (2.30 ml, 21.2 mmol, 1.0 eq) in 
anhydrous THF (100 ml) was cooled to -78°C. n-BuLi (1.53 M solution in hexanes, 
13.90 ml, 21.2 mmol, 1.0 eq) was then added dropwise to the solution over 15 min so 
that the temperature did not rise above -78°C. The solution was stirred at -78°C 
under nitrogen for 30 mm, after which time a solution of the lactone 134 (3.95 g, 
21.0 mmol, 1.0 eq) in anhydrous THF (10 ml) was added dropwise via nitrogen 
pressure transfer through a double tipped needle. The solution was stirred at -78°C 
for 2 h 30 min before being quenched with saturated aqueous ammonium chloride 
(35 ml). The reaction mixture was allowed to warm to room temperature before 
being poured into diethyl ether (200 ml). The organic layer was separated and the 
aqueous portion was extracted with diethyl ether (100 ml). The combined organic 
layers were washed with brine (2 x 150 ml), dried over sodium sulfate, filtered and 
concentrated to give a yellow solid. Recrystallisation of the solid from petroleum 
ether-diethyl ether gave the phosphonate 140 as a white solid (4.00 g, 61%); mp 64-
65°C; (Found: C, 42.63; H, 6.84. C11H2108P requires C, 42.31; H, 6.78%); Rf 0.20 
(EtOAc:PE, 1:1); [aID24  —43.0 (c 1.05 in CHC13); v(nujol)/cm' 3228 (OH), 2988 
(CH), 1383 (CMe2), 1300 (P-Q, 1231 (P=O), 1116 (CO), 1042 (P-0-alkyl); 6H(200 
MHz; CDC13) 5.63 (1H, s, OH), 5.00 (1H, s, 1-H), 4.74 (1H, d, J6.0, 3-H), 4.56 (1H, 
d, J6.0, 2-H), 3.85 (3H, d, JpH 11.0, POCH3), 3.74 (3H, d, J 11 11.0, POCH3), 3.40 
(3H, s, OCH3), 2.52-2.23 (1H, q, HH 15.5 and PH  25.0, CH2), 2.43-2.15 (1H, q, JHH 
15.5 and PH  25.0, CH2), 1.44 (3H, s, CCH3), 1.30 (3H, s, CCH3); 8(63 MHz; CDCI3) 
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112.6 (CMe2), 109.6 (C-1H), 106.4 (1C, d, J C 7.0, C-4), 85.1 (1C, d, JpC 10.0, C-
3H), 85.0 (C-2H), 54.9 (OCH3), 53.2 (1C, d, Jpc 6.0, POCH3), 51.8 (1C, d, Jpc 6.5, 
POCH3), 31.1 (1C, d,Jpc 137.0, PCH2), 26.1 (CH3), 24.7 (CH3); (101 MHz; CDC13) 
31.76; m/z (ES) 313 (MH, 80%); [Found: (El) M, 312.09769. C11H2108P requires 
M, 312.09741]. 
(I) 	[(Methoxymethoxy)methyl]tri-n-butylstannane 110102 
[CH3(CH2)313SnCH20CH20CH3 
To a solution of diisopropylamine (10.60 ml, 75.6 mmol, 1.1 eq) in anhydrous 
THF (120 ml) at 0°C was added dropwise n-BuLi (1.51 M solution in hexanes, 45.40 
ml, 68.6 mmol, 1.0 eq). The resulting solution was stirred for 5 min at 0°C, after 
which time tri-n-butyltin hydride (18.50 ml, 68.6 mmol, 1.0 eq) was added dropwise. 
After stirring for 5 min at 0°C the mixture was allowed to warm to room temperature 
over 10 min before solid paraformaldehyde (2.06 g, 68.6 mmol, 1.0 eq) was added 
and the mixture was stirred at room temperature for 3 h 30 mm. The pale yellow 
reaction mixture was poured into petroleum ether (600 ml) and washed with water (3 
x 200 ml). The organic phase was dried over magnesium sulfate, filtered and 
concentrated to give the crude (tri-n-butylstannyl)methanol as a colourless liquid. 
This was redissolved in dichioromethane (200 ml) and dimethylaniline (18 ml) was 
added. The mixture was cooled to 0°C then chloromethyl methyl ether (8 ml) was 
added and the mixture was stirred at 0°C for 30 mm, after which the reaction mixture 
was stirred at room temperature for 16 h. The resulting brown solution was poured 
into petroleum ether (600 ml) and washed with cold 0.5 M HC1 (2 x 200 ml), water 
(2 x 200 ml) and saturated aqueous sodium bicarbonate (200 ml). The organic layer 
was dried over magnesium sulfate, filtered and concentrated under reduced pressure. 
The resulting yellow liquid was purified by flash column chromatography using 
petroleum ether (500 ml) then ethyl acetate-petroleum ether (1:24) (500 ml) then 
ethyl acetate-petroleum ether (1:9) (500 ml) as the eluent to give the stannane 110 as 
a colourless liquid (which was stored in the fridge under an atmosphere of nitrogen) 
(21.39 g, 85%); Rf O.76 (EtOAc:PE, 1:3); vm (neat)/cm 1 2954, 2924, 2871 and 2859 
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(CH), 1145 (CO), 5H(250 MHz; CDC13) 4.50 (2H, s, OCH20), 3.72 (2H, s, SnCH2), 
3.31 (3H, s, OCH3), 1.59-0.81 (27H, complex m, Bu3); 6(63  MHz; CDC13) 99.4 
(OCH20), 57.5 (SnCH), 54.8 (OCH3), 29.0 (3 x CH2 of Bu3), 27.2 (3 x CH2 of Bu3), 
13.6 (3 x CH3 of Bu3), 8.8 (3 x CH2 of Bu3); m/z (FAB) 369 (0.3%), 368 (0.3), 367 
(0.1), 366 (0.1), 365 (2.2), 364 (0.4), 363 (1.6), 362 (0.2), 361 (0.8), 313 (17), 311 
(15), 310 (12), 309 (100), 308 (35), 307 (76), 306 (29), 305 (45), 45 (CH30CH2, 22). 
Spectroscopic data was consistent with that stated in the literature. 102 





To a solution of [(methoxymethoxy)methyl]tri-n-butylstannane 110 (928 mg, 2.54 
mmol, 1.4 eq) in anhydrous THF (7 ml) at -78°C was added n-BuLi (1.76 M solution 
in hexanes, 1.40 ml, 2.46 mmol, 1.3 eq) dropwise over a period of 2 min so as to 
maintain the temperature below -70°C. The solution was stirred under nitrogen for 
5 mm, after which time the enone 61 (282 mg, 1.83 mmol, 1.0 eq) dissolved in 
anhydrous THF (2 ml) was added via nitrogen pressure transfer through a double 
tipped needle. After the mixture was stirred for 30 min at -78°C, the reaction was 
quenched by the addition of saturated aqueous ammonium chloride (10 ml). The 
mixture was extracted with ethyl acetate (100 ml) and the organic layer was washed 
with saturated aqueous ammonium chloride (2 x 100 ml). The aqueous layers were 
saturated with sodium chloride then extracted with ethyl acetate (2 x 100 ml). The 
combined organic layers were dried over magnesium sulfate, filtered and 
concentrated under reduced pressure. The resulting yellow oil was purified by 
column chromatography using ethyl acetate-petroleum ether (3:7) as the eluent to 
give the alcohol 135 as a colourless oil (301 mg, 72%); Rf 0.41 (EtOAc:PE, 1:1); 
[ct]D22 +77.5 (c 0.40 in MeOH); vmax(neat)/cm 1 3504 (OH), 2987 and 2946 (CH), 
1372 (CMe2), 1213 (CO); H(200 MHz; CDC13) 5.91 (1H, dd, J 2.0 and 6.0, 3-H), 
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5.76 (1H, d, J6.0,2-H), 5.05 (1H, dd, J2.0 and 5.5, 4-H), 4.63 (2H, s, OCH200.51 
(1H, d, J 5.5, 5-H), 3.62 (1H, d, J 10.0, CH20CH20CH3), 3.48 (1H, d, J 10.0, 
CH20CH20CH3), 3.34 (3H, s, OCH3), 3.21 (1H, s, OH), 1.44 (3H, s, CCH3), 1.39 
(3H, s, CCH3); 6(63  MHz; CDC13) 136.8 (=CH), 132.8 (=CH), 112.6 (CMe2), 96.6 
(OCH20), 83.7 (CH), 81.4 (C- 1), 80.0 (CH), 71.6 (CH2), 55.2 (OCH3), 27.5 (CH3), 
26.4 (CH3); m/z (FAB) 231 (MH, 4%),214 (MH-OH, 4), 185 (M-CH20CH3, 5), 155 
(M-CH20CH20CH3, 9), 45 (CH30CH21  100); [Found: MH, 231.12339. C1 1H1805 
requires MH, 231.12325]. Spectroscopic data was consistent with that stated in the 
literature.'0' 




DMAP (2 10 mg, cat.) was added to a stirred solution of alcohol 135 (1.77 g, 7.69 
mmol, 1.0 eq), anhydrous pyridine (5.10 ml, 63.1 mmol, 8.2 eq) and acetic anhydride 
(4.10 ml, 43.5 mmol, 5.7 eq) in anhydrous dichloromethane (25 ml). After stirring 
the solution at room temperature under nitrogen for 2 days the reaction mixture was 
poured into dichloromethane (200 ml) and washed with water (3 x 100 ml). The 
aqueous portion was extracted with dichloromethane (2 x 150 ml) and the combined 
organic layers were dried over magnesium sulfate, filtered and concentrated under 
reduced pressure. After the removal of excess pyridine by azeotropic distillation 
with toluene (3 x 50 ml), the residue was purified by flash column chromatography 
using ethyl acetate-petroleum ether (1:4) as the eluent to give the ester 136 as a pale 
yellow oil (1.85 g, 89%); Rf O.52 (EtOAc:PE, 1:1); [a]D25 +114.2 (c 1.05 in CHC13) 
lit.97 [ct]D23 +110.3 (c 0.22 in CHC13); vmax(neat)/cm' 2979 and 2920 (CH), 1744 
(C=O), 1371 (CMe2), 1238 (CO); 84250 MHz; CDCI3) 6.00 (2H, s, 2-H and 3-H), 
5.03 (1H, d, J 5.5, 4-H), 4.76 (1H, d, J 5.5, 5-H), 4.55 (2H, s, OCH20), 3.95 (1H, d, J 
10.0, CH20CH20CH3), 3.79 (1H, d, J 10.0, CH20CH20CH3), 3.30 (3H, s, OCH3), 
139 
Experimental 
2.06 (3H, s, OC(0)CH3), 1.36 (3H, s, CCH3), 1.35 (3H, s, CCH3); 8(63  MHz; 
CDC13) 169.9 (C=O), 134.2 (=CH), 133.4 (=CH), 112.0 (CMe2), 96.5 (OCH20), 88.5 
(C-i), 83.6 (CH), 80.5 (CH), 69.1 (CH205.2 (OCH3), 27.5 (CH3), 26.9 (CH3), 21.4 
(OC(0)CH3); m/z (FAB) 273 (MH, 22%), 45 (CH30CH21  100); [Found: MH, 
273.13321. C,3H2006 requires MH 273.13381]. 
(i) 	(1S,2R,3R)-2,3-(Isopropylidenedioxy)-4-[(methoxymethoxy)methyl] - 
cyclopent-4-enyl-1-acetate 137 17 
bAc 
°X0 
To a solution of the ester 136 (476 mg, 1.75 mmol, 1.0 eq) in anhydrous THF (15 
ml) was added bis(acetonitrile)dichloropalladium(II) complex (16.2 mg, 0.062 
mmol, 4 mol %) and benzoquinone (77.5 mg, 0.72 mmol, 0.4 eq). The resulting 
orange solution was heated at reflux under nitrogen for 6 h. After cooling to room 
temperature the mixture was concentrated under reduced pressure. The resulting 
orange/brown oil was purified by flash column chromatography using ethyl acetate-
petroleum ether (1:3) as the eluent to give the acetate 137 as a pale yellow oil (316 
mg, 66%); Rf 0.27 (EtOAc:PE, 1:3); v,nax(neat)/cm' 3019 (C=CH), 2937 (CH), 1734 
(C=O), 1374 (CMe2), 1216 (CO); 84200 MHz; CDC13) 5.76 (1H, d, J2.0, 6-H), 5.35 
(1H, in, 1-H), 4.93 (2H, in, 2-H and 3-H), 4.66 (2H, s, OCH20), 4.26 (2H, m, 
CH20CH20CH3), 3.37 (3H, s, OCH30.10 (3H, s, OC(0)CH3), 1.38 (3H, s, CCH3), 
1.36 (3H, s, CCH3); 6(63 MHz; CDC13) 170.4 (C=O), 145.3 (C=), 126.2 (=CH), 
112.8 (CMe2), 96.0 (OCH20), 82.7 (CH), 77.2 (CH), 75.1 (CH), 63.4 (CH2), 55.3 
(OCH3), 27.2 (CH3), 26.6 (CH3), 20.7 (OC(0)CH3). 'Hand '3C NIMR spectra also 
showed minor peaks due to an impurity. The acetate was used in the next step 




cyclopent-4-en-1-ol 130 97 
CH3o ' o\ç'7 
°X0 
To a solution of the impure acetate 137 (817 mg, 3.00 mmol, 1.0 eq) in anhydrous 
methanol (28 ml) was added anhydrous potassium carbonate (2.08 g, 15.0 mmol, 5.0 
eq, excess). After stirring at room temperature under nitrogen for 1 h 30 min the 
mixture was diluted with ethyl acetate (30 ml) and filtered through a pad of silica. 
The filtrate was then concentrated under reduced pressure. The resulting yellow oil 
was purified by flash column chromatography using ethyl acetate-petroleum ether 
(1:1) as the eluent to give the alcohol 130 as a colourless oil (599 mg, 87%); Rf O.4l 
(EtOAc:PE, 1:1). 'H and '3C NMR spectra showed the presence of the same 
impurity that was present in the impure acetate 137 starting material. The alcohol 
was not further purified but was subjected to the oxidation-reduction sequence 
described. 
o-Iodoxybenzoic acid 141'°  
HO\ / oç2o 
Potassium bromate (17.97 g, 0.11 mol, 1.3 eq) was added over 45 min to a 
mixture of 2-iodobenzoic acid (20.00 g, 81.0 mmol, 1.0 eq) in 0.73 M H2SO4  (500 
ml) at 55°C. 	The mixture was stirred at 68°C for 1 h after which time the 
temperature was increased to 84°C and the mixture was stirred for a further 2 h 30 
mm. The reaction mixture was cooled in an ice bath and the solid was filtered off. 
The collected solid was washed with water (1 litre), acetone (500 ml) and diethyl 
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ether (500 ml) before being dried in a vacuum desiccater to give the IBX 141 as a 
white powder (11.60 g, 5 1%). 
CAUTION: IBX has been reported to be explosive under heavy impact and heating 




o-Iodoxybenzoic acid 141 (2.19 g, 7.82 mmol, 3.0 eq) was stirred in DMSO (16 
ml) for 15 mm, after which time the IBX had dissolved. The alcohol 130 (599 mg, 
2.61 mmol, 1.0 eq) dissolved in the minimum amount of THF was then added to the 
IBX solution and the resulting pale yellow solution was stirred at room temperature 
for 1 h 30 mm. Water (15 ml) was added to the reaction mixture and the white solid 
which precipitated was filtered off. The filtrate was transferred to a separating 
funnel and after separation of the organic portion, the aqueous layer was saturated 
with sodium chloride and extracted with diethyl ether (2 x 50 ml). The combined 
organic layers were then dried over sodium sulfate, filtered and concentrated under 
reduced pressure. 	The resulting orange oil was purified by flash column 
chromatography using ethyl acetate-petroleum ether (3:7) as the eluent to give the 
enone 138 as a colourless oil (517 mg, 87%); Rf 0.64 (EtOAc:PE, 1:1); [aID24  —13.5 
(c 1.01 in CHC13) lit.'05 [aID2° —13.1 (c 1.10 in CHC13); vmax(neat)/cm' 3019 (C=CH), 
2989 and 2936 (CH), 1759 (C=O), 1376 (CMe2)1  1216 (CO); 64200 MHz; CDC13) 
6.15 (1H, t, J2.0, 6-H), 5.10 (1H, d,J5.5, 3-H), 4.70 (2H, s, OCH20), 4.53 (1H, dd, 
J 2.0 and 17.5, CH2), 4.48 (1H, d, J 5.5, 2-H), 4.39 (111, dd, J 2.0 and 17.5, CH2), 
3.39 (311, s, OCH3), 1.39 (6H, s, CH3CCH3); 8(63 MHz; CDC13) 201.5 (C0), 173.4 
(C=), 128.2 (=CH), 115.4 (CMe2)1  96.3 (OCH20), 77.9 (CH), 77.6 (CH), 64.6 (CH2), 
55.5 (OCH3), 27.3 (Cl3), 26.1 (Cl3); m/z (FAB) 229 (MH, 10%), 45 (CH30CH21  
100); [Found: MH, 229.10830. C,1H1605 requires MH, 229.10760]. 
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(1S,2S,3R)-2 ,3-(Isopropylidenedioxy)-4-I(methoxymethoxy) methyl] - 
cyclopent-4-en-1-ol 130 
Sodium borohydride (88 mg, 2.33 mmol, 1.3 eq) was added in small portions to a 
stirred solution of enone 138 (419 mg, 1.84 mmol, 1.0 eq) and cerium trichloride 
heptahydrate (1.17 g, 3.13 mmol, 1.7 eq) in anhydrous methanol (15 ml). The 
mixture was stirred at room temperature for 30 min before being poured into ethyl 
acetate (50 ml) and washed with brine (3 x 30 ml). The aqueous portions were 
saturated with sodium chloride and extracted with ethyl acetate (2 x 100 ml). The 
combined organic layers were dried over magnesium sulfate, filtered and 
concentrated. 	The resulting pale yellow oil was purified by flash column 
chromatography using ethyl acetate-petroleum ether (3:7) as the eluent to give the 
alcohol 130 as a colourless oil (363 mg, 86%); R10.50 (EtOAc:PE, 1:1); MD 25 +25.6 
(c 0.36 in MeOH) lit."' [a]D2° +36.8 (c 0.80 in CHC13); vm (neat)/cm' 3429 (OH), 
3019 (C=CH), 2931 (CH), 1375 (CMe2), 1215 (CO); 84200 MHz; CDC13) 5.76 (1H, 
in, 6-H), 4.95 (1H, d, J 5.5, 3-H), 4.75 (1H, t, J 5.5, 2-H), 4.64 (2H, s, OCH200.55 
(1H, in, 1-H), 4.10-4.26 (2H, in, CH20CH20CH3), 3.36 (3H, s, OCH3), 2.70 (1H, br 
s, OH), 1.41 (3H, s, CCH3), 1.39 (3H, s, CCH3); 8(63 MHz; CDC13) 142.2 (C=), 
131.2 (=CH), 112.4 (CMe2), 95.9 (OCH20), 82.8 (CH), 77.7 (CH), 73.2 (CH), 63.1 
(CH2), 55.2 (OCH3), 27.5 (CH3), 26.5 (CH3); m/z (FAB) 231 (MW, 24%), 45 







Amberlite JR 120 (H) (2.70 g, excess) was added to a solution of alcohol 130 (55 
mg, 0.24 mmol, 1.0 e in methanol (4 ml) and water (0.4 ml) and the mixture was 
stirred at room temperature for 3 h. The liquid was then decanted off and the resin 
was washed with methanol (3 x 5 ml). The decanted portions were combined and 
concentrated to give a yellow oil which was purified by flash column 
chromatography using methanol-chloroform (1:4) as the eluent to give the MOM-
protected triol 142 as a colourless oil (26 mg, 57%); Rf 0.52 (MeOH:CHC131  1:4); 
vmax(neat)/cm' 3412 (OH), 3019 (C=CH), 2949 (CH), 1219 (CO); 64250 MHz; 
CDC13) 5.93 (1H, d, J 1.5, 6-H), 4.64 (2H, s, OCH20), 4.43 (1H, in, 1-H), 4.37 (1H, 
d, J 5.5, 3-H), 4.22 (2H, s, CH20CH20CH3), 4.08 (1H, t, J 5.5, 2-H), 3.36 (3H, s, 
OCH3); 6(63 MHz; CDCI3) 145.4 (C=), 130.2 (=CH), 96.0 (OCH20), 73.4 (CH), 
73.1 (CH), 71.3 (CH), 64.1 (CH2), 55.3 (OCH3); m/z (FAB) 191 (MH, 26%), 159 
(M-OCH3, 48), 45 (CH30CH2, 70); [Found: MH, 191.09261. C8H1405 requires 
191.09 195]. 
(o) 	(1S,2S,3R)-4-Hydroxymethylcyclopent-4-en-1,2,3-triol 83a 
Amberlite JR 120 (H) (5.00 g, excess) was added to a solution of alcohol 130 (92 
mg, 0.40 mmol, 1.0 eq) in methanol (7 ml) and water (0.7 ml) and the mixture was 
stirred at room temperature for 4 days. The reaction mixture was filtered through 
Celite; the Celite being washed with ethanol and the filtrate was concentrated under 
reduced pressure. 	The resulting yellow oil was purified by flash column 
chromatography using methanol-chloroform (1:3) as the eluent to give the tetrol 83a 
as a colourless oil (30 mg, 52%); Rf O.lS (MeOH:CHC131  1:4); [aID24  +22.8 (c 1.10 in 
H20); Vmax(neat)/cm 1 3378 (OH), 2949 (CH), 1676 (C=C), 1213 (CO); 5H(250 MHz; 
D20) 5.91 (1H, in, 6-H), 4.49 (1H, in, 1-H), 4.44 (1H, d, J 5.5, 3-H), 4.32 (2H, in, 
CH2), 4.16 (1H, t, J 5.5, 2-H); 8(63 MHz; D20) 147.8 (C=), 127.0 (=CH), 72.6 
(CH), 72.4 (CH), 71.2 (CH), 58.1 (CH2); m/z (FAB) 147 (MH, 10%); [Found: MH, 
147.06557. C6H1004 requires MH, 147.06573]. 
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5.3.2 Synthesis of tetrol 83a via para-methoxybenzyl-protected compounds 
(a) 	[(p-Methoxybenzyloxy)methyl] tri-n-butylstannane 108 
(p-Methoxybenzyl)trichloroacetimidate 147: 
ri 
A solution of p-methoxybenzyl alcohol (23.96 g, 0.17 mol ,1.0 eq) in anhydrous 
diethyl ether (30 ml) was added via nitrogen pressure transfer through a double 
tipped needle to a mixture of sodium hydride (60% dispersion in mineral oil, 0.81 g, 
20.2 mmol, 12 mol %) in anhydrous diethyl ether (30 ml). The mixture was cooled 
to 0°C and trichloroacetonitrile (17.40 ml, 0.17 mol, 1.0 eq) was added dropwise. 
The resulting pale brown solution was stirred at 0°C under nitrogen for 1 h 20 mm 
after which time the cooling bath was removed and the solution was stirred at room 
temperature for 2 h 20 mm. The reaction mixture was concentrated then anhydrous 
methanol (7 ml, 0.17 mol, 1.0 eq) was added followed by pentane (70 ml). The 
mixture was shaken vigorously and then stirred for 10 min before being filtered 
through Celite. The filtrate was concentrated under reduced pressure to give the 
trichioroacetimidate 147 as a brown liquid (46.04 g). 
(Tri-n-butylstannyl)methanol 146: 
To a stirred solution of diisopropylamine (11.50 ml, 81.4 mmol, 1.1 eq) in 
anhydrous THF (100 ml) at 0°C was added n-BuLi (1.48 M solution in hexanes, 
50.00 ml, 74.0 mmol, 1.0 eq) followed by tri-n-butyltin hydride (20.00 ml, 74.0 
mmol, 1.0 eq). The cooling bath was removed and the yellow solution was allowed 
to warm to room temperature over 10 min before solid paraformaldehyde (2.22 g, 
74.0 mmol, 1.0 eq) was added and the mixture was stirred at room temperature for 4 
h. The yellow solution was poured into hexane (300 ml) and washed with water (3 
x 200 ml). 	The organic phase was dried over sodium sulfate, filtered and 
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concentrated to give the (tri-n-butylstannyl)methanol 146 as a pale yellow liquid 
(25.56 g). 
[(p-Methoxybenzyloxy)methyl]tri-n-butylstannane 108: 
Triflic acid (1 ml, cat.) was added dropwise to a solution of (p-
methoxybenzyl)trichloroacetimidate 147 (46.04 g, 0.16 mol, 2.04 ed) and (tn-n-
butylstannyl)methanol 146 (25.56 g, 80.0 mmol, 1.0 eq) in anhydrous 
dichioromethane (100 ml). The resulting yellow solution containing white solid was 
stirred at room temperature under nitrogen for 2 days before being filtered through 
Celite. The filtrate was concentrated to give a yellow oil containing white solid to 
which pentane (70 ml) was added and the mixture was again filtered through Celite 
and the filtrate concentrated. The resulting yellow oil was purified by flash column 
chromatography using ethyl acetate-hexane (1:99) (2 litres), ethyl acetate-hexane 
(2:98) (4 litres) then ethyl acetate-hexane (3:97) (1 litre) as the eluent to give a 
colourless liquid. This was further purified by distillation at 0.02 mbar (150°C) to 
give the stannane 108 as a colourless liquid (which was stored in the fridge under an 
atmosphere of nitrogen) (13.68 g, 42% from Bu3SnH); Rf 0.75 (EtOAc:hexane, 1:9); 
vmax(neat)/cm' 2956, 2925, 2871 and 2852 (CH); 1513 (C=C); 1248 (CO); 84250 
MHz; CDC13) 7.23 (2H, d, J 9.0, 2 x Har), 6.87 (2H, d, J 9.0, 2 x Har), 4.34 (2H, s, 
PhCH20.80 (3H, s, OCH3), 3.71 (2H, s, SnCH2), 1.56-0.85 (27H, complex m, Bu3); 
6 (63  MHz; CDC13) 158.9 (Car), 130.9 (Car), 129.0(2 x CHar), 113.5 (2 x CHar), 76.7 
(PhCH2), 61.0 (SnCH2), 55.1 (OCH3), 29.0 (3 x CH2 of Bu3), 27.2 (3 x CH2 of Bu3), 
13.6(3 x CH3 of Bu3), 8.9 (3 x CH2 of Bu3); m/z (FAB) 445 (1.1%), 444 (3.9), 443 
(2.3), 442 (2.3), 441 (3.5), 440 (4.4), 439 (2.7), 438 (1.0), 437 (1.5), 389 (7.3), 388 
(3.8), 387 (18), 386 (11), 385 (34), 384 (32), 383 (37), 382 (12), 381 (26), 121 







A solution of [(p-methoxybenzyloxy)methyl]tri-n-butylstannane 108 (8.98 g, 20.4 
mmol, 1.0 ea) in anhydrous THF (100 ml) was cooled to -78°C. n-BuLi (1.54 M 
solution in hexane, 13.00 ml, 20.0 mmol, 1.0 eq) was then added dropwise over 2 
min so as to maintain the temperature below -70°C and the resulting yellow solution 
was stirred at -78°C under nitrogen for 5 mm. A solution of the enone 61 (3.08 g, 
20.0 mmol, 1.0 e) in anhydrous THF (50 ml) was then added via nitrogen pressure 
transfer through a double tipped needle and the solution was stirred at -78°C for 16 
min before being quenched by the addition of saturated aqueous ammonium chloride 
(100 ml). The mixture was poured into ethyl acetate (350 ml) and the organic layer 
was separated. The aqueous phase was extracted with ethyl acetate (150 ml) and the 
combined organic layers were washed with water (300 ml) and brine (300 ml), dried 
over sodium sulfate, filtered and concentrated. The resulting yellow oil was purified 
by flash column chromatography using ethyl acetate-hexane (3:7) as the eluent to 
give the alcohol 125 as a colourless oil (4.48 g, 73%); Rf 0.69 (EtOAc:hexane, 1:1); 
[()LID 
21 +68.7 (c 1.10 in CHC13) lit.  107 [aID25  +68.7 (c 1.20 in CH2C12); vm (neat)Icm' 
3513 (OH), 2987, 2935 and 2857 (CH), 1612 (C=C), 1513 (C=C1 ), 1371 (CMe2)1  
1246 (CO); 8H(250 MHz; CDC13) 7.21 (2H, d, J 9.0, 2 x Ba), 6.85 (2H, d, J 9.0, 2 x 
Har) 5.89 (1H, dd, J 1.5 and 6.0, 3-H), 5.73 (1H, d, J 6.0, 2-H), 5.01 (1H, dd, J 1.5 
and 5.5, 4-H), 4.47 (3H, m, PhCH2 and 5-H), 3.79 (3H, s, OCH3), 3.51 (1H, d, J9.5, 
CH2), 3.39 (1H, d, J9.5, CH2), 3.17 (1H, br s, OH), 1.43 (3H, s, CCH3), 1.37 (3H, s, 
CCH3); (63 MHz; CDC13) 159.1 (Ca), 136.9 (=CH), 132.8 (=CH), 129.9 (Ca), 
129.1 (2 x CH), 113.6(2 x CH,,,), 112.4 (CMe2), 83.7 (CH), 81.6 (C- 1), 80.3 (CH), 
73.4 (CH), 73.1 (CH2), 55.1 (OCH3), 27.6 (CH3), 26.5 (CH3); m/z (El) 306 (M, 1%), 










DMAP (177 mg, cat.) was added to a stirred solution of alcohol 125 (1.83 g, 5.97 
mmol, 1.0 eq), anhydrous pyridine (3.96 ml, 49.0 mmol, 8.2 eq) and acetic anhydride 
(3.21 ml, 34.1 mmol, 5.7 eq) in anhydrous dichioromethane (25 ml). After stirring 
at room temperature under nitrogen for 2 days the reaction mixture was poured into 
dichloromethane (200 ml) and washed with water (3 x 120 ml). The aqueous 
portion was extracted with dichioromethane (3 x 150 ml) and the combined organic 
layers were dried over sodium sulfate, filtered and concentrated under reduced 
pressure. 	After the removal of excess pyridine by azeotropic distillation with 
toluene (3 x 100 ml), the residue was purified by flash column chromatography using 
ethyl acetate-hexane (3:17) as the eluent to give the ester 143 as a colourless oil 
which formed a white solid in the freezer (2.00 g, 96%); mp 57-59°C; (Found: C, 
65.27; H, 6.66. C19H2406 requires C, 65.50; H, 6.94%); Rf 0.72 (EtOAc:hexane, 1:1); 
[()CID 24 +100.4 (c 0.98 in CHC13) lit.107  lab 25  +94.2 (c 1.00 in CH2C12); v(nujol)/cm' 
2979 (CH), 1736 (C0), 1607 (C=C), 1512 (CCar), 1377 (CMe2)1  1248 (CO); 
611(250 MHz; CDC13) 7.17 (2H, d, J 9.0, 2 x Hat), 6.85 (2H, d, J 9.0, 2 x Har), 5.98 
(2H, s, 2-H and 3-H), 5.00 (1H, d, J 5.5, 4-H), 4.74 (1H, d, J 5.5, 5-H), 4.41 (2H, s, 
PhCH2), 3.81 (1H, d,J9.5, CH20.79 (3H, s, OCH3), 3.74 (1H, d,J9.5, CH20.05 
(3H, s, OC(0)CH3), 1.36 (3H, s, CCH3), 1.34 (3H, s, CCH3); 6(63 MHz; CDC13) 
169.9 (C0), 159.1 (Car), 134.2 (=CH), 133.4 (=CH), 129.7 (Cr), 129.0 (2 x CHar), 
113.6(2 x CHar), 111.9 (CMe2), 88.7 (C- 1), 83.7 (CH), 80.6 (CH), 73.0 (CH200.9 
(CH2), 55.1 (OCH3), 27.5 (CH3), 26.9 (CH3), 21.5 (OC(0)CH3); m/z (FAB) 349 











To a solution of the ester 143 (475 mg, 1.36 mmol, 1.0 eq) in anhydrous THF (27 
ml) was added bis(acetonitrile)dichloropalladium(II) complex (38 mg, 0.15 mmol, 
11 mol %) and benzoquinone (62 mg, 0.58 mmol, 0.4 eq). The resulting orange 
solution was heated at reflux under nitrogen for 4 h 15 mm. After cooling to room 
temperature the mixture was concentrated under reduced pressure. The resulting 
brown oil was purified by flash column chromatography using ethyl acetate-hexane 
(1:3) as the eluent to give the acetate 144 as a yellow oil (299 mg, 63%); Rf 0.67 
(EtOAc:hexane, 11) vmax(neat)/cm' 3018 (CCH), 2959 (CH), 1736 (C0), 1513 
(C=Car), 1379 (CMe2), 1218 (CO); 6H(250 MHz; CDCI3) 7.26 (2H, d, J 9.0, 2 x Ha), 
6.87 (2H, d, J9.0, 2 X Har), 5.76 (1H, d, J2.0, 6-H), 5.34 (1H, m, 1-H), 4.91 (2H, m, 
2-H and 3-H), 4.49 (2H, s, PhCH2), 4.15 (2H, m, CH20.79 (3H, s, OCH3), 2.10 (3H, 
s, OC(0)CH3), 1.38 (3H, s, CCH3), 1.36 (3H, s, CCH3); 6(63 MHz; CDC13) 170.5 
(C0), 159.1 (Car), 145.6 (C=), 129.8 (Ca), 129.2 (2 x CH"), 126.2 (CH), 113.7 (2 
x CHar), 112.8 (CMe2), 82.7 (CH), 77.1 (CH), 75.1 (CH), 72.6 (CH2), 66.1 (CR2), 
55.2 (OCH3), 27.2 (CH3), 26.5 (CH3), 20.7 (OC(0)CH3). 'H and '3C NMR spectra 
also showed minor peaks due to an impurity. The acetate was not further purified 
but was carried on to the next reaction. 
(1S,2R,3R)-2,3-(Isopropylidenedioxy)-4-hydroxymethylcyclopent-4-enyl-1-
acetate 148'°  
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DDQ (121 mg, 0.53 mmol, 1.5 eq) was added to a solution of the acetate 144 (124 
mg, 0.36 mmol, 1.0 eq) in CH2Cl2:H20 (20:1) (8 ml) at 0°C. The mixture was 
allowed too warm to room temperature and after stirring for 10 min a pink solid 
precipitated. Stirring was continued for 2 h 30 min after which time saturated 
aqueous sodium bicarbonate (10 ml) was added and the mixture was extracted with 
dichioromethane (3 x 20 ml). The organic portion was washed with water (30 ml) 
and brine (30 ml). 	The aqueous portions were further extracted with 
dichioromethane (2 x 30 ml) and the combined organic portions were dried over 
sodium sulfate, filtered and concentrated. The resulting yellow oil was purified by 
flash column chromatography using ethyl acetate-hexane (1:1) as the eluent to give 
the acetate 148 as a pale yellow oil (68 mg, 84%); Rf 0.23 (EtOAc:hexane, 1:1); 
[a]D24  —55.1 (c 1.15 in CHC13) lit.107  [aJD25  —55.5 (c 1.30 in CHC13); vmax(neat)/cm' 
3459 (OH), 2989 and 2938 (CH), 1732 (C=O), 1372 (CMe2), 1238 (CO); 8H(250 
MHz; CDCI3) 5.72 (1H, d, J 2.0, 6-H), 5.35 (1H, m, 1-H), 4.94 (2H, m, 2-H and 3-
H), 4.34 (211, m, CH2), 2.10 (3H, s, OC(0)CH3), 1.39 (3H, s, CCH3), 1.35 (311, s, 
CCH3); 6(63  MHz; CDC13) 170.5 (C=O), 147.5 (C=), 125.3 (=CH), 112.9 (CMe2), 
82.9 (CH), 77.2 (CH), 75.0 (CH), 59.9 (CH2), 27.1 (CH3), 26.4 (CH3), 20.7 




A solution of the acetate 148 (166 mg, 0.73 mmol) in ammonia saturated 
methanol (23 ml) was stirred at room temperature for 19 h 30 min before being 
concentrated under reduced pressure. The resulting brown oil was then purified by 
flash column chromatography using ethyl acetate-hexane (1:1) (150 ml), ethyl 
acetate-hexane (3:1) (250 ml) and then ethyl acetate as the eluent to give the 
protected diol 129 as a pale yellow oil (130 mg, 96%); Rf O.37 (EtOAc); lab  24 +41.0 
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(c 1.20 in CHC13); Vmax(fleat)/Cm' 3402 (OH), 2987 and 2934 (CH), 1650 (C=C), 
1374 (CMe2), 1238 (CO); 811(250 MHz; CDC13) 5.72 (1H, d, J 1.5, 6-H), 4.96 (1H, d, 
J5.5, 3-H), 4.76 (1H, t,J5.5, 2-H), 4.55 (1H, in, 1-H), 4.28 (2H, in, CH2), 2.76 (1H, 
br d, OH), 2.24 (1H, br s, OH), 1.42 (3H, s, CCH3), 1.38 (3H, s, CCH3); 8J63 MHz; 
CDC13) 144.4 (C=), 130.1 (CH), 112.5 (CMe2)1  83.0 (CH), 77.7 (CH), 73.1 (CH), 
59.6 (CH2), 27.4 (CH3), 26.3 (CH3); m/z (FAB) 187 (MH, 10%); [Found: MH, 
187.09765. C9H1404 requires 187.09703]. 
(g) 	(1S,2S,31?)-4-Hydroxymethylcyclopent-4-en-1,2,3-triol 83a 
HO 
HO bH 
To a solution of the protected diol 129 (111 mg, 0.60 mmol) in THF:H20 (4:1) (3 
ml) at 0°C was added trifluoroacetic acid (0.25 ml). The cooling bath was removed 
and the pale yellow solution was stirred at room temperature for 16 h after which 
time TLC showed that starting material remained, therefore additional trifluoroacetic 
acid (0.1 ml) was added. The solution was stirred for a further 15 h before being 
concentrated under reduced pressure. The resulting brown oil was purified by flash 
column chromatography using methanol-chloroform (3:7) as the eluent to give the 
tetrol 83a as a colourless oil (82 mg, 94%); Rf 0.23 (MeOH:CHC131  1:4); [aID24 
+23.7 (c 0.84 in H2O); vm (neat)/cm' 3369 (OH), 2930 (CH), 1677 (C=C), 1203 
(CO); 64250 MHz; D20) 5.83 (1H, m, 6-H), 4.44 (1H, in, 1-H), 4.38 (1H, d, J 5.5, 
3-H), 4.22 (2H, in, CH2), 4.11 (1H, t, J 5.5, 2-H); 8(63 MHz; D20) 147.2 (C), 
127.9 (=CH), 72.8 (CH), 72.5 (CH), 71.8 (CH), 58.4 (CH2); m/z (FAB) 147 (MH, 








To a solution of the acetate 144 (299 mg, 0.86 mmol, 1.0 eq) in anhydrous 
methanol (38 ml) was added anhydrous potassium carbonate (498 mg, 3.60 mmol, 
4.2 eq, excess). After stirring at room temperature under nitrogen for 1 h the 
mixture was diluted with ethyl acetate (30 ml) and filtered through a pad of silica. 
The filtrate was then concentrated under reduced pressure. The resulting brown oil 
was purified by flash column chromatography using ethyl acetate-hexane (7:13) as 
the eluent to give the PMB-protected alcohol 145 as a yellow oil (160 mg, 61%); Rf  
0.46 (EtOAc:hexane, 1:1); [a]D24  +34.1 (c 1.10 in CHC13); vmax(fleat)/cm' 3449 (OH), 
3034 (C=CH), 2933 (CH), 1612 (C=C), 1513 (CCar), 1380 (CMe2), 1247 (CO); 
84250 MHz; CDCI3) 7.26 (2H, d, J 9.0, 2 x Bar), 6.86 (2H, d, J 9.0, 2 x H), 5.77 
(1H, d, J 1.5, 6-H), 4.95 (1H, d, J5.5, 3-B), 4.74 (1H, t, J5.5, 2-B), 4.52 (1H, m, 1-
H), 4.47 (2H, s, PhCH2), 4.10 (2H, m, CH2), 3.79 (3H, s, OCH3), 2.70 (1B, br d, 
OH), 1.40 (3H, s, CCH3), 1.39 (3H, s, CCH3); 8(63 MHz; CDC13) 159.1 (Car), 142.5 
(C=), 131.2 (CH), 129.9 (Car), 129.2 (2 x CHar), 113.7 (2 x CHar), 112.4 (CMe2), 
82.9 (CH), 77.5 (CH), 73.2 (CH), 72.5 (CH2), 65.8 (CH2), 55.2 (OCH3), 27.5 (CH3), 
26.5 (CB3); m/z (FAB) 307 (MH, 2%), 121 (CH30C6H4CH2, 100); [Found: MH, 








DDQ (177 mg, 0.78 mmol, 1.5 eq) was added to a solution of the PMB-protected 
alcohol 145 (159 mg, 0.52 mmol, 1.0 eq) in CH2C12:H20 (20:1) (12 ml) at 0°C. The 
cooling bath was removed and the mixture was stirred at room temperature for 3 h 30 
min before saturated aqueous sodium bicarbonate (20 ml) was added and the mixture 
was extracted with dichloromethane (4 x 30 ml). The organic portion was washed 
with saturated aqueous sodium bicarbonate (20 ml), water (30 ml) and brine (30 ml). 
The aqueous portions were saturated with sodium chloride and further extracted with 
ethyl acetate (5 x 75 ml) and the combined organic portions were dried over sodium 
sulfate, filtered and concentrated. The resulting yellow oil was purified by flash 
column chromatography using ethyl acetate as the eluent to give the protected diol 
129 as a pale yellow oil (37 mg, 38%). Spectroscopic data was consistent with that 
for the previous procedure. 
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5.3.3 Synthesis of phosphorylated compounds 





I \SiM Cl 
Diethylamine (20.70 ml, 0.20 mol, 2.0 eq) was added dropwise to a solution of 
phosphorous trichloride (8.70 ml, 0.10 mol, 1.0 eq) in anhydrous THF (60 ml) 
cooled to -40°C. The cooling bath was replaced with an ice bath and after stirring 
for 30 min the ice bath was removed and the resulting thick yellow mixture was 
stirred at room temperature for 4 h. The yellow mixture was filtered through an 
oven-dried sintered funnel and the solid was washed with anhydrous THF (2 x 50 
ml). The filtrate was then concentrated under reduced pressure to give a pale yellow 
liquid. Distillation at 16 mbar (68°C) gave the N,N-diethylphosphorochloridite 149 
as a colourless liquid (9.11 g, 53%). 
A solution of 2-(trimethylsilyl)ethanol (6.05 ml, 42.2 mmol, 2.0 eq) and 
triethylamine (6.50 ml, 46.6 mmol, 2.2 eq) in anhydrous THF (15 ml) at 0°C, was 
added via nitrogen pressure transfer through a double tipped needle to a solution of 
N,N-diethylphosphorochloridite 149 (3.68 g, 21.1 mmol, 1.0 eq) in anhydrous THF 
(10 ml) cooled to 0°C. The cooling bath was removed and the mixture was stirred at 
room temperature for 4 h. Aqueous sodium bicarbonate (5% w/v, 50 ml) was then 
added followed by ethyl acetate (100 ml). The organic layer was washed with 
aqueous sodium bicarbonate (5% w/v, 2 x 50 ml) and brine (75 ml), dried over 
sodium sulfate, filtered and concentrated to give a pale yellow liquid. Distillation at 
1.0 mmHg (120°C) (lit.  107 bp 119-122°C at 3.0 mmHg) gave the phosphoramidite 
150 as a colourless liquid (2.90 g, 41% from NN-diethyl-phosphoramidous 
dichloride); Rf 0.89 (MeOH:CHCI31  1:9); vm (neat)/cm' 2954, 2896 and 2867 (CH), 
1249 (SiMe3), 1202 (CO), 1043 (P-0-alkyl), 838 (SiMe3); 6H(250 MHz; CDC13) 
3.78-3.58 (4H, m, 2 x OCH20.09-2.97 (4H, dq,J 7.0 and pH  9.5,2 x CH2N), 1.02 
(6H, t, J 7.0, 2 x CH3CH2N), 1.01-0.94 (4H, m, 2 x CH2Si), -0.01 (18H, s, 2 x 
SiMe3); 5(63 MHz; CDC13) 60.4 (2CH2, d, Jpc 16.5, 2 x OCH2), 37.3 (2CH, d, Jpc 
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20.5, 2 x CH2N), 19.9 (2CH2, d, Jpc 6.0, 2 x CH2Si), 14.9 (2CH3, d, Jpc 3.0, 2 x 
CH3CH2N), -1.5 (6CH3, 2 x SiMe3); 6(101 MHz; CDC13) 145.65; m/z (FAB) 338 
(MH, 4%), 192 (MH-(SiMe3)2, 82), 73 (SiMe31  100); [Found: MH, 338.20950. 
C14H36NO2PSi2 requires MH, 338.2 1005]. 
(b) 	(1S,2R,3R)_2,3-(Isopropylidenedioxy)-4-I(methoxymethoxy)methyll -1- 





A solution of alcohol 130 (78 mg, 0.34 mmol, 1.0 eq) in anhydrous THF (0.8 ml) 
was added dropwise via syringe to a stirred solution of 1H-tetrazole (81 mg, 1.16 
mmol, 3.4 ea) and bis[2-(trimethylsilyl)ethyl]-NN-diethylphosphoramidite 150 (140 
mg, 0.41 mmol, 1.2 eq) in anhydrous THF (3 ml). The reaction mixture was stirred 
at room temperature for 1 h 10 min before being cooled to -40°C. A solution of 
MCPBA (68 mg, 0.39 mmol, 1.2 eq) in anhydrous dichioromethane (0.8 ml) was 
then added via nitrogen pressure transfer through a double tipped needle and the 
mixture was stirred at -40°C for 30 mm. The cooling bath was removed and the 
mixture was allowed to warm to room temperature before being stirred at room 
temperature for 1 h. Diethyl ether (40 ml) was added and the solution was washed 
with aqueous sodium bisulfite (10% w/v, 2 x 20 ml) and aqueous sodium bicarbonate 
(5% wlv, 2 x 20 ml). The aqueous portions were further extracted with diethyl ether 
(30 ml) and the combined organic layers were dried over sodium sulfate, filtered and 
concentrated. 	The resulting yellow oil was purified by flash column 
chromatography using ethyl acetate-hexane (1:3) + triethylamine (5 ml in 1 litre) as 
the eluent to give the fully protected phosphate 151 as a pale yellow oil (95 mg, 
55%); Rf 0.60 (EtOAc:hexane, 1:1); lab 24  +6.8 (c 0.90 in CHC13); vmax(neat)/cm1  
2955 (CH), 1641 (CC), 1379 (CMe2), 1262 (SiMe3), 1251 (P=O), 1212 (CO), 1052 
(P-0-alkyl), 838 (SiMe3); 8(250 MHz; CDC13) 5.79 (1H, m, 6-H), 5.15 (1H, m, 1-
H), 4.90 (1H, d, J5.0, 3-H),  4.84 (1H, t, J5.0, 2-H),  4.64 (2H, s, OCH20), 4.24-4.11 
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(6H, m, CH2 and 2 x POCH2CH2Si), 3.36 (3H, s, OCH3), 1.38 (3H, s, CCH3), 1.36 
(3H, s, CCH3), 1.26-1.06 (4H, m, 2 x CH2Si), 0.02 (18H, s, 2 x SiMe3); 6(63  MHz; 
CDC13) 144.6 (C=), 127.1 (1CH, d, Jpc 6.5, CH), 112.7 (CMe2), 96.0 (OCH20), 
82.6 (C-3H), 77.7 (1 CH, d, Jpc 3.0, C-2H), 77.3 (1 CH, d, Jpc 5.5, C-1H), 66.3 (1 CH2, 
d, Jpc 6.5, POCH2CH2Si), 66.2 (1CH2, d, Jpc 6.5, POCH2CH2Si), 63.1 (CH2), 55.2 
(CH30), 27.5 (CH3), 26.8 (CH3), 19.4 (1CH2, d, Jpc 5.0, CH2Si), 19.3 (1CH2, d, Jpc 
5.0, CH2Si), -1.6 (6CH3, 2 x SiMe3); 8(101  MHz; CDC13) —1.10; m/z (FAB) 511 
(MH, 1%), 1022 (MH dimer, 7), 73 (SiMe31  100), 45 (CH30CH2, 48); [Found: 
MH, 511.23321. C21H43O8PSi2 requires MH, 511.23124]. 
(c) Attempted deprotection of (1S,2R,3R)-2,3-(Isopropylidenedioxy)-4-
[(methoxymethoxy)methylJ-1-bis L2-(trimethylsilyl)ethyll-cyclopent-4-enyl-
1-phosphate 151 
CH300 \ç 0 ON HO \ç7 0 ON 
HO 
oH "ONa 	HO OH ONa 
The fully protected phosphate 151 (72 mg, 0.14 mmol) was placed in a Teflon 
bottle. Acetonitrile (10.9 ml) was added followed by deionized water (1.9 ml) and 
the colourless solution was cooled to 0°C. Hydrofluoric acid (48-51% aqueous 
solution, 1.3 ml) was added and the ice bath was removed. The solution was then 
stirred at room temperature for 24 h after which time methoxytrimethylsilane (10 ml) 
was added and the mixture was stirred for 10 min before being transferred to a 
round-bottomed flask and concentrated under reduced pressure. 	Further 
methoxytrimethylsilane (10 ml) was added and the solution was again concentrated. 
Deionized water (5 ml) was added to the resulting yellow glass and the solution was 
filtered through a plug of cotton wool, the filtrate being concentrated to give the 
phosphate (free acid) as a pale yellow glass (39 mg). 
1 M NaOH (approximately 0.2 ml) was added dropwise to a solution of the 
phosphate (free acid) (39 mg) in deionized water (2 ml), until a pH = 8 was obtained. 
The pale yellow solution was concentrated under reduced pressure to give a yellow 
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solid that was washed repeatedly with ethyl acetate and then dried under vacuum to 
give a pale yellow solid (39 mg). 'H, '3C, 3'P NMR and mass spectrometry appeared 
to show that a mixture of the desiredfully deprotected phosphate (disodium salt) 152 
and the MOM-protected phosphate (disodium salt) 153 had been formed. However, 
the NMR data was complex and difficult to assign unambiguously. 
(IS, 2R. 3R)-4-Hydroxymethyl-2, 3-dihydroxy-cyclopent-4-enyl-i-phosphate 
(disodium salt) 152; Rf 0.57 (MeCN:0.1 M NH4C1, 6:4); m/z (ES-) 269.1 ((M-H), 
82%), 225.0 (MH-2Na, 41). 
(iS, 2R, 3R)-4-[(Methoxymethoxy)methyl]-2, 3-dihydroxy-cyclopent-4-enyl-1-
phosphate (disodium salt) 153; Rf 0.66 (MeCN:0.1 M NH4C1, 6:4); mlz (ES-) 313.1 
((M-H), 86%). 
(d) 	(1S,2R,3R)-2,3-(Isopropylidenedioxy)-4- L(p-methoxybenzyloxy)methyll-1- 







A solution of alcohol 145 (99 mg, 0.32 mmol, 1.0 eq) in anhydrous THF (1 ml) 
was added dropwise via syringe to a stirred solution of 1H-tetrazole (88 mg, 1.26 
mmol, 3.9 eq) and bis[2-(trimethylsilyl)ethyl]-NN-diethylphosphoramidite 150 (156 
mg, 0.46 mmol, 1.4 eq) in anhydrous THF (4 ml). The reaction mixture was then 
stirred at room temperature under nitrogen for 1 h 40 min before being cooled to - 
70°C. A solution of MCPBA (69 mg, 0.40 mmol, 1.2 eq) in anhydrous 
dichloromethane (1 ml) was added via syringe and the mixture was stirred at -70°C 
for 30 mm. The cooling bath was then removed and the mixture was allowed to 
warm to room temperature before being stirred at room temperature for a further 1 h 
30 mm. Diethyl ether (40 ml) was added and the solution was washed with aqueous 
sodium bisulfite (10% w/v, 2 x 20 ml) and aqueous sodium bicarbonate (5% w/v, 2 x 
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20 ml). The aqueous portions were further extracted with diethyl ether (2 x 50 ml) 
and the combined organic layers were dried over sodium sulfate, filtered and 
concentrated under reduced pressure. The resulting yellow oil was purified by flash 
column chromatography using ethyl acetate-hexane (1:3) as the eluent to give the 
fully protected phosphate 154 as a pale yellow oil (157 mg, 83%); Rf 0.47 
(EtOAc:hexane, 1:1); [ct]D26 +7.5 (c 1.02 in CHC13); vmax(neat)/cm' 2953 and 2902 
(CH), 1613 (C=C), 1514 (CCar), 1379 (CMe2), 1250 (P=O), 1211 (CO), 1065 (P-0-
alkyl), 857 (SiMe3); 8H(250 MHz; CDC13) 7.25 (2H, d, J 8.5, 2 x Har), 6.86 (2H, d, J 
8.5,2 X Har), 5.80 (1H, S, 6-H), 5.14 (1H, m, 1-H), 4.90 (1H, d, J5.5, 3-H), 4.83 (1H, 
t, J 5.5, 2-H), 4.48 (2H, s, PhCH2), 4.25-4.11 (6H, m, CH2 and 2 x POCH2CH2Si), 
3.79 (3H, s, OCH3), 1.38 (3H, s, CCH3), 1.36 (3H, s, CCH3), 1.27-1.06 (4H, m, 2 x 
CH2Si), 0.02 (18H, s, 2 x SiMe3); 6(63 MHz; CDC13) 159.1 (Car), 144.9 (C=), 129.8 
(Car), 129.2 (2 x CHar), 127.2 (1 CH, d, jpc 6.5, =CH), 113.7 (2 x CHar), 112.7 (CMe2), 
82.6 (C-3H), 77.7 (1CH, d, Jpc 3.5, C-2H), 77.2 (id, d, Jpc 5.5, C-1H), 72.5 
(PhCH2), 66.3 (1CH2, d, Jpc 7.0, POCH2CH2Si), 66.2 (1CH2, d, Jpc 7.0, 
POCH2CH2Si), 65.7 (CH2), 55.2 (OCH3), 27.5 (CH3), 26.8 (CH3), 19.4 (1CH2, d, JPc 
5.0, CH2Si), 19.3 (1CH2, d, Jpc 5.0, CH2Si), -1.6 (6CH3, 2 x SiMe3); (101 MHz; 
CDC13) —1.08; m/z (FAB) 587 (MH, 1%), 1174 (MH dimer, 2), 121 
(CH30C6H4CH2, 100), 73 (SiMe3, 89); [Found: MH, 587.26318. C27H4708PSi2 
requires MH, 587.26254]. 








Si Me3  
DDQ (52 mg, 0.23 mmol, 1.5 eq) was added to a solution of the fully protected 
phosphate 154 (87 mg, 0.15 mmol, 1.0 eq) in CH2C12:H20 (20:1) (4 ml) cooled to 
0°C. The cooling bath was removed and the mixture was allowed to warm to room 
temperature before being stirred at room temperature for 4 h 30 mm. Saturated 
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aqueous sodium bicarbonate (15 ml) was added and the mixture was extracted with 
dichioromethane (3 x 25 ml). The combined organic portions were washed with 
water (40 ml) and brine (30 ml), dried over sodium sulfate, filtered and concentrated. 
The resulting yellow oil was purified by flash column chromatography using ethyl 
acetate-hexane (4:1) as the eluent to give the alcohol 155 as a colourless oil (65 mg, 
94 %); Rf 0.38 (EtOAc:hexane, 9:1); [a]D24  +5.4 (c 1.09 in CHC13); vmax(neat)/Cm '  
3400 (OH), 2953 and 2901 (CH), 1664 (C=C), 1379 (CMe2), 1250 (P=O), 1212 
(CO), 1060 (P-0-alkyl), 856 (SiMe3); 6H(250 MHz; CDC13) 5.76 (1H, m, 6-H), 5.14 
(1H, m, 1-H), 4.93 (1H, d, J 5.5, 3-H), 4.85 (1H, t, J 5.5, 2-H), 4.42-4.25 (2H, m, 
CH2), 4.24-4.05 (4H, m, 2 x POCH2CH2Si), 2.03 (1H, br s, OH), 1.40 (3H, s, CCH3), 
1.36 (3H, s, CCH3), 1.14-1.06 (4H, m, 2 x CH2Si), 0.02 (18H, s, 2 x SiMe3); 6 (63  
MHz; CDCI3) 146.8 (Crn), 126.2 (1CH, d, Jc  7.0, CH), 112.8 (CMe2), 82.8 (C-3H), 
77.8 (1CH, d, Jpc 3.0, C-2H), 77.3 (1CH, d, Jpc 5.5, C-1H), 66.4 (1CH2, d, Jpc 7.0, 
POCH2CH2Si), 66.3 (1CH2, d, Jpc 7.0, POCH2CH2Si), 59.6 (CH2), 27.5 (CH3), 26.6 
(CH3), 19.4 (1CH2, d, Jpc 5.0, CH2Si), 19.3 (1CH2, d, Jpc 5.0, CH2Si), -1.6 (6CH3, 2 x 
SiMe3); (101 MHz; CDC10 —1.13; m/z (FAB) 467 (MH, 3%),934 (MH dimer, 4), 
73 (SiMe, 100); [Found: MH, 467.20593. C19H3907PSi2 requires MH, 467.20503]. 
(1) (1S,2R,3R)-4-Hydroxymethyl-2,3-dihydroxy-cyclopent-4-enyl-1-phosphate 
(triethylammonium salt) 152 
HO \çyO OH 
HO 	OH 	
0 HNEt3  
Via the disodium salt 
A solution of alcohol 155 (46 mg, 0.10 mmol), acetonitrile (7.6 ml) and deionized 
water (1.3 ml) in a Teflon bottle was cooled to 0°C. Hydrofluoric acid (48-51% 
aqueous solution, 0.9 ml) was then added, the cooling bath was removed and the 
mixture was stirred at room temperature for 6 h after which time additional HF (0.5 
ml) was added and the mixture was stirred for a further 1 h. Approximately half of 
the solvent was evaporated by passing nitrogen over the solution then 
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methoxytrimethylsilane (10 ml) was added and the mixture was stirred at room 
temperature for 10 min before being transferred to a round-bottomed flask and 
concentrated under reduced pressure. Further methoxytrimethylsilane (8 ml) was 
added to the concentrated residue, which was again concentrated to give the 
phosphate (free acid) as an off-white solid (16 mg). 
The phosphate (free acid) (16 mg) was dissolved in the minimum volume of 
deionized water (approximately 2 ml) and 0.1 M NaOH (approximately 3 ml) was 
added dropwise until a pH = 8 was obtained. The solution was then concentrated to 
give a pale yellow glass. Methanol: acetone (1:1) (2 ml) was added and the glass 
was scratched with a spatula at which point an off-white solid crashed out. The 
solid was washed with diethyl ether (2 x 5 ml) before being dried under vacuum to 
give an off-white solid (26 mg). 'H, 13C, 31P NMR and mass spectrometry showed 
that the product was a mixture of the fully deprotected phosphate and the phosphate 
with one (trimethylsilyl)ethyl group still attached. 
The phosphate mixture (20 mg) was purified by ion-exchange chromatography 
using triethylammonium bicarbonate buffer solution to give the desired fully 
deprotected phosphate 152 as a pale yellow glass (18 mg, 60%) and the 
(trimethylsilyl) ethyl-protected phosphate 156 as a colourless glass (1 mg). The 10 
mM and 15 mM portions of the buffer solution eluted the trimethylsilylethyl-
protected phosphate and the 20, 25, 30, 35 and 40 mM portions eluted the fully 
deprotected phosphate. 
(IS, 2R, 3R) -4-Hydroxymethyl-2, 3-dihydroxy-cyclopent-4-enyl-i-phosphate 
(triethylammonium salt) 152; Rf 0.38 (MeCN:0.1 M NH4C1, 6:4); [a]D24  +16.6 (c 
0.82 in H20); Vma,(neat)/cm' 3399 (OH), 2985 (CH), 1651 (C=C), 1250 (P0), 1214 
(CO), 1055 (P-0-alkyl); 8H(250 MHz; D20) 5.95 (111, d, J 1.5, 6-11), 4.41 (111, d, J 
5.5, 3-H), 4.31-4.21 (4H, m, C1121  1-H and 2-H), 3.17 (6H, q, J7.5, 3 x NCH2), 1.25 
(9H, t, J 7.5, 3 x NCH2CH3); 8(91 MHz; D20) 148.6 (C=), 126.9 (1CH, d, Jpc 3.0, 
=CH), 76.7 (1CH, d, Jpc 5.5, C-211), 72.9 (C-311), 72.1 (1CH, d, Jpc 5.5, C-111), 58.8 
(CH2), 47.0 (3 x NCH2), 8.6 (3 x NCH2C}13); 6(101 MHz; D20) 0.89; m/z (FAB) 
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328 (MH, 24%), 429 (M+CH3CH2N, 7), 102 (Et3NH, 100); [Found: MH, 
328.15283. C6H1007P.C6H16N requires MH, 328.15252]. 






A solution of alcohol 148 (61 mg, 0.27 mmol, 1.0 eq) in anhydrous THF (0.8 ml) 
was added dropwise via syringe to a stirred solution of 1H-tetrazole (68 mg, 0.97 
mmol, 3.6 eq) and bis[2-(trimethylsilyl)ethyl]-NN-diethylphosphoramidite 150 (133 
mg, 0.39 mmol, 1.5 eq) in anhydrous THF (3 ml). The reaction mixture was stirred 
at room temperature for 1 h 35 min before being cooled to -60°C. A solution of 
MCPBA (56 mg, 0.33 mmol, 1.2 eq) in anhydrous dichioromethane (0.8 ml) was 
then added via nitrogen pressure transfer through a double tipped needle and the 
mixture was stirred at -60°C for 30 mm. The cooling bath was removed and the 
mixture was allowed to warm to room temperature before being stirred at room 
temperature for a further 1 h. Diethyl ether (40 ml) was added and the solution was 
washed with aqueous sodium bisulfite (10% w/v, 2 x 20 ml) and aqueous sodium 
bicarbonate (5% w/v, 2 x 20 ml). The combined organic layers were dried over 
sodium sulfate, filtered and concentrated under reduced pressure. The resulting pale 
yellow oil was purified by flash column chromatography using ethyl acetate-hexane 
(1:3) + triethylamine (6 ml in 1 litre) as the eluent to give the acetate 157 as a pale 
yellow oil (116 mg, 85%); Rf 0.53 (EtOAc:hexane, 1:1); [ct]D24 —18.5 (c 1.30 in 
CHC13); vmax(neat)/cm '  2952 and 2900 (CH), 1740 (C=O), 1644 (C=C), 1371 
(CMe2), 1265 (SiMe3), 1249 (P=O), 1179 (CO), 1050 (P-0-alkyl), 857 (SiMe3); 
8H(250 MHz; CDC13) 5.81 (1H, d, J2.0, 6-H), 5.36 (1H, m, 1-H), 4.93 (2H, m, 2-H 
and 3-H), 4.68 (2H, m, CH2), 4.20-4.09 (4H, m, 2 x POCH2CH2Si), 2.09 (3H, s, 
OC(0)CH3), 1.36 (3H, s, CCH3), 1.35 (3H, s, CCH3), 1.12-1.05 (4H, m, 2 x CH2Si), 
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0.02 (18H, s, 2 x SiMe3); 6(63  MHz; CDC13) 170.4 (C=O), 143.6 (1C, d, Jpc 7.5, 
C=), 127.0 (=CH), 112.9 (CMe2), 82.2 (CH), 77.3 (CH), 74.9 (CH), 66.3 (2CH2, d, 
Jpc 6.5, 2 x POCH2CH2Si), 63.1 (1CH2, d, Jpc 5.0, CH2), 27.2 (CH3), 26.6 (CH3), 20.6 
(OC(0)CH3) 19.4 (2CH2, d, Jpc 5.5, 2 x CH2Si), -1.6 (6CH3, 2 x SiMe3); 6(101 
MHz; CDCI3) —0.48; m/z (FAB) 509 (MH, 2%),1018 (MH dimer, 1), 73 (SiMe31  
100), 43 (CH3CO, 65); [Found: MH, 509.21574. C21H4J08PSi2 requires MH, 
509.2 1559]. 'H and '3C NMR data was consistent with that stated in the literature."' 






A solution of the acetate 157 (109 mg, 0.21 mmol) in ammonia saturated 
methanol (7 ml) was stirred at room temperature for 8 h 30 min before being 
concentrated under reduced pressure. The resulting brown oil was purified by flash 
column chromatography using ethyl acetate-hexane (1:1) + triethylamine (6 ml in 1 
litre) as the eluent to give the alcohol X as a colourless oil (73 mg, 73%); Rf 0.35 
(EtOAc:hexane, 1:1); [cc]D24 +26.6 (c 1.01 in CHC13); vmax(neat)/cm' 3406 (OH), 
2954 and 2901 (CH), 1656 (C=C), 1381 (CMe2), 1269 (SiMe3), 1251 (P0), 1213 
(CO), 1049 (P-0-alkyl), 858 (SiMe3); 84200 MHz; CDC13) 5.81 (lB. m, 6-H), 4.95 
(1H, d, J 5.5, 3-H), 4.76 (1H, t, J 5.5, 2-H), 4.66-4.54 (3H, m, CH2 and 1-H), 4.21-
4.08 (4H, m, 2 x POCH2CH2Si), 2.71 (1H, br d, OH), 1.40 (3H, s, CCH3), 1.38 (3H, 
s, CCH3), 1.13-1.04 (4H, m, 2 x CH2Si), 0.02 (18H, s, 2 x SiMe3); 6(63 MHz; 
CDC13) 140.7 (1C, d, Jpc 7.5, C=), 132.0 (=CH), 112.6 (CMe2), 82.3 (CH), 77.8 
(CH), 73.1 (CH), 66.3 (2CH2, d, jc  6.0, 2 X POCH2CH2Si), 63.0 (1CH2, d, Jpc 5.0, 
CH2), 27.5 (CH3), 26.5 (CH3), 19.5 (2CH2, d, Jpc 5.5, 2 x CH2Si), -1.6 (6CH3, 2 x 
SiMe3); (81 MHz; CDC13) —0.40; m/z (FAB) 467 (MH, 2%), 934 (MH dimer, 2), 
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73 (SiMe, 100); [Found: MH, 467.20659. C19H3907PSi2 requires MH, 467.20503]. 
'H and '3C NMR data was consistent with that stated in the literature. 107 




P —o 	 P —o 
Et3MI 0 	 Et3NH 0 	
OH 
HO OH 	 HO 
Via the cyclohexylammonium salt 
A stirred solution of alcohol 158 (49 mg, 0.11 mmol) in acetonitrile (8.5 ml) and 
deionized water (1.5 ml) in a Teflon bottle was cooled to 0°C. Hydrofluoric acid 
(48-51% aqueous solution, 0.5 ml) was then added, the cooling bath was removed 
and the mixture was stirred at room temperature for 5 h after which time additional 
HF (0.2 ml) was added and the mixture was stirred for a further 2 h. 
Methoxytrimethylsilane (5 ml) was added and the mixture was stirred at room 
temperature for 10 min before being transferred to a round-bottomed flask and 
concentrated under reduced pressure. Further methoxytrimethylsilane (5 ml) was 
added to the concentrated residue, which was again concentrated to give the 
phosphate (free acid) as a colourless glass (49 mg). 
The phosphate (free acid) (49 mg) was dissolved in the minimum volume of 
deionized water (approximately 1 ml) and cyclohexylamine (approximately 5 ml) 
was added. The resulting solution was stirred at room temperature for 15 min after 
which time toluene (5 ml) was added and the solution was concentrated. Further 
toluene (5 ml) was added and the mixture was again concentrated to give a pale 
brown solid (52 mg). 'H, '3C, 31P NIMR and mass spectrometry showed that the 
product was a mixture of the desired fully deprotected phosphate and the phosphate 
with one (trimethylsilyl)ethyl group still attached. 
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The phosphate mixture (29 mg) was then purified by ion-exchange 
chromatography using triethylammonium bicarbonate buffer solution to give the 
(trimethylsilyl) ethyl-protected phosphate 159 as a colourless glass (12 mg) and the 
desiredfully deprotected phosphate 83b as a colourless glass (13 mg). The 10 MM 
and 15 mlvi portions of the buffer solution eluted the trimethylsilylethyl-protected 
phosphate and the 20, 25, 30, 35 and 40 mM portions eluted the fully deprotected 
phosphate. 
(is, 2S, 3R)-i, 2, 3-Trihydroxy-4-cyclopent-4-enemethanol-5-phosphate 
(triethylammonium salt) 83b; Rf 0.50 (MeCN:0.1 M NH4C1, 6:4); [cx]D23 +17.4 (c 
0.58 in H20); vmax(CHC13)/cm' 3311 (OH), 2980 (CH), 1650 (C=C), 1253 (P0), 
1213 (CO), 1054 (P-0-alkyl); 6H(250 MHz; D20) 5.96 (1H, m, 6-H), 4.54-4.45 (4H, 
m, CH2, 2-H and 3-H), 4.16 (1H, t, J 5.5, 1-H), 3.18 (6H, q, J 7.5, 3 x NCH2), 1.25 
(9H, t, J 7.5, 3 x NCH2CH3); 8J63 MHz; D20) 144.8 (1C, d, Jpc 7.0, C=), 129.5 
(=CH), 72.6 (C-2H and C-3H), 71.8 (C-1H), 62.0 (1CH2, d, Jpc 4.5, CH2), 46.7 (3 x 
NCH2), 8.2 (3 x NCH2CH3);  o(101 MHz; D20) 1.44; m/z (FAB) 328 (MH, 6%), 
102 (Et3NH, 100); [Found: MH, 328.15256. C6H1007P.C6H16N requires MH, 
328.15252]. 
(is, 2S, 3R)-i, 2, 3-Trihydroxy-4-[(trimethylsilyl)ethyl]-phosphoryloxymethyl- 
cyclopent-4-ene (triethylammonium salt) 159; Rf 0.76 (MeCN:0. 1 M NH4C1, 6:4); 
[()CID 23 +8.7 (c 0.60 in H20); vmax(CHC13)/cm' 3309 (OH), 2952 (CH), 1652 (C=C), 
1249 (P=O), 1206 (CO), 1051 (P-0-alkyl), 838 (SiMe3); 84250 MHz; D20) 5.97 
(1H, m, 6-H), 4.51-4.45 (4H, m, CH2, 2-H and 3-H), 4.16 (1H, t, J 5.5, 1-H), 4.02-
3.93 (2H, m, POCH2CH2Si), 3.17 (6H, q, J 7.5, 3 x NCH2), 1.25 (9H, t, J 7.5, 3 x 
NCH2CH3), 1.05-0.98 (2H, m, CH25i), 0.00 (9H, s, 5iMe3); 6(63  MHz; D20) 144.5 
(1C, d, Jpc 7.5, C=), 129.6 (=CH), 72.6 (C-2H and C-3H), 71.8 (C-1H), 64.8 (1CH21  
d, Jpc 6.0, POCH2CH2Si), 62.1 (1CH2, d, Jpc 	CH2), 46.7 (3 x NCH2), 18.9 (1CH21  
d, Jpc 6.0, CH25i), 8.2 (3 x NCH2GH3), -2.5 (3CH31  5iMe3); 6(101 MHz; D20) 1.42; 
m/z (FAB) 428 (MW, 3%), 102 (Et3NH, 100), 73 (5iMe3, 44); [Found: MH, 
428.22262. C11H2207PSi.C6H16N requires MH, 428.22335]. 
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Via the sodium salt 
A solution of alcohol 158 (44 mg, 0.09 mmol), acetonitrile (7.6 ml) and deionized 
water (1.3 ml) in a Teflon bottle was cooled to 0°C. Hydrofluoric acid (48-51% 
aqueous solution, 0.5 ml) was added, the cooling bath was removed and the mixture 
was stirred at room temperature for 6 h, after which time approximately half of the 
solvent was evaporated by passing nitrogen over the solution. 
Methoxytrimethylsilane (2 ml) was then added and the mixture was stirred at room 
temperature for 10 min before being transferred to a round-bottomed flask and 
concentrated under reduced pressure. Further methoxytrimethylsilane (2 ml) was 
added to the concentrated residue, which was again concentrated to give the 
phosphate (free acid) as a pale yellow glass (28 mg). 
The phosphate (free acid) (28 mg) was dissolved in the minimum volume of 
deionized water (approximately 1 ml) and 1 M NaOH (approximately 0. 15 ml) was 
added dropwise until a pH = 8 was obtained. The solution was then concentrated to 
give a pale yellow glass. Methanol: acetone (1:1) (1 ml) was added and the glass 
was scratched with a spatula, at which point a pale yellow solid crashed out. The 
solid was washed with methanol: acetone (1:1) (4 x 2 ml) before being dried under 
vacuum to give a pale yellow solid (18 mg). 	'H, '3C, 3'P NMR and mass 
spectrometry showed that the product was a mixture of the fully deprotected 
phosphate and the phosphate with one (trimethylsilyl)ethyl group still attached. 
The phosphate mixture (18 mg) was purified by ion-exchange chromatography 
using triethylammonium bicarbonate buffer to give the desired fully deprotected 
phosphate 83b as a pale yellow glass (16 mg, 53%) and the (trimethylsilyl) ethyl-
protected phosphate 159 as a colourless glass (5 mg). The 10 MM and 15 mlvi 
portions of the buffer solution eluted the trimethylsilylethyl-protected phosphate and 
the 20, 25, 30, 35 and 40 mM portions eluted the fully deprotected phosphate. 
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Crystal data and structure refinement for (2S,3R,4R)-2,3-(isopropylidenedioxy)-
4-acetoxy-cyclopentan-1-one 118 
A. Crystal data 
Empirical formula C10H1405 
Formula weight 214.21 
Wavelength 1.54178 A 
Temperature 220 (2) K 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 5.4949 (4) A 
b = 6.6049 (5) A 
c = 14.7595 (11) A 
Volume 527.45 (7) A3 
Number of reflections for cell 56 (20 < 8 <22°) 
Z 	 2 
Density (calculated) 	 1.349 Mg/m' 
Absorption coefficient 	 0.921 mm' 
F(000) 	 228 
a = 90° 
= 100.049 (6)0 
y=90° 
B. Data collection 
Crystal description 
	 Colourless tablet 
Crystal size 
	 0.55 x 0.43 x 0.08 mm 
0 range for data collection 
	 3.04 to 70.13° 









	 Optimised numerical 
(Tmin = 0.789, Tmax = 0.969) 
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C. Solution and refinement 
Solution 
Refinement type 
Program used for refinement 
Hydrogen atom placement 
Hydrogen atom treatment 
Data/restraints/parameters 
Goodness-of-fit on F2 
Conventional R [F>4c (F)] 
Weighted R (F2 and all data) 
Absolute structure parameter 
Extinction coefficient 
direct (SHELXS-97 (Sheidrick, 1990)) 






RI = 0.0465 [1733 data] 
wR2 = 0.1261 
-0.1(2) 
0.014(3) 
Final maximum 	 0.000 
Weighting scheme 	 calc 
w = 1/[\s2  (F02) + (0.0982P)2 + 0.0572PJ where P = (F02 + 2Fc2)/3 
Largest diff. Peak and hole 	 0.336 and —0.303 e.A 3 
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Table 1 	Atomic co-ordinates (x 10') and equivalent isotropic displacement 
parameters (A2  x 10') for (2S,3R,4R)-2,3-(isopropylidenedioxy)-4-acetoxy- 
cyclopentan-1-one 118. 	U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
Atom x y z U(eq) 
Cl -2787(4) -6728(4) -2593 (2) 34(l) 
01 -1255 (3) -7881(3) -2792(l) 47(l) 
C2 -3019(3) -4497(4) -2863(l) 32(l) 
02 -4464(2) -4439(3) -3764(l) 38(l) 
C3 -4648(3) -3565 (3) -2232(l) 31(1) 
03 -6991(2) -3281(2) -2823(l) 33(l) 
C4 -4990(4) -5213(4) -1539 (2) 33(l) 
04 -2872(3) -5018 (3) -804(l) 34(l) 
C5 -4785 (4) -7198(4) -2028(2) 37(l) 
C6 -6515(4) -3111(4) -3745 (l) 32(1) 
C7 -5869(5) -972(4) -3949(2) 47(l) 
C8 -8706(4) -3933(4) -4396(2) 40(l) 
C9 -3232(4) -5436(3) 56(l) 33(l) 
09 -5191(3) -5986 (3) 224(l) 43(l) 
CIO -934(4) -5095(5) 741 (2) 45(l) 
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Table 2 	Bond lengths (A) for (2S,3R,4R)-2,3-(isopropylidenedioxy)-4- 
acetoxy-cyclopentan- 1-one 118. 
Bond 	 Bond Lengths (A) 
cl-Ui 1.209(3) 
C1-05 1.521 (3) 
C1-C2 1.526 (3) 
C2-02 1.426(2) 














Table 3 	Bond angles (°) for (2S,3R,4R)-2,3-(isopropylidenedioxy)-4-acetoxy- 
cyclopentan- 1-one 118. 
Angle 	 Angle Size (°) 
01-C1-05 127.2(2) 
01-C1-C2 125.0(2) 
C5-C1-C2 107.74 (18) 
02-C2-C1 106.09 (17) 
02-C2-C3 105.48 (15) 
C1-C2-C3 105.11 (17) 
C2-02-C6 108.07 (15) 
03-C3-C4 107.34 (15) 
03-C3-C2 103.94 (15) 
C4-C3-C2 105.94 (18) 
C6-03-C3 107.09 (14) 
04-C4-05 108.51 (17) 
04-C4-C3 105.13 (17) 
C5-C4-C3 105.63 (18) 
C9-04-C4 117.09 (16) 
C4-05-C1 101.91 (19) 
02-C6-03 104.20 (16) 
02-C6-C7 111.00 (19) 
03-C6-C7 110.70 (19) 
02-C6-C8 108.11 (18) 




04-C9-C10 111.22 (18) 
Symmetry transformations used to generate equivalent atoms. 
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Table 4 	Anisotropic displacement parameters (A2 x 1 0) for (2S,3R,4R)-2,3 - 
(isopropylidenedioxy)-4-acetoxy-cyclopentan- 1-one 118. 
The anisotropic displacement factor exponent takes the form: 
2 it2 [h2 a*2 U11 + ••. +2hk a*b*U12] 
Atom Ui! U22 U33 U23 U13 U12 
Cl 20(l) 47(l) 35 (l) -5 (l) 3(l) -1(1) 
01 32(l) 56 (l) 53 (l) -7(l) 7(l) 8(l) 
C2 17(l) 47(l) 30(l) -1(1) 4(l) -2(l) 
02 21(1) 61(1) 31(1) -2(l) 6(l) 7(l) 
C3 16(1) 45(1) 31(1) -2(1) 1(1) -1(1) 
03 18(1) 53(1) 28(1) 2(1) 3(1) 4(1) 
C4 17(l) 52 (1) 30(l) 1(1) 2(l) -2(l) 
04 19(1) 56(1) 28(1) 0(1) 3(1) 1(1) 
C5 23(1) 48(1) 38(1) 4(1) 4(1) -3(1) 
C6 22(1) 46(1) 28(1) 1(1) 5(1) 1(1) 
C7 44(1) 53(2) 42(1) 6(1) 0(1) -10(1) 
C8 25(l) 59 (2) 34(l) -2(l) 1 (1) -2(l) 
C9 30(l) 38(l) 30(l) O(l) 6(l) 4(l) 
09 32(1) 60(1) 38(1) 3(1) 9(1) -9(1) 
CIO 26(l) 73 (2) 35 (l) -1(1) -2(l) 3(l) 
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Table S 	Hydrogen co-ordinates (x 10') and isotropic displacement parameters 
(A2  x 1 0) for (2S,3R,4R)2,3(isopropylidenedioxy)-4-acetoxy-cyclopentan- 1-one 
118. 
Atom x y z U(eq) 
H2 -1401 -3811 -2822 38 
H3 -3959 -2295 -1936 37 
H4 -6578 -5081 -1314 40 
H5A -6348 -7558 -2424 44 
H5B -4282 -8299 -1591 44 
H7A -5557 -888 -4575 71 
H7B -4401 -561 -3525 71 
H7C -7232 -86 -3880 71 
H8A -8409 -3822 -5023 60 
H8B -10170 -3162 -4333 60 
H8C -8952 -5343 -4253 60 
H1OA 378 -4644 426 68 
H1OB -446 -6349 1065 68 
















959.5 (11) A3 


















Unit cell dimensions 
Volume 















0.43 x 0.38 x 0.23 mm 
5.60 to 70.010 
-9:!~,h:!~9,-12:!~-k:!~ 12,-6!~I:!~ 14 
3972 
1732 [R(int) = 0.0088] 
omega-theta 
Psi-scans 
(Tmin = 0.33 1, T.ax = 0.463) 
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C. Solution and refinement 
Solution 
Refinement type 
Program used for refinement 
Hydrogen atom placement 
Hydrogen atom treatment 
Data/restraints/parameters 
Goodness-of-fit on F2 
Conventional R [F>4cr (F)] 
Weighted R (F2 and all data) 
Absolute structure parameter 
Extinction coefficient 
Final maximum öla 
direct (SHELXS-97 (Sheldrick, 1990)) 
Full-matrix least-squares on F2 
SHELXL-97 
geometric/difmap (OH) 
riding/rotating group (OH) 
1732/0/130 
1.040 





Weighting scheme 	 calc 
W = 1/[\52 (Fo2) + (0.0565p)2  + 0.2747P] where P = (1702 + 2Fc2)/3 
Largest diff. Peak and hole 	 0.240 and —0.163 e.A 3 
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Table 1 	Atomic co-ordinates (x 10') and equivalent isotropic displacement 
parameters (A2  x 10') for (2R,3S,45)-2,3-(isopropylidenedioxy)-4-hydroxymethYl-4-
hydroxy-cyclopentan-1-one 119. U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor. 
Atom 	 x 	 y 	 z 	 U(eq) 
Cl 488(2) 	- 4046(2) 2433(l) 31(1) 
01 -405 (2) 4745 (l) 1871(l) 47(l) 
02 2826(2) 3245(1) 1325(1) 33(1) 
C2 2478 (2) 3961 (2) 2329 (1) 29(l) 
03 3434(2) 1930(1) 2775(1) 30(1) 
C3 3062 (2) 3108 (2) 3312(l) 27(1) 
04 1473(2) 1774(1) 4668(1) 34(1) 
C4 1452 (2) 2937 (2) 4086(l) 27(1) 
C5 -110(2) 3103(2) 3291(1) 31 (1) 
06 1526(2) 5134(1) 4429(1) 41(1) 
C6 1469 (3) 3949 (2) 4995 (l) 34(l) 
C7 3941 (2) 2199 (2) 1644(l) 31(1) 
C8 3515 (3) 1077 (2) 925 (2) 42(l) 
C9 5832 (3) 2609 (2) 1580 (2) 48(l) 
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Table 2 	Bond lengths (A) for (2R,3S,45)-2,3-(isopropylidenedioxy)-4- 
hydroxymethyl-4-hydroxy-cyclopentan- 1-one 119. 











C4-C6 1.520 (2) 






Table 3 	Bond angles (°) for (2R,3S,45)-2,3 -(isopropylidenedioxy)-4-hydroxy- 
methyl-4-hydroxy-cyclopentan- 1-one 119. 
Angle 	- Angle Size (°) 
01-C1-05 127.64 (18) 
01-Cl-C2 123.73 (18) 
C5-Cl-C2 108.59 (14) 
C2-02-C7 107.23 (12) 
02-C2-C1 106.37 (14) 
02-C2-C3 105.33 (13) 
Cl-C2-C3 105.23 (13) 
C7-03-C3 107.42 (12) 
03-C3-C2 103.39 (13) 
03-C3-C4 108.67 (13) 
C2-C3-C4 106.66 (13) 
04-C4-C6 105.57 (13) 
04-C4-05 114.20 (14) 
C6-C4-05 111.23 (15) 
04-C4-C3 112.56 (14) 
C6-C4-C3 109.29 (14) 
C5-C4-C3 104.05 (13) 
C1-05-C4 104.87 (14) 
06-C6-C4 106.68 (13) 
03-C7-02 103.78 (13) 
03-C7-C8 108.54 (14) 
02-C7-C8 109.25 (14) 
03-C7-C9 111.43 (15) 
02-C7-C9 109.33 (16) 
C8-C7-C9 114.01 (16) 




Table 4 	Anisotropic displacement parameters (A2 x 10) for (2R,3S,45)-2,3- 
(isopropylidenedioxy)-4-hydroxymethyl-4-hydroxy-cycloPefltan- 1-one 119. 
The anisotropic displacement factor exponent takes the form: 
2 it2 [h2 a*2 U11 +... +2hk a*b*U12] 
Atom 	Ull 	U22 	U33 	U23 	U13 	U12 
Cl 41(1) 28(1) 25(1) -4(1) -3(1) 6(1) 
01 55 (l) 45 (l) 40(1) 6(1) -7(1) 19(1) 
02 45 (l) 31(1) 23(l) 2(l) 3(l) 8(l) 
C2 39(l) 23(l) 25(l) 1(1) 2(l) -1(1) 
03 37(1) 26(1) 26(1) 2(1) 2(1) 3(1) 
C3 31(1) 24(1) 25(1) -1(1) -2(1) -1(1) 
04 47(1) 27(1) 27(1) 5(1) 0(1) -2(1) 
C4 33(1) 23(1) 25(1) 2(1) 0(1) -1(1) 
C5 30(1) 31(1) 33(1) 1(1) -1(1) 0(1) 
06 65(1) 27(1) 32(1) -3(1) 0(1) -3(1) 
C6 47(1) 31(1) 25(1) -1(1) 1(1) -2(1) 
C7 36(1) 30(1) 27(1) 4(1) 3(1) 6(1) 
C8 57(1) 36(1) 34(1) -7(1) -3(1) 11 (1) 
C9 35(l) 55 (l) 53(l) 3(l) g(l) 2(l) 
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Table 5 	Hydrogen co-ordinates (x 104 )  and isotropic displacement parameters 
(A2  x 10') for (2R,3S,45)-2,3 -(isopropylidenedioxy)-4-hydroxymethyl-4-hydroxy-
cyclopentan- 1-one 119. 
Atom x y z U(eq) 
H2 3058 4797 2332 35 
H3 4086 3454 3721 32 
H4 1320 1188 4214 51 
H5A -415 2300 2930 38 
H513 -1132 3418 3703 38 
H6 1719 5704 4893 62 
H6A 416 3890 5463 41 
H6B 2496 3849 5482 41 
H8A 3850 1248 151 64 
H813 2269 911 960 64 
H8C 4151 346 1199 64 
H9A 6138 2784 801 71 
H9B 6575 1941 1869 71 
H9C 5996 3366 2029 71 
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